annual repor johnson johnson continue bring meaningful innovations people around world live better healthier lives deeply committed dedicated people use products employees communities live work shareholders important never lose sight cover matt cox type diabetes uses waterproof animas vibe insulin pump swam english channel relay raise money juvenile diabetes research foundation matt wants show son jack also type diabetes condition need hold back life read matts story chairmans letter shareholders hroughout annual report year youll read severe economic decline tightening consumer johnson johnson bringing meaningful spending health care budgets overthecounter otc innovation patients customers making product quality issues mcneil consumer healthcare difference lives personal wayfrom recall depuy asr hip system brunhilde wecker made full recovery stroke company severely tested thanks new blood clot retrieval removal device managing stretch relied heavily resolve bill hait oncologist whose vision insights people timetested business model broad helped accelerate approval wholly new treatment base health care decentralized management structure prostate cancer managing long term values set forth credo stories remind us health care rewarding made necessary restructurings business manage endeavor excite future johnson johnson cost structure simplify operations ensure past years navigated steadily efficient use capital longterm benefit patients series significant challenges keeping longterm perspective shareholders maintaining disciplined approach management team employees managing investments growth took critical actions preserve core portfolio broadly based businesses values strengths business staying true operating model remained committed retaining values turned corner trust patients customers taking particularly difficult period responsibility instituting new measures year johnson johnson ensure products live celebrated th anniversary high quality standards customers returned sales growth launched expect deserve number innovative new products came close moved address unmet health care needs across turning point headwinds patent globe advanced pipelines expirations tough portfolio choices litigation today among best industry matters otc product quality issues strengthened product portfolios addressed leadership positions many areas time continued including immunology oncology surgical william c weldon investments research development chairman board directors devices emerging markets rd equaling nearly billion chief executive officer focused scientific innovation maintain past five years yielded nine major approvals build share key growth markets new pharmaceutical products delivering meaningful innovations health care united statesincluding stelara ustekinumab simponi building agile company seize market opportunities golimumab immunology prezista darunavir weve remained committed credo intelence etravirine hiv zytiga abiraterone acetate longheld values enabled us succeed decades oncology xarelto rivaroxaban cardiovascular disease though continue face difficult uncertain emphasis place rd also led exciting macroeconomic conditions ongoing investments us innovations medical devices diagnostics mdd well positioned grow increase market leadership consumer platforms contact lenses electrophysiology one important rewarding industries world advanced energy biosurgicals oral care skin care delivering sustainable growth shareholders replenished advanced pipelines new technologies like fibrin pad hemostasis well fiveyear journey compounds like canagliflozin diabetes bapineuzumab several years ago set build strong foundation alzheimers disease sustain track record growth even prepared focus financial discipline capital address daunting challenge patent expirations two returned shareholders form dividends share major drugs risperdal risperidone topamax repurchases capital also used important longterm topiramate together products combined peakyear investments strategic alliances acquisitions like pfizer sales billion also prepared consumer healthcare beijing dabao cosmetics company ltd market issues good line sight consumer business crucell nv elan corporation plc additional developments could easily foreseen pharmaceuticals business pending acquisition chairmans letter synthes inc mdd business creating demand health care populations look back faced period industry developed world aging rapidly consume global change managed proud health care grow older global expansion growth people johnson johnson shown ingenuity though slower years ago also lead growing resiliency tenacity integrity compassion would demand health care especially emerging markets expect global leader human health care investments continue aligned market opportunities address unmet medical needs cancers results mental health disorders diabetes heart disease stroke johnson johnson returned delivering operational sales growth rheumatoid arthritis hiv among grew adjusted earnings th consecutive year significant diseasesand markets today worldwide sales billion increase percent either leadership increasing investments gain sales increased operationally percent reflecting strength leadership new product launches pharmaceuticals business segment steady performance across mdd franchise sciencebased g overnment payers regulators health care reform innovations consumer business strong growth evolves around world governments requiring emerging markets costeffective health care solutions approximately percent sales products recognize priorities making investments global market share positions approximately personalized medicine companion diagnostics percent sales products introduced past especially areas oncology antipsychotics five years geared toward better target treatments continued focus financial discipline adjusted monitor results efficient product development earnings billion adjusted earnings per share regulatory environment become much representing increases percent percent intense share common goal regulators saving lives respectively easing peoples suffering addressing unmet medical needs invested billion rd advanced robust pipelines meaningful innovations support strong regulatory across three business segments environments ensure patient safety enabling generated significant free cash flow approximately fast efficient approval potentially lifesaving medicines billion maintained aaa credit rating increased treatments dividend shareholders th consecutive year industry trends bringing new innovations market solid consistent returns shareholders requires significant investments access best minds hallmark johnson johnson generated talent adaptability everchanging markets oneyear total shareholder return nearly percent exceeding important ever companies agile standard poors dow jones industrial average collaborative able thrive new business models longer timeframes continue compare favorably always looked complement development indices longterm management focus company efforts acquisitions collaborations help us remained solid investment choice decades details gain new capabilities provide access technology see business segment highlights pages products compounds accelerate market collaborations alzheimers disease elan pfizer forces shaping health care hiv gilead sciences inc look ahead see three major forces shaping health promising ventures care environment macroeconomic conditions role government payers regulators industry trends clearly well positioned growth poses continuing challenges inherent also overall johnson johnson well positioned address opportunities seizing evolving market forces opportunities macroeconomic conditions slowing economic growth b ecause ways delivering meaningful innovations uncertainty financial markets high unemployment patients customers pressure health care costs contributed b ecause steps taken build agile company constraints health care spending dynamics balanced demographic trends nd commitment operating model net sales diluted earnings per share dividends paid per share billions dollars dollars dollars johnson johnson annual reportvalues enabled consistent track record approach decision patients customers first success employees communities shareholders last years offered significant challenges achieving meaningful inno vation commitment credo remained foundation learned many paths achieving meaningful response provides common set values hold together innovation us first step identify significant unmet approximately employees countries need market opportunity believe johnson johnson operating companies make difference patients responsibility global citizen rooted credo first look areas capabilities insights years innovations philanthropy unique advantages shape opportunity touched lives billions people particularly areas search inside outside companies find latest world access basic health care challenge science research address needs addition honored recognized united rd use strategic alliances licensing arrangements nations humanitarian year work regard acquisitions venture capital investments give us insight reported strong progress inaugural year fiveyear access next big breakthrough finally leverage pledge help save improve lives million women breadth resources development supply chain children annually developing countries part marketing sales bring innovative products market united nations millennium development goals pharmaceuticals business followed model proud many programs driven pursuit better treatments hepatitis c cardiovascular passion employees hundreds equally passionate disease hepatitis c infects million people partners around world worldwide partnered vertex pharmaceuticals inc development telaprevir approved commitment marketed incivo europe honor privilege serve chief also partnered bayer healthcare executive officer past years success development launch xarelto prevention deep developing outstanding leaders within johnson johnson vein thrombosis knee hip replacement surgery reflected selection alex gorsky next ceo lead reducing risk stroke systemic embolism patients great company forward effective april date nonvalvular atrial fibrillation annual meeting shareholders decision involved times may choose acquisition broaden rigorous thorough formal multiyear process portfolio new capability gain entry new piece alex experienced disciplined leader take market technology dont pipeline reins company turbulent time health care case revive se device innovative promising time johnson johnson product helped save mrs weckers life came us assure shareholders johnson johnson acquisition micrus endovascular llc continue shape lead future health care important new option treatment ischemic stroke delivering meaningful innovations patients case fibrin pad started strategic partners customers building agile business seize new market israelbased omrix pharmaceuticals ltd working solve opportunities remaining committed proven operating unmet medical needs surgical bleeding collaboration model set values embodied credo make developed determined acquisition would allow us us proud better manage complex development intricate regulatory thanks extraordinary achievements dedication filings necessary achieve success convergent product people johnson johnson better positioned today anxiously awaited surgeons time recent history deliver sustainable growth another approach use broad base businesses loyal shareholders expertise tackle disease state multiple fronts diabetes one example offer devices like blood glucose monitors insulin pumps develop new drugs canagliflozin help patients consumers achieve healthier william c weldon living consumer wellness prevention business chairman board directors chief executive officer nutritional products splenda sweeteners march operating agility base trong values important way innovate way operate focused improving operations reflect commitment delivering highquality products adapt rapidly evolving marketplace beyond meaningful innovations agility foundation decades sustained growth remains unwavering excludes special items commitment operating model values f ree cash flow defined operating cash flow less capital spending see tenets credo provide clear focus reconciliation nongaap financial measures chairmans letter business segment highlights fter two challenging years collaborations companies like pharmacyclics inc jointly develop market anticancer johnson johnson returned compound building strength oncology delivering operational sales terms pipeline progress us leader new molecular entity approvals three zytiga growth continued oncology xarelto rivaroxaban cardiovascular strengthen platform leadership disease edurant rilpivirine hiv progress pharmaceuticals business segment result profitable growth new commitment continued investment product launches product launches strong pipelines pipeline compounds investments key growth areas medical devices diagno stics billion sales medical devices johnson johnson three distinct business segments diagnostics mdd business unit largest medical device share common focus human health business world operational sales growth percent pharmaceuticals year saw many challenges several mdd markets billion sales eighth largest well issues depuy asr hip system recall european pharmaceuticals business world sixth largest austerity measures pricing pressures slowdown elective biotech business strong operational growth percent surgeries driven continued economic pressures driven recently launched products like stelara contributed tempered growth rates despite ustekinumab simponi golimumab zytiga abiraterone challenges mdd business segment competing well acetate incivo telaprevir invega sustenna global market undergone dynamic change paliperidone palmitate mdd showed strong doubledigit growth built continued success recently bric brazil russia india china markets launched products strengthen leadership position introduced many innovative products core therapeutic areas including immunology infectious meanwhile asiapacific europe rolling disease neuroscience oncology products launched day acuvue moist brand contact lenses johnson johnson led united astigmatism states new pharmaceutical products past year continued advance important products expanded immunology leadership sales regulatory process percent mdd amendment global distribution agreement merck co pipeline advanced next major milestone breakthrough largestselling product remicade infliximab products like sedasys system first computerassisted simponi golimumab personalized sedation system fibrin pad area also received approval incivo europe surgical bleeding progressing us food hepatitis c marketed incivek strategic drug administration also increasing investments partner vertex pharmaceuticals inc us emerging markets new innovation centers india completed acquisition crucell nv building china continuing support number training key leadership position vaccines entered new institutes around world johnson johnson annual reportwith actions others pharmaceutical segment sales mdd business unit able remicade sales major product sustain leadership billions dollars positions percent key sales risperd l consta platforms growing maintaining sales change share majority platforms total weve also made strategic operational procr eprex v el ca e portfolio decisions business segment refocusing cardiovascular business prezista exited drugeluting stent business shifted investments levaquinfloxin highergrowth higherneed areas like electrophysiology decisions concerta help fund growth potential promising areas decisions aciphexpariet acquire synthes inc strengthen leadership position orthopaedics well acquisition sterilmed inc experience reprocessing surgical instruments examples medical devices diagnostics ethicon continuously looking across segment sales endo u r gery business best longterm sales major franchise growth opportunities billions dollars sales consumer et h ic n sales change orthoclinical billion sales diagnostics total consumer business segment operational sixth largest consumer health care company world operational sales declined percent reflecting impact remediation supply v cis ai ro en issues associated us overthe diab et e care counter otc business decline partially offset solid growth certain franchises including skin care oral c na er ue w ri oth g et nro g p ne dr f hr em la tce es r f ir nom e e pu card co av ra e scular mouthwash brands consumer group continued expanding emerging markets acquisition line otc consumer segment sales skin care coughandcold brands russia sales major franchise jb chemicals pharmaceuticals billions dollars limited also continued innovate sales introducing neutrogena naturals sales change aveeno smart essentials total nicorette quickmist operational listerine zero womens recovery remediation pharmao ct ec u ticals h e al h mcneil consumer healthcare nu tr onals business continues major commitments date consent decree us food drug wound care administration achieved several products already returned market volume continue ramp oral care products reintroduced baby care throughout operationalexcludestheimpactofcurrency business highlights pharmaceuticals accelerating cancer rd f bill hait compelling science johnson johnson acquired cougar biotechnology july based holds greatest promise developing positive results completed phase iii medicines address high unmet needs study marketing applications filed regulatory authorities us network allows insights europe countries going world science essential entire development program proceeded says hait md phd global head janssen research rapidly less six years time first patient treated development llc takes understanding marketing approvals us canada medical need compelling science european union switzerland get meaningful innovations patients quickly new approa ch cancer rd one example zytiga abiraterone surgical reduction hormones noted oncologist joining acetate oral oncedaily medication cancers continue rely johnson johnson march hait use combination prednisone approval zytiga treatment catalyst change bringing treatment men metastatic options extend life men focus helping centralize rd within castrationresistant prostate cancer kind metastatic castration therapeutic areas within oncology hait crpc received prior resistant prostate cancer limited created tumor strategy groups tsg chemotherapy containing docetaxel chemotherapy longer focused three areas high unmet us food drug administration effective patients treatment need hematological malignancies lung granted marketing approval zytiga options cancer prostate cancer tsgs april expedited abiraterone acetate discovered specialize using tumor micro sixmonth review accelerated imperial cancer research royal environment strategic research focus regulatory review process granted marsden hospital london tumor longer viewed european medicines agency led licensed cougar biotechnology inc tumor cell living isolation tumor cell marketing authorization european began testing compound men close environment commission september crpc taking androgen using environment grow better transformative prostate deprivation therapy says hait cancer treatment came market breakthrough research hinged kind insight enabled exemplifies fundamental shift scientific understanding tumor paradigmchanging scientific progress approach research development microenvironmentspecifically idea led zytiga validating tsg applied across janssen tumor could source approach research development remaining testosterone says importantly hait also helped open compound leader abiraterone acetate minds look beyond companys transforming prostate cancer michael l meyers md phd janssen labs invest science wherever treatment research development llc science may globally prostate cancer second identifying key science drug development competitive frequently diagnosed cancer men patients fact drug difficult says hait one way fifth common cancer overall already developed way cutting edge walled inside according estimates national accelerate process try brick mortar cancer institute new collaborate acquire drug says hait see exciting new cases prostate cancer diagnosed recognized value abiraterone things developing us nearly men acetate championed acquisition collaborations one way died disease cougar biotechnology fact promise fuel advances androgen hormones worked well shortened timeline oncology research development testosterone known fuel prostate start phase iii trial example ongoing agreement cancer tumors despite chemical registration drug david h koch institute integrative johnson johnson annual reportsights set cience bill hait vision future research development focus finding mining compelling science bring products market faster cancer research massachusetts massachusetts general hospital develop drug discovery development institute technology fosters oncology commercialize nextgeneration hait says key meaningful research technology development circulating tumor cell ctc technology collaborations right people areas cancer diagnostics cancer capturing counting characterizing internally likeminded people seek biology premalignancies genetic models tumor cells found patients blood says hait end day disease profiles tumor micro enable ctcs used oncologists terms contract get environment diagnostic tool personalizing point company group another important collaboration patient care researchers confidence people announced january accelerate improve process working really experts johnson johnson annual report curing hepatitis c incivo telaprevir new directacting antiviral protease inhibitor treatment genotype chronic hepatitis c virus hcv combination pegylated interferon ribavirin approved european member states september arrival directacting antivirals offer patients hope cure says charles gore president world hepatitis alliance according world health organization million people worldwide infected hepatitis c serious longterm health consequences cirrhosis liver cancer liver transplanta tionhepatitis c carries high economic burden patients society named one top medical innovations moving treatment manufacturing vaccines cleveland clinic telaprevir kyung mi choi works doubles chances clearing prevention crucells ultramodern vaccine virus half treatment manufacturing facility time compared prior opened standard treatments incheon south korea majority hcv genotype vaccines fundamentally thats affordable one largest patients different pharmaceutical majority globe facilities world jim witek global medical medicines thats crucell affairs leader incivo vaccine prepares acquired affiliate vaccine used worldwide says product new body whenever virus johnson johnson unicef worlds largest highlight janssen attacks explains jaap february working distributor childhood pharmaceutical companies goudsmit chief scientific new ultramodern vaccines expanding infectious disease officer crucell nv manufacturing facility crucell also working portfolio rd serious vaccinate healthy people incheon south korea evaluate possibilities using infections hivaids whereas drugs used treat one largest vaccines beyond preventing hcv tuberculosis sick people aim facilities world infectious diseases one area allowed us bring innovative vaccination prevent capable making focus prevention diseases therapies helping disease million doses per year elderly certain redefine improve treat takes scientific pentavalent vaccine cancers alzheimers ment outcomes says expertise pharmaceu combination five vaccines disease incivo telaprevir codeveloped ticals business grows beyond one diphtheria tetanus dream world vertex pharmaceuticals tibotec affiliate janssen pharmaceutical treatment model one whooping cough hepatitis b companies johnson johnson includes prevention haemophilus influenza infectious diseases says johan janssen companies right commercialize telaprevir europe latin vaccines equally important type b bacteria van hoof managing director america middle east africa india consideration ability causes meningitis pneumonia crucell australia new zealand make hundreds millions otitis facility makes infectious diseases theyre commercial name incivo common genotype europe doses vaccine price half pentavalent control us johnson johnson annual reportaddressing burden hiv expanding march several non multiple medicines one since licensing agree immunology exclusive licenses granted tablet simplify hiv ments used generic manufacturers therapy four agree generic manufacturers make leadership south africa india ments signed prior hiv medicines available manufacture market receiving regulatory approvals low special access price distribute rilpivirine rilpivirine allowing generic countries high investigational antihiv manufacturers make generic hiv burden including india medication subsequently rilpivirine combination nations subsaharan global approvals granted approval us pill available quickly africa recently agree amended distribution food drug administration collaboration generic ments modified agreement merck co fda european companies extends beyond provide access rilpivirine inc helped janssen medicines agency licensing sharing technical lowresource countries pharmaceuticals inc expand johnson johnson skills providing help including vietnam leadership geographic expanded scope ensure safety quality well thailand covering presence immunology global access program may fda percent people living serving patients licensed generic partners granted approval edurant hiv worldwide stelara ustekinumab speed access rilpivirine rilpivirine treatment treatment moderate important new medicine nave adults access medicines severe plaque psoriasis treat hiv says alan never taken hiv therapy hiv medications help thabo approved countries staple manager strategic third antihiv medication feel strong enjoy recognized prestigious relationships clinton commercialized janssen time mother south prix galien usa award health access initiative therapeutics division africa johnson johnson best biotechnology product agreements exist janssen products lp together expanded global access stelara phase iii five generic manufacturers prezista darunavir program make studies treatment ensure widespread access intelence etravirine hiv portfolio available psoriatic arthritis crohns supply rilpivirine company provide people like disease phase ii studies singleagent medicine treatment options patients otherwise might get treatment sarcoidosis fixeddose combination stages disease medicines need primary biliary cirrhosis simponi golimumab oncemonthly subcutaneously administered antitnfalpha therapy achieved approvals countries simponi phase iii stud ies treatment ulcerative colitis juvenile idiopathic arthritis intravenous formulation rheumatoid arthritis also phase ii study sarcoidosis september remicade infliximab received us food drug administration approval first biologic treatment pediatric ulcer ative colitis marking th approval us remicade available countries july marketing rights remicade simponi transferred merck janssen pharmaceutical companies approximately territories johnson johnson annual report consumer innovating iconic brands mother seven mommy blogger christine bandaid brand adhesive bandages use quiltvent technology young tends good number scrapes promotes breathabilitya feature cuts kids bike skateboard climb trees consumers said wantand enables bandage wick away blood always go theres always scrape leaving wound clean cut bruise says christine whose daughter six neosporin brand meanwhile entering eczema skin care area sons range age neosporin essentials christine treats childrens campaign also brought fun activities three new products designed people owies sings always squeeze commercials brightly colored puppets eczema plus trial pack stick song tv commercial large events including baby buggy contains line includes cheerful puppets sing bedtime bash charity event attended gentle nonirritating daily care always using neosporin antibiotic celebrity parents children wash moisturizing cream ointment together bandaid brand initiative reached influential clinically shown restore visibly adhesive bandages minor wounds mommy daddy bloggers spread healthier skin three days catchy gets stuck heads word social media itch flareups hydrocortisone cream singing day long christine says christine example used unique relipid formulas two products together long contain humectant emollient marketing todays consumers became ambassador campaign lipid botanical blend help retain nearly years old bandaid brand promoted always squeeze stick moisture essential healthy one first johnson johnson brands twitter several parent looking skin neosporin brand joined blogger events hosted video contest put much heart sweat johnson johnson trademark portfolio blogs readers posted video passion innovating formulas pfizer consumer healthcare family lincoln calif dancing says elena fernandezkleinlein senior acquisition long represented gold singing song director rd global topical health care standard antibiotic ointments appeals broader audience johnson johnson family consumer brands naturally meant beyond us moms christine says companies proud able together neosporin older kids pretty good help eczema sufferers bandaid brands says susan tang helping treat younger kids heritage brands also group brand director us topical health mom squeezing sticking launching innovative products care johnson johnson family oldest siblings meet consumer needs example consumer companies notes neutrogena yearold iconic parents trusted generations developing trusted new produc ts brand learned consumer insight care children products across johnson johnson family parents hard time getting share store aisle used consumer companies iconic brands little swimmer sit still long enough together provide exceptional wound care using innovation drive growth dry reapply sunscreen led yet percent consumers use meet consumer needs efforts range launch neutrogena wet antibiotic cream bandage marketing educational tools skin sunblock spray first sunscreen according one study reinforce creative packaging research designed applied directly wet skin message products used development leads new products sprays quickly became topselling together johnson johnson consumer historic brands new products sun category companies inc developed always neosporin bandaid also neutrogena corporation squeeze stick initiative ran brands example also launching launched first products line commercial english spanish new products early new neutrogena naturals face johnson johnson annual reportbringing brands together christine youngs children experience scrape cut sings always squeeze stick song uses neosporin antibiotic ointment bandaid brand adhesive bandages help feel better marketing campaign brings together two iconic brands lip products five products packaging built firstofitskind easytouse design marketing average percent naturally derived green server runs brands campaign commercials focused harsh chemical sulfates parabens website solely solar wind energy demonstrating sprays fast action petrochemicals dyes phthalates nicorette team meanwhile deeply resonated consumers neutrogena science team examined extended brands long history consumers trusted thousands natural ingredients find launch nicorette quickmist brands generations must invest best bionutrients peruvian fastacting mouth spray relief heritage brands keep tara seed promote healthylooking cigarette cravings development successful relevant consumer skin addition neutrogena launch involved host innovations needs says jesse wu worldwide naturals uses environmentally sensitive based consumer insight including chairman consumer group postconsumer recycled material desire speed effectiveness johnson johnson johnson johnson annual report aspiring customers consumers want better understanding emerging market consumers like heleneide pereira de brito helps emerging markets consumer business satisfy needs population thecounter business jb listerine essencial chemicals pharmaceuticals appeals consumers ltd including doktor mom heleneide pereira de brito consumers new design brand wellknown line paulo brazil feels emerging markets lower cost comprehensive products midtier confident fresh breath including brazil marketing campaign consumers russia beautiful smile many people aspire speaks aspirations acquisitions helping feeling good purchase traditional western consumer business expand portfolio look helps brands looking continues gain deeper products meet consumer consumers also feel affordability combination understanding needs needs emerging markets prepared accomplish benefits create value emerging markets leveraging existing things daily lives says takis baladis area world leading capabilities well says karina lensing senior vice president emerging enhanced products consumer marketing brand manager listerine markets europe middle east marketing better connect strengths continue johnson johnson industrial africa johnson johnson consumers innovate drive growth ltda brazil sharing consumer family example meet new consumer needs insight helped bring companies consumers johnson johnson family emerging markets listerine essencial make significant portion companies acquired baladis says johnson johnson annual reportsupporting sustainable sourcing consumers palm oil increasing equal percent nongovernmental france unwrap le petit unsustainable rate causing estimated palm oil use organizations ngos marseillais bar damage rainforests purchased greenpalm supporting projects increase soap may notice threatening environments program endorsed availability certified additional logo several endangered species rspo sustainable palm oil supplies greenpalm program le petit even though represent greenpalm program example partnership marseillais recently began small portion global palm oil allows us demonstrate dutch ngo solidaridad using greenpalm logo usageless percent commitment healthy trains farmers sustainable packaging highlight efforts joined future goal sourcing palm oil farming techniques supporting sustainable palm roundtable sustainable palm oil palm oil everything oil production palm oil rspo derivatives certified accelerate palm oil ingredients help make difference sustainable sources says promote growth derived palm oil sustainability important simon perry sourcing sustainable palm oil says commonly used personal ingredient says paulette frank manager johnson johnson frank small user care products soaps vice president sustainability family consumer companies big voice lotions shampoos creams environment health achieve goal oil comes safety johnson johnson johnson johnson returning fruit oil palm tree also family consumer companies global palm oil sourcing used production food strategy includes engaging quality biofuel demand sustainable palm oil certificates suppliers collaborating mcneil products mcneil consumer healthcare continues make progress commitments return highquality products shelves consumers shipments resumed number adult childrens tylenol products anticipate key selected products continue reintroduced throughout number johnson johnson manufacturing facilities hundreds supply chain associateshave involved effort return trusted brands store shelves work also continues outfit manufacturing facility fort washington pa stateoftheart equipment processes provide quality products consumers upon reopening site worldclass facility reducing impa ct part efforts encourage sustainable palm oil supply sourcing manufacturing overthe johnson johnson works organizations engage sustainable palm oil farming practices counter liquid medicines johnson johnson annual report medical devices diagnostics reviving recovering w hen ehrenfried wecker wiesenbach germany returned home bakery breakfast rolls one morning august found wife brunhilde bed waving one arm unable speak took hand let change paradigms medicine go hand fell says prof bendszus says dramatic realized couldnt move right side knew immediately wife significant need severe stroke every minute would year million people suffer stroke count mr wecker says ambulance worldwide million die rushed mrs wecker hospital another million permanently evaluation including mri disabled stroke leading cause showed experiencing acute death heart disease cancer ischemic stroke blockage artery leading cause serious long leading brain term disability hemorrhagic strokes doctor proposed using new occur artery brain bursts option revive se device self ischemic strokes blood flow expanding blood clot retrieval removal brain blocked account device designed remove blood clots percent strokes year restore blood flow brain patients revive se device first acute ischemic stroke said device codman shurtleff inc dont think could get much worse ischemic stroke marks new growth asked thought would area johnson johnson company best wife mr wecker recalls developing additional stroke minimally invasive procedure took products beginning long minutes advantage term commitment bring forward micrus endovascular corporation damage become serious innovations advance treatment global developer manufacturer longer brain deprived blood stroke improve patient care minimally invasive devices patient could suffered outcomes says karen prange general hemorrhagic ischemic stroke severe permanent impairment could manager vice president codman operates codman neurovascular died says surgeon prof martin neurovascular business global neuroscience neurovascular bendszus md chairman department company received european union company develops markets neuroradiology university hospital approval revive se device products diagnosis treatment heidelberg germany could move february launched device neurological disorders codman part body speak next day left september depuy family companies hospital one week later shes approved distribution united rich history pioneering products absolutely fine nowits really amazing states clinical trials planned orthopaedic neurological care hospital routinely uses potential future use fastgrowth area neurovascular revive se device acute ischemic revive se device represents market expanding stroke rare experience success september acquisition percent annually johnson johnson annual reportlife stroke revive se device helped save brunhilde weckers life suffered stroke enjoys active lifestyle time garden husband ehrenfried full life res tored stroke complete paralysis weckers husband son visited mrs weckers mri located blood right side procedure couldnt believe sitting clot vessel left side brain neurologists also administered waving smiling us prof bendszus inserted revive se standard treatment ischemic stroke could speak perfectly fine mr wecker device groin microcatheter tpa clotdissolving drug says left hospital six days guided artery blockage next day mrs wecker served stroke needing rehabilitation area watching image screen potatoes roast pork lunch home mrs wecker resumed devices mesh basket expanded one cut meat full lifestyle working tax adviser pushing clot vessel wall tried cutting meat visiting grandchildren enjoying restoring blood flow brain prof hand worked says day garden everything bendszus retrieved removed couldnt move hand says operation took blood clot caused mrs weckers cutting schweinebraten mrs minutes probably saved life johnson johnson annual report setting example animas vibe device undertaking matt june first persevered continuous glucose monitoring got water cgmenabled insulin pump say scared would diabetes never almost hour relay system dexcom g massive understatement one factors ive swim across english cgm technology allowed hold back channel raise money allows realtime glucose huge relief says matt medical condition juvenile diabetes research information alerts high diabetes big youve got deal foundation three swimmers low readings glucose trend part life says matt cox lives diabetes wore information background thats village high lane waterproof animas vibe animas vibe try keep northwest england insulin pumps braved device helped matt manage animas insulin pump water matt setting cold waters diabetes channel proof meters hours positive example especially without pump swim still easy dexcom g transmitter waterproof meters hours important son would possible jack also type diabetes clearly doable inspirational swim matt cox took part relay swim across july matt joined right tools says matt english channel support family wanted six swimmers two animas corporation show son jack diabetes shouldnt hold back also type diabetes received ce mark approval accomplishing goals johnson johnson annual reportmanaging growth number strategic decisions made reshape portfolio devices diagnostics businesses redeploy resources accelerate growth long term april johnson johnson announced planned acquire synthes inc premier global developer manufacturer orthopaedics devices acquisition would largest purchase johnson johnson history strengthen companys leadership position global orthopaedics market september ethicon endosurgery inc announced agreement acquire sterilmed inc leader reprocessing replacing knee remanufacturing medical improved outlook devices broadens successful knee replacement restoring life portfolio products offered surgery mrs kamatchi left increasingly costconscious daughter dhanalakshmi hospital customers focus family cardiovascular care household tasks franchise exited drug mrs ramasamy kamatchi underserved patients like pain eluting stent business better yearold farmer trichy mrs kamatchi company focus areas india whose life also committed safe neurological disorders significant medical needs transformed depuy effective use products teach also learn greatest opportunities reach knee suffering india need needs sur growth leading debilitating knee pain three times many joint geons patients electrophysiology business years replacement surgeons feed insights continue make underwent kneereplacement today treat number product innovation progress aspects surgery able care patients suffering market access strategies says synthes acquisition including family enjoy activities debilitating arthritis helping michael del prado company integration planning grandchildren address gap group chairman asiapacific process continue pay less attention stateoftheart depuy strategies work expect transaction close knee family institute advanced together help build health first half synthes says mrs kamatchi education research care capacity india depuy franchise happy satisfied opened near chennai throughout region well positioned succeed developing new rd capital city tamil nadu depuy institute time dramatic change commercial models july transfer chennai one orthopaedics market meet specific emerging market knowledge development professional education centers offering patients surgeons needs depuy orthopaedics skills facility johnson johnson hospitals broad range inc making life increase capacity indias family companies built innovative technologies changing technologies health care professionals around world serve meet orthopaedics accessible affordable care people suffering unique patient needs needs hundreds millions osteoarthritis spinal emerging markets johnson johnson annual report commitment remaining steadfast tohoku pacific coast earthquake tsunami struck japan friday march wake disaster toshiaki kobayashi responsible operations manufacturing distribution labeling facility sukagawawas one johnson johnson colleagues japan whose immediate concern others earthquake tsunami vision care operations tokyo suffered first priority ensure water damage due sprinklers employees safe facility major damage reestablished safe community safe percent function march anxious get work orthoclinical diagnostics ocd customers says kobayashi sukagawa office sendai severely damaged plant manager johnson johnson employees relocated medical company jjmc division jjmc office repairs could made johnson johnson kk ocd office reopened later month sukagawa plant primarily janssen facility escaped initial damage manufacturing distribution center suffered minor damage four days medical devices including sterrad later earthquake mount sterilization products carto fuji area operations resumed system advanced imaging technology march sendai branch office handles labeling almost medical jjmc operational heavily devices diagnostics products sold damaged sukagawa closed undergo japan damages facility repairs concurrently supply chain leaders significant identified contacted hundreds suppliers assess validate safety assessing damage measures raw materials finished regulatory agencies secured immediately disaster products labeling face subsequent risk radiation manufacturing suspended exposure damaged nuclear power recovery begins affected product cidex opa plant leaders johnson johnson toured sukagawa building also produced gargrave united supply chain initiated extensive day disaster kingdom facility jjmc team ongoing assessments miserable says hiroyuki watanabe fasttracked regulatory approval make companys operations distribution senior manager jjmc quality assurance uk product available japan supplier networks throughout japan kobayashi year employee says recovery external manufacturer priority ensure safety products first couple days focused contracted ramp production raw materials companys cleaning everything became challenge cover demand supply chain supplies stopped says working turnaround time within first days cross sukagawa plant difficult regulatory review approval functional team quickly located water toilet food available unprecedented thanks strong employees found safe emergency supplies including food support jjmc team including assessments made water arrived tokyo helped regulatory affairs explains watanabe operating company consumer company recovery work plant march five labeling rooms sites damage within hours labeling sukagawa restarted operating almost percent capacity disaster products ready percent capacity nearly week repairs manufacturing line donated shelter camps towns disaster additional space continued repairs automated anywhere else needed tokyo promptly audited approved distribution warehouse completed johnson johnson annual reportcaring customers employees found safe earthquake tsunami toshiaki kobayashi says focused fast could get back serving customers despite significant damage sukagawa facility thinking much faster children world vision shortages fuel electricity food get back distributing products japan janssen pharmaceutical kks necessary items employees japan customers says kobayashi support rescue efforts included worked tirelessly around clock employees shared focus worked donating medical equipment supplies reestablish support supplies togetherit amazing funding group doctors patients doctors families need working affected areas vision care products repaired damaged facilities aid japan division provided free lenses patients provided much needed assistance assist people japan relief workers seven affected tohoku region difficult time johnson johnson prefectures identifying clinics serve culturally japanese people family companies made significant emergency lens distribution points strong team spirit important financial commitment well product japan presidents council approved helping us make successful recovery says donations addition employees recommendation use funds pledged kobayashi still could expected retirees johnson johnson johnson johnson family surprisingly good teamwork companies donated generously disaster companies japan mid longer emphasizes caring people relief partners including japanese term projects also part japanese culture says red cross society direct relief biggest lesson id like others learn international international rescue back business caring disaster importance committee project hope save spite indescribable hardships caring helping johnson johnson annual report caring together meaningful difference w hen look woman passion order make difference local organizations look mothers look private sector perspective family says babatunde osotimehin bring enthusiasm strategic planning willingness try implement md executive director unfpa innovative approaches says sharon united nations population fund important dagostino vice president worldwide corporate contributions community holistic way dealing poverty relations bring rigor metrics evaluation work help factors make women children vulnerable programs demonstrate measurable particularly program countries women outcomes provides organizations data attract additional sources children live funding unfpa together unaids subsaharan africa companys diverse partners unicef world bank world south asia every woman dies aligned strategic mission health organization make around seriously injured making lifechanging longterm h partnership coordinated suffer disabilities every day differences human health initiative ensures international newborns die within first recognize closest organizations work together womens days life pressing health care concerns best able childrens health local deaths prevented address local needs says dagostino programs johnson johnson factors including poor health infra example japan became first private sector partner structure lack qualified health johnson johnson supports support h workers mean basic organization called resilience happy natural act giving life instead becomes provides assistance women johnson johnson first private cause deatha time hope involved gone abusive sector organization coming forward future instead becomes time family relationships resilience offers session true partner initiative says crisis despair series workshops lectures aim dr osotimehin believe ethiopia tanzania areas educate survivors abuse enable support johnson johnson risk mothers newborns high heal better make even bigger difference governments commitments equipped reenter community start ground save lives improving maternalchild health working build new relationships strong h johnson johnson could get connected others building legacy caring providing training programs areas able provide support partnership h one health care workers critical care needed think could change component response united reach mothers newborns world bit bit says sachi nakajima nations secretary generals call action organizations founder renewed global effort achieve working communitybased survivor millennium development goals organizations says joy marini director corporate johnson johnson inspired relationships gro w contributions johnson johnson credo partner hundreds many partner relationships grow efforts keeping long organizations caring people time ways contribute peoples standing commitment health throughout world company lives planet business one wellbeing mothers children works partners programs longstanding collaboration global maternal mortality countries helping world wildlife fund wwf reduced onethird past implement new approaches often years ago johnson johnson years h members report every enable programs expand reach became early adopter wwf day approximately women die people employees around climate savers program company pregnancy complications childbirth world volunteer time skills set goal achieve percent absolute johnson johnson annual reportcaring women children dr babatunde osotimehin executive director unfpa greatest hope h collaboration make difference lives people serve says bring efforts together synergy lot individual organizations reduction co emissions wwfs healthy communities healthy way wwf provided critical johnson johnson ecosystems program africa input responsible sourcing policy surpassed goal achieving absolute links health environment palm oil johnson johnson working reduction percent health local people johnson johnson wwf identify opportunities johnson johnson set really high bar also early participant wwfs support projects promote sustainable time companies global forest trade network focused practices field setting greenhouse gas reduction targets reliable sustainable sourcing johnson johnson says suzanne apple vice president paper wood products working number areas business industry wwf sent strong company paper pulp important us says apple message companies participate business apple says johnson johnson joining forces bigger collaboration expanded sent strong message time impact creating sustainable include philanthropic commitment suppliers came table future planet johnson johnson annual report first row left right board directors william c weldon chairman board directors chief executive officer chairman executive committee mary sue coleman phd president university michigan james g cullen retired president chief operating officer bell atlantic corporation second row left right ian el davis senior advisor apax partners former chairman worldwide managing director mckinsey company michael johns md chancellor emory university susan l lindquist phd member former director whitehead institute biomedical research professor biology massachusetts institute technology third row left right anne mulcahy former chairman chief executive officer xerox corporation leo f mullin retired chairman chief executive officer delta air lines inc william perez senior advisor greenhill co inc retired president chief executive officer wm wrigley jr company fourth row left right charles prince retired chairman chief executive officer citigroup inc david satcher md phd director center excellence health disparities director satcher health leadership institute poussaintsatcher cosby chair mental health morehouse school medicine former us surgeon general ronald williams former chairman chief executive officer aetna inc johnson johnson annual reportnominating corporate governance committees nominating corporate governance committee composed entirely independent directors responsible board overseeing corporate governance matters reviewing possible candidates board membership recommending nominees election committee also responsible overseeing process performance evaluations board committees additionally committee reviews companys executive succession plans executive resources audit william perez chairman audit committee composed entirely independent james g cullen directors helps board oversee companys financial anne mulcahy accounting reporting practices recommends charles prince independent public auditor appointment board reviews performance addition committee monitors adequacy internal accounting practices procedures public policy controls reviews companys financial reporting process public policy advisory committee reviews companys disclosure procedures helps board oversee policies programs practices public health issues companys legal compliance programs regarding environment health safety employees committee also reviews companys james g cullen chairman governmental affairs policies public policy issues mary sue coleman phd facing company committee advises makes ian el davis recommendations board issues appropriate leo f mullin public policy advisory committee composed independent directors one companys vice chairmen compensation benefits executive committee vice presidents global compensation benefits committee composed entirely corporate affairs government affairs policy independent directors establishes companys executive global supply chain compensation philosophy principles approves leo f mullin chairman annual compensation longterm incentives ian el davis companys directors executive officers committee susan l lindquist phd also reviews philosophy policies nonboard david satcher md phd management compensation committee determines ronald williams management compensation establishes perquisites compensation policies nonexecutive employees alex gorsky additionally committee oversees management clifford e holland various retirement pension longterm incentive savings robert salerno health welfare plans cover companys employees michael e sneed charles prince chairman science technology michael johns md science technology advisory committee composed anne mulcahy independent directors companys vice president william perez science technology helps board scientific matters ronald williams impacting companys business including monitoring strategy effectiveness companys research finance development organization reviewing effectiveness finance committee exercises authority board scientific aspects companys product safety processes intervals board meetings finance overseeing major business development activities related committee composed chairman board acquisition new science technology identifying presiding director understanding significant new science technology policy issues trends william c weldon chairman james g cullen david satcher md phd chairman mary sue coleman phd michael johns md susan l lindquist phd garry neil md johnson johnson annual report board directors corporate officers executive committee william c weldon alex gorsky executive committee johnson johnson chairman board directors vice chairman principal management group responsible chief executive officer executive committee strategic operations allocation chairman executive committee sherilyn mccoy resources company committee oversees vice chairman coordinates activities consumer dominic j caruso vice president finance executive committee pharmaceuticals medical devices diagnostics chief financial officer business segments john papa executive committee treasurer douglas k chia michael h ullmann corporate secretary vice president assistant general counsel general counsel executive committee stephen j cosgrove corporate controller chief accounting officer peter fasolo vice president global human resources executive committee worldwide chairmen company group chairmen jesse j wu charles e austin consumer group roberto de marques joaquin duato michael jf del prado paul stoffels md grace del rosario castano pharmaceuticals group seth hz fischer karen licitra gary p fischetti global medical solutions jane griffiths group william n hait md phd gary j pruden jose antonio justino global surgery group guy j lebeau md ashley mcevoy patrick mutchler michel paul jacques peeters pericles p stamatiades jennifer l taubert kim taylor nicholas j valeriani johnson johnson annual reportcorporategovernanceandmanagementsresponsibility johnsonjohnsonisguidedbythevaluessetforthinourcredo pricewaterhousecoopersllpanindependentregisteredpublic createdbygeneralrobertwoodjohnsonintheseprinciples accountingfirmisengagedtoperformanintegratedauditofour haveguidedusovertheyearsandcontinuetosetthetoneof consolidatedfinancialstatementsandinternalcontroloverfinancial integrityfortheentirecompanyatalllevelstheemployeesof reportingthereportofindependentregisteredpublicaccounting johnsonjohnsonarecommittedtotheethicalprinciplesembod firmisonpage iedinourcredoandtheseprincipleshavebeenwovenintothe theauditcommitteeofourboardofdirectorsiscomposed fabricofthecompany solelyofindependentdirectorswiththefinancialknowledgeand thevaluesarticulatedinourcredoextendtoouraccounting experiencetoprovideappropriateoversightwereviewinternal andfinancialresponsibilitiestojohnsonjohnsonshareholders controlmattersandkeyaccountingandfinancialreportingissues andinvestorswethemanagementofjohnsonjohnsonare withtheauditcommitteeonaregularbasisinadditiontheinde responsiblefortheintegrityandobjectivityoftheaccompanying pendentauditorsthegeneralcounselthechieffinancialofficer financialstatementsandrelatedinformationwearealsoresponsi thechiefcomplianceofficerandthevicepresidentofinternal bleforensuringthatfinancialdataisreportedaccuratelyandina auditregularlymeetinprivatesessionswithourauditcommittee mannerthatfacilitatestheunderstandingofthisdata todiscusstheresultsoftheirworkincludingobservationsonthe asevidenceofourcommitmenttothisresponsibilitywe adequacyofinternalfinancialcontrolsthequalityoffinancial maintainawelldesignedsystemofinternalaccountingcontrols reportingandconfirmationthattheyareproperlydischargingtheir encouragestrongandeffectivecorporategovernancefromour responsibilitiesandotherrelevantmatters boardofdirectorscontinuouslyreviewourbusinessresultsand ourexecutivecommitteeiscontinuouslyinvolvedinthe strategicchoicesandfocusonfinancialstewardship reviewoffinancialresultsaswellasdevelopingandunderstanding ourcorporatestaffofprofessionallytrainedinternalauditors strategiesandkeyinitiativesforlongtermgrowthourintentisto whotravelworldwidemonitoroursystemofinternalaccounting ensurethatwemaintainobjectivityinourbusinessassessments controlsdesignedtoprovidereasonableassurancethatassetsare constructivelychallengetheapproachtobusinessopportunitiesand safeguardedandthattransactionsandeventsarerecordedproperly issuesandmonitorourbusinessresultsandtherelatedcontrols ourinternalcontrolsincludeselfassessmentsandinternalreviews ourconsolidatedfinancialstatementsandfinancialdatathat ofouroperatingcompanies followhavebeenpreparedinconformitywithaccountingprinciples duringthecompanycontinuedtoinvestsignificanttime generallyacceptedintheunitedstatesofamericaandinclude andresourcesinordertoensurecompliancewithsectionof amountsthatarebaseduponourbestjudgmentswearecommit thesarbanesoxleyactofbasedontheworkperformedwe tedtopresentanddiscussresultsofoperationsinaclearand haveconcludedthatourinternalcontroloverfinancialreporting transparentmannerinordertoprovidetimelycomprehensiveand waseffectiveasofjanuarywereferyoutomanagements understandableinformationtoourshareholders reportoninternalcontroloverfinancialreportingonpage werequirethemanagementteamsofouroperatingcompa niestocertifytheircompliancewithourpolicyonbusinessconduct whichsetsforththecompanyscommitmenttoconductitsbusi nessaffairswithintegrityandcomplywiththegoverninglawsand regulationswehaveasystematicprogramdesignedtoensure compliancewiththesepoliciesandprovidemeansofreportingany concernsaboutviolationsofthepolicypleasevisitourwebsiteat williamcweldon dominicjcaruso wwwinvestorjnjcomgovernanceconductcfmtoviewourpolicy chairmanboardofdirectors vicepresidentfinance onbusinessconduct andchiefexecutiveofficer andchieffinancialofficer tableofcontents managementsdiscussionandanalysis auditedconsolidatedfinancialstatements organizationandbusinesssegments consolidatedbalancesheets resultsofoperations consolidatedstatementsofearnings analysisofsalesbybusinesssegments consolidatedstatementsofequity analysisofconsolidatedearningsbeforeprovision consolidatedstatementsofcashflows fortaxesonincome notestoconsolidatedfinancialstatements liquidityandcapitalresources reportofindependentregisteredpublicaccountingfirm otherinformation managementsreportoninternalcontrolover cautionaryfactorsthatmayaffectfutureresults financialreporting supportingschedules summaryofoperationsandstatisticaldata shareholderreturnperformancegraphs reconciliationofnongaapfinancialmeasures johnson johnson annual report managementsdiscussionandanalysisofresultsofoperationsandfinancialcondition organizationandbusinesssegments managementsobjectives thecompanymanageswithinastrategicframeworkaimedat descriptionofthecompanyandbusinesssegments achievingsustainablegrowthtoaccomplishthisthecompanys johnsonjohnsonanditssubsidiariesthecompanyhave managementoperatesthebusinessconsistentwithcertainstrate approximatelyemployeesworldwideengagedinthe gicprinciplesthathaveprovensuccessfulovertimetothisendthe researchanddevelopmentmanufactureandsaleofabroadrange companyparticipatesingrowthareasinhumanhealthcareandis ofproductsinthehealthcarefieldthecompanyconductsbusiness committedtoattainingleadershippositionsinthesegrowthareas invirtuallyallcountriesoftheworldwiththeprimaryfocuson throughthedevelopmentofhighqualityinnovativeproductsand productsrelatedtohumanhealthandwellbeing servicesnewproductsintroducedwithinthepastfiveyears thecompanyisorganizedintothreebusinesssegments accountedforapproximatelyofsalesinbillion consumerpharmaceuticalandmedicaldevicesanddiagnostics orofsaleswasinvestedinresearchanddevelopmentthis theconsumersegmentincludesabroadrangeofproductsusedin investmentreflectsmanagementscommitmenttotheimportance thebabycareskincareoralcarewoundcareandwomenshealth ofongoingdevelopmentofnewanddifferentiatedproductsand fieldsaswellasnutritionalandoverthecounterpharmaceutical servicestosustainlongtermgrowth productsandwellnessandpreventionplatformstheseproducts withmorethanoperatingcompanieslocatedin aremarketedtothegeneralpublicandsoldbothtoretailoutlets countriesthecompanyviewsitsprincipleofdecentralizedman anddistributorsthroughouttheworldthepharmaceuticalsegment agementasanassetandfundamentaltothesuccessofabroadly includesproductsinthefollowingareasantiinfectiveantipsy basedbusinessitalsofostersanentrepreneurialspiritcombining choticcontraceptivedermatologygastrointestinalhematology theextensiveresourcesofalargeorganizationwiththeabilityto immunologyneurologyoncologypainmanagementthrombosis anticipateandreactquicklytolocalmarketchangesandchallenges vaccinesandinfectiousdiseasestheseproductsaredistributed thecompanyiscommittedtodevelopingglobalbusinesslead directlytoretailerswholesalersandhealthcareprofessionalsfor erswhocanachievegrowthobjectivesbusinessesaremanagedfor prescriptionusethemedicaldevicesanddiagnosticssegment thelongterminordertosustainleadershippositionsandachieve includesabroadrangeofproductsdistributedtowholesalershos growththatprovidesanenduringsourceofvaluetoourshareholders pitalsandretailersusedprincipallyintheprofessionalfieldsby ourcredounifiesthemanagementteamandthecompanys physiciansnursestherapistshospitalsdiagnosticlaboratoriesand dedicatedemployeesinachievingtheseobjectivesandprovidesa clinicstheseproductsincludecardiovascularcareselectrophysi commonsetofvaluesthatserveasaconstantreminderofthe ologyandcirculatorydiseasemanagementproductsdepuys companysresponsibilitiestoitscustomersemployeescommuni orthopaedicjointreconstructionspinalcareneurologicaland tiesandshareholdersthecompanybelievesthatthesebasic sportsmedicineproductsethiconssurgicalcareaestheticsand principlesalongwithitsoverallmissionofimprovingthequality womenshealthproductsethiconendosurgerysminimallyinva oflifeforpeopleeverywherewillenablejohnsonjohnsonto sivesurgicalproductsandadvancedsterilizationproductsdiabetes continuetobeamongtheleadersinthehealthcareindustry caresbloodglucosemonitoringandinsulindeliveryproducts orthoclinicaldiagnosticsprofessionaldiagnosticproductsand resultsofoperations visioncaresdisposablecontactlenses thecompanysstructureisbasedupontheprincipleof analysisofconsolidatedsales decentralizedmanagementtheexecutivecommitteeof inworldwidesalesincreasedtobillioncompared johnsonjohnsonistheprincipalmanagementgroupresponsible todecreasesofinandinthesesales forthestrategicoperationsandallocationoftheresourcesofthe changesconsistedofthefollowing companythiscommitteeoverseesandcoordinatestheactivities oftheconsumerpharmaceuticalandmedicaldevicesand salesdecreaseincreasedueto volume diagnosticsbusinesssegments inallofitsproductlinesthecompanycompeteswithcompa price niesbothlocallyandgloballythroughouttheworldcompetition currency existsinallproductlineswithoutregardtothenumberandsizeof total thecompetingcompaniesinvolvedcompetitioninresearchinvolv ingthedevelopmentandtheimprovementofnewandexisting salesbyuscompanieswerebillioninbillionin productsandprocessesisparticularlysignificantthedevelopment andbillioninthisrepresentsdecreasesof ofnewandinnovativeproductsisimportanttothecompanyssuc ininandinsalesbyinternational cessinallareasofitsbusinessthisalsoincludesprotectingthe companieswerebillioninbillioninand companysportfolioofintellectualpropertythecompetitiveenvi billioninthisrepresentsanincreaseofin ronmentrequiressubstantialinvestmentsincontinuingresearchand anincreaseofinandadecreaseofin inmaintainingsalesforcesinadditionthedevelopmentandmain tenanceofcustomerdemandforthecompanysconsumerproducts involvessignificantexpendituresforadvertisingandpromotion johnson johnson annual reportintheminimummedicaidrebateratefromtoandalso usand extendedtherebatetodrugsprovidedthroughmedicaidmanaged internationalsales careorganizationsadditionallyindiscountswereprovided foryears inbillionsofdollars onthecompanysbrandnamedrugstopatientswhofallwithinthe medicarepartdcoveragegapdonutholetheimpactwasan us increaseinsalesrebatesreducingsalesrevenuebyapproximately international millionandmillioninandrespectively incompaniesthatsellbrandedprescriptiondrugstospeci fiedusgovernmentprogramspaidanannualnontaxdeductiblefee basedonanallocationofthecompanysmarketshareoftotalbranded prescriptiondrugsalesfromtheprioryearthefullyearimpactto sellingmarketingandadministrativeexpenseswasmillionunder thecurrentlawbeginninginthecompanywillberequiredtopay thefiveyearcompoundannualgrowthratesforworldwide ataxdeductibleexcisetaximposedonthesaleofcertainmedical usandinternationalsaleswereandrespec devicesthetaxisestimatedtobebetweenmillion tivelythetenyearcompoundannualgrowthratesforworldwide andwillberecordedinsellingmarketingandadministrativeexpenses usandinternationalsaleswereandrespectively salesby segment salesby geographic inbillionsofdollars region inbillionsofdollars consumer pharmaceutical us medicaldevices e wu ero sp tee rnhemisphere anddiagnostics excludingus asia pacificafrica analysisofsalesbybusinesssegments salesineuropeachievedgrowthofascomparedtothe prioryearincludingoperationalgrowthofandapositiveimpact consumersegment fromcurrencyofsalesinthewesternhemisphereexcluding consumersegmentsalesinwerebillionanincreaseof theusachievedgrowthofascomparedtotheprioryear fromaoperationaldeclinewasoffsetbyapositive includingoperationalgrowthofandapositiveimpactfrom currencyimpactofusconsumersegmentsaleswere currencyofsalesintheasiapacificafricaregionachieved billionadecreaseofinternationalsaleswerebillion growthofascomparedtotheprioryearincludingoperational anincreaseofwhichincludedoperationalgrowthanda growthofandapositiveimpactfromcurrencyof positivecurrencyimpactof inandthecompanydidnothaveacustomer theoverthecounterotcpharmaceuticalsandnutritionals thatrepresentedormoreoftotalconsolidatedrevenues franchisesaleswerebillionadecreaseoffrom theresultsbenefitedfromtheinclusionofardweek salesintheuswerenegativelyimpactedbythesuspensionofpro seenotetotheconsolidatedfinancialstatementsforannual ductionatmcneilconsumerhealthcaresfortwashingtonpenn closingdatedetailsthecompanyestimatedthatthefiscalyear sylvaniafacilityaswellastheimpactonproductionvolumesrelated growthratewasenhancedbyapproximatelyduetothe toongoingeffortstoenhancequalityandmanufacturingsystemsat rdweek itsothermanufacturingsites duringthefiscalfirstquarterofaconsentdecreewas ushealthcarereform signedwiththeusfoodanddrugadministrationfdawhichgov thepatientprotectionandaffordablecareactandthehealthcare ernscertainmcneilconsumerhealthcaremanufacturingoperations andeducationreconciliationactofweresignedintolawin theconsentdecreeidentifiesproceduresthatwillhelpprovideaddi marchthehealthcarereformlegislationincludedanincrease tionalassuranceofproductqualitytothefdamcneilcontinuesto majorconsumerfranchisesales change dollarsinmillions vs vs otcpharmaceuticalsnutritionals skincare babycare womenshealth oralcare woundcareother total managements discussion analysis results operations financial condition operatethemanufacturingfacilitiesinlaspiedraspuertoricoand procritepoetinalfaandeprexepoetinalfahadcom lancasterpennsylvaniahoweverproductionvolumesfromthesefacil binedsalesofbillioninadeclineofcomparedtothe itieshavebeenimpactedduetotheadditionalreviewandapproval prioryearlowersalesofprocritandeprexwereprimarilydue processesrequiredregardingtheproductspreviouslyproducedatthe toadecliningmarketforerythropoiesisstimulatingagentsesas fortwashingtonfacilitymcneilcontinuestoworkontheresitingof andincreasedcompetitionforeprex theseproductstootherfacilitiesmcneilismakingprogressonthe risperdalconstarisperidonealongactinginjectable validationsatthesealternativesitesandamodestamountofproducts antipsychoticachievedsalesofbillioninrepresentingan returnedtothemarketinthefourthquarterofproductswill increaseofascomparedtotheprioryearduetointernational continuetobereintroducedthroughoutand growthtotalussalesofthecompanyslongactinginjectables theskincarefranchiseachievedsalesofbillionin includingrisperdalconstaandinvegasustenna aincreaseascomparedttootheprioryearprimarilyduetogrowth paliperidonepalmitateincreasedbystrongdoubledigitsversus intheneutrogenadabaojohnsonsadultandlepetit ayearagoduetoanincreaseinthecompanyscombinedmarket marseillaisproductlinesthebabycarefranchisesalesgrew shareintheantipsychoticmarket bytobillioninprimarilyduetogrowthincleansers velcadebortezomibaproductforthetreatmentof wipesandhaircarethewomenshealthfranchisesaleswere multiplemyelomaforwhichthecompanyhascommercialrights billionadecreaseofprimarilyimpactedbythedivestiture inmarketsoutsidetheusachievedsalesofbillionin ofcertainbrandstheoralcarefranchisesalesgrewbyto representinganincreaseofprimarilyduetostronggrowth billioninprimarilyduetoincreasedsalesoflisterine inasiaandlatinamerica productsthewoundcareotherfranchisesaleswerebillion concertamethylphenidatehclsaleswerebilliona inflatascomparedtotheprioryear declineofcomparedtotheprioryeartheussupplyanddis consumersegmentsalesinwerebillionadecrease tributionagreementwithwatsonlaboratoriesinctodistributean offromwithofthischangeduetoanoperational authorizedgenericversionofconcertabecameeffectivemay declinepartiallyoffsetbypositivecurrencyimpactofuscon allregionsoutsidetheusachievedsalesgrowth sumersegmentsaleswerebillionadecreaseofinterna prezistadarunaviraproteaseinhibitorforthetreatment tionalsaleswerebillionanincreaseofwithanoperational ofhivachievedsalesofbillioninrepresentingan declineofoffsetbypositivecurrencyimpactof increaseofascomparedtotheprioryearprimarilydueto marketsharegrowth pharmaceuticalsegment aciphexparietrabeprazolesodiumsaleswere thepharmaceuticalsegmentachievedsalesofbillionin billionadeclineofversustheprioryearduetoincreased representinganincreaseofovertheprioryearwithopera competitionfromgenericsinthecategory tionalgrowthofandapositivecurrencyimpactof levaquinlevofloxacinfloxinofloxacinsaleswere ussaleswerebillionadecreaseofinternational billionadeclineofversustheprioryearduetotheloss saleswerebillionanincreaseofwhichincluded ofmarketexclusivityintheusinjunelevaquinsales operationalgrowthandapositivecurrencyimpactof willcontinuetodeclineinthefirsthalfofversusthefirsthalf remicadeinfliximababiologicapprovedforthetreatment ofanumberofimmunemediatedinflammatorydiseasesachieved inotherpharmaceuticalsaleswerebillionrepre salesofbillioninwithgrowthofovertheprioryearon sentinggrowthofovertheprioryearcontributorstothe acombinedbasisusexportandinternationalsalesofremicade increaseweresalesofnewlyacquiredproductsfromcrucellnv increasednearlyduetotheimpactoftheagreementwithmerck crucellandnewlyapprovedproductsincludingzytiga coincmerckcomplementedbyinternationalmarketgrowth abirateroneacetateandincivotelapreviradditionalcontrib onaprilthecompanyannounceditreachedanagreement utorstothegrowthwerestelaraustekinumabinvega withmerckwhichincludeddistributionrightstoremicadeand sustennapaliperidonepalmitatesimponigolimumab simponigolimumabwherebyeffectivejulycertainterrito nucyntatapentadolandintelenceetravirinethis rieswererelinquishedtothecompanyonjulythecompany growthwaspartiallyoffsetbylowersalesofduragesicfentanyl begantorecordsalesofproductpreviouslyrecordedbymerckfrom transdermalfentanyltransdermalsystemandtopamax certainterritoriesincludingcanadabrazilaustraliaandmexico topiramateduetocontinuedgenericcompetition whichwerepreviouslysuppliedbymerck majorpharmaceuticalproductsales change dollarsinmillions vs vs remicadeinfliximab procriteprexepoetinalfa risperdalconstarisperidone velcadebortezomib concertamethylphenidatehcl prezistadarunavir aciphexparietrabeprazolesodium levaquinfloxinlevofloxacinofloxacin otherpharmaceuticals total prioryearamountshavebeenreclassifiedtoconformtocurrentpresentation johnson johnson annual reportduringthecompanyreceivedseveralregulatoryapprovals theethiconendosurgeryfranchiseachievedsalesofbillion includingusapprovalfortwoindicationsforxareltorivaroxa inaincreaseovertheprioryeargrowthwasattributable banananticoagulantcodevelopedwithbayerhealthcarethe toincreasedsalesofadvancedsterilizationandharmonicprod firstoneforthepreventionprophylaxisofdeepveinthrombosis uctlinesandoutsidetheustheendomechanicalproductline dvtwhichmayleadtoapulmonaryembolismpeinpeople additionallysalesofnewlyacquiredproductsfromsterilmedcon undergoingkneeorhipreplacementsurgeryandthesecondoneto tributedtothegrowthtotalgrowthwasnegativelyimpactedbythe reducetheriskofstrokeandsystemicembolisminpatientswithnon divestitureofthebreastcarebusinessinthethirdquarterof valvularatrialfibrulationedurantrilpivirineinboththeus theethiconfranchiseachievedsalesofbillionin andtheeuropeanunioneuforhivintreatmentnavepatients anincreaseovertheprioryearemergingmarketgrowth incivotelaprevirintheeuforthetreatmentofhepatitiscvirus insuturesnewlylaunchedproductsethiconphysiomeshand andzytigaabirateroneacetateintheusandeuforthetreat ethiconsecurestrapandgrowthinthebiosurgicalwomens mentofmetasticcastrationresistantprostatecancerinaddition healthandurologyandacclarentproductlinescontributedtothe thefdaapprovedadditionalindicationsforremicadeinflix increaseinsales imabforthetreatmentofmoderatelytoseverelyactiveulcerative thevisioncarefranchiseachievedsalesofbillionin colitisinpediatricpatientsandnucyntaertapentadol anincreaseovertheprioryearcontributorstothegrowth extendedreleasetabletsanoralanalgesicforthemanagementof weredayacuvueandastigmatismlenses moderatetoseverechronicpaininadults thediabetescarefranchiseachievedsalesofbillionin thecompanysubmittednewdrugapplicationsndasto aincreaseovertheprioryearthegrowthwasprimarily thefdaseekingapprovalfortheuseofxareltorivaroxaban duetosalesintheonetouchproductline anoralanticoagulanttoreducetheriskofthromboticcardio salesinthecardiovascularcarefranchisewerebilliona vasculareventsinpatientswithacutecoronarysyndromeandfor declineofversustheprioryearsaleswereimpactedbythe nucyntaertapentadolextendedreleasetabletsanoral companysdecisiontoexitthedrugelutingstentmarketandlower analgesicforthemanagementofneuropathicpainassociatedwith salesofendovascularproductsduetoincreasedcompetitionsales diabeticperipheralneuropathyinadults fordrugelutingstentswereapproximatelyandofthetotal pharmaceuticalsegmentsalesinwerebilliona cardiovascularcarefranchisesalesinandrespectively decreaseoffromwithanoperationaldeclineof thedeclineinsaleswaspartiallyoffsetbystronggrowthin andapositivecurrencyimpactofussaleswerebillion biosensewebsterthecompanyselectrophysiologybusiness adecreaseofinternationalsaleswerebillionan theorthoclinicaldiagnosticsfranchiseachievedsalesof increaseofwhichincludedoperationalgrowthanda billioninaincreaseovertheprioryearthegrowth positivecurrencyimpactof wasprimarilyattributabletothestrengthofthevitrosand analyzerspartiallyoffsetbylowersalesindonorscreening medicaldevicesanddiagnosticssegment themedicaldevicesanddiagnosticssegmentachievedsales themedicaldevicesanddiagnosticssegmentachievedsalesof ofbillioninrepresentinganincreaseofoverthe billioninrepresentinganincreaseofovertheprior prioryearwithoperationalgrowthofandapositivecurrency yearwithoperationalgrowthofandapositivecurrencyimpact impactofussaleswerebillionanincreaseof ofussaleswerebillionadecreaseofascom overtheprioryearinternationalsaleswerebillionanincrease paredtotheprioryearinternationalsaleswerebillionan ofovertheprioryearwithgrowthoffromoperations increaseofovertheprioryearwithoperationalgrowthof andapositivecurrencyimpactof andapositivecurrencyimpactof thedepuyfranchiseachievedsalesofbillionina analysisofconsolidatedearnings increaseovertheprioryearthisgrowthwasprimarilydueto beforeprovisionfortaxesonincome salesofmiteksportsmedicineandtraumaproductlinesandnewly acquiredproductsfrommicrusthegrowthwaspartiallyoffsetby consolidatedearningsbeforeprovisionfortaxesonincome lowersalesofkneesandhipsintheusduetoincreasedcompeti decreasedbybilliontobillioninascomparedto tioncontinuedpricingpressureasoftermarketandtheimpactof billioninadecreaseofthedecreasewasprimarily thedepuyasrhiprecall duetocostsassociatedwithproductliabilityandlitigationexpenses theimpactoftheotcanddepuyasrhiprecallsandtherestruc turingexpenserelatedtothecardiovascularcarebusinessaddi tionallyinvestmentspendingthefeeonbrandedpharmaceutical majormedicaldevicesanddiagnosticsfranchisesales change dollarsinmillions vs vs depuy ethiconendosurgery ethicon visioncare diabetescare cardiovascularcare orthoclinicaldiagnostics total previouslyreferredtoascordis managements discussion analysis results operations financial condition productsincurredduetotheushealthcarereformlegislationand incostofproductssoldasapercenttosalesincreasedcom theintegrationcostsincludinganinventorystepupchargeassoci paredtotheprioryearthiswasprimarilyattributabletoongoing atedwiththeacquisitionofcrucellcontributedtothedecreasein remediationcostsintheconsumerotcbusinessandinventory earningsthiswaspartiallyoffsetbygainsfromdivestitures writeoffsduetotherestructuringofthecardiovascularcarebusi theincreaseofascomparedtowasprimarily nessinadditionlowermarginsandintegrationcostsincludingan relatedtolowersellingmarketingandadministrativeexpensesdue inventorystepupchargeassociatedwiththeacquisitionofcrucell tocostcontainmentactionsresultingfromtherestructuringplanini negativelyimpactedcostofproductssoldpercenttosalesofsell tiatedandimplementedinincomefromlitigationsettlements ingmarketingandadministrativeexpensesincreasedincom andthegainonthedivestitureofthebreastcarebusinessofethicon paredtotheprioryearprimarilyduetoinvestmentspendingaswell endosurgeryincthiswaspartiallyoffsetbycostsassociatedwith asthefeeonbrandedpharmaceuticalproductsincurredduetothe productliabilityexpenseandtheimpactoftheotcanddepuy ushealthcarereformlegislation asrhiprecallsadditionaloffsetswerelowernetsellingpricesin incostofproductssoldasapercenttosalesincreased thepharmaceuticalbusinessduetoushealthcarereformlegisla comparedtotheprioryearprimarilyduetocostsassociatedwith tionandpricereductionsincertainmedicaldevicesanddiagnostics theimpactoftheotcrecallandremediationeffortsinthecon businessesthedecreaseofascomparedto sumerbusinesslowernetsellingpricesinthepharmaceuticalbusi wasprimarilyrelatedtolowersalesthenegativeimpactofproduct nessduetoushealthcarereformlegislationandpricereductions mixlowerinterestincomeduetolowerratesofinterestearned incertainmedicaldevicesanddiagnosticsbusinessesaddition andrestructuringchargesofbillionthiswaspartiallyoffsetby allyunfavorableproductmixattributabletothelossofmarket lowersellingmarketingandadministrativeexpensesduetocost exclusivityfortopamaxcontributedtotheincreasetherewasa containmenteffortsacrossallthebusinessesasapercenttosales decreaseinthepercenttosalesofsellingmarketingandadminis consolidatedearningsbeforeprovisionfortaxesonincomein trativeexpensesincomparedtotheprioryearprimarilydueto wasversusin costcontainmentinitiativesprincipallyresultingfromtherestruc thesectionsthatfollowhighlightthesignificantcomponents turingplanimplementedinthedecreasewaspartiallyoffset ofthechangesinconsolidatedearningsbeforeprovisionfortaxes bylowernetsellingpricesinthepharmaceuticalbusinessdueto onincome ushealthcarereformlegislationandpricereductionsincertain medicaldevicesanddiagnosticsbusinesses costofproductssoldandsellingmarketingandadministrative incostofproductssoldasapercenttosalesincreased expensescostofproductssoldandsellingmarketingand comparedtotheprioryearprimarilyduetothecontinuednegative administrativeexpensesasapercenttosaleswereasfollows impactofproductmixandinventorywriteoffsassociatedwith ofsales therestructuringactivityadditionallyincludedcertainnon costofproductssold recurringpositiveitemstherewasadecreaseinthepercentto percentpointincreaseovertheprioryear salesofsellingmarketingandadministrativeexpensesin comparedtotheprioryearprimarilyduetocostcontainmentefforts sellingmarketingandadministrativeexpenses acrossallthebusinessesandtheannualizedsavingsrecognized percentpointincreasedecreaseoverthe fromtherestructuringprograminadditioninthe prioryear companyutilizedtheproceedsassociatedwiththedivestitureof theprofessionalwoundcarebusinessofethiconinctofund increasedinvestmentspending researchanddevelopmentexpensebysegmentofbusinesswasasfollows dollarsinmillions amount ofsales amount ofsales amount ofsales consumer pharmaceutical medicaldevicesanddiagnostics totalresearchanddevelopmentexpense percentincreasedecreaseovertheprioryear asapercenttosegmentsales researchanddevelopmentexpenseresearchanddevelopment restructuringincordiscorporationasubsidiaryof activitiesrepresentasignificantpartofthecompanysbusiness johnsonjohnsonannouncedthediscontinuationofitsclinical theseexpendituresrelatetotheprocessesofdiscoveringtesting developmentprogramforthenevosirolimuselutingcoronary anddevelopingnewproductsimprovingexistingproductsaswell stentandcessationofthemanufactureandmarketingofcypher asensuringproductefficacyandregulatorycompliancepriorto andcypherselectplussirolimuselutingcoronarystentsby launchthecompanyremainscommittedtoinvestinginresearch theendofthecompanywillfocusonothercardiovascular anddevelopmentwiththeaimofdeliveringhighqualityandinnova therapieswheresignificantpatientneedsexistinthefiscalsecond tiveproductsinworldwidecostsofresearchanddevelopment quarterofthecompanyrecordedapretaxchargeof activitiesincreasedbycomparedtotheincreasein millionofwhichmillionisincludedincostofproductssold thepharmaceuticalsegmentwasprimarilyduetohigherlevelsof inthecompanyannouncedglobalrestructuringinitiatives spendingtoadvancethecompanyspharmaceuticalpipelinethe expectedtogeneratepretaxannualcostsavingsofapproximately decreaseinthemedicaldevicesanddiagnosticssegmentwasdue billionwhenfullyimplementedtheassociatedsavingshaspro tothediscontinuationofitsclinicaldevelopmentprogramforthe videdadditionalresourcestoinvestinnewgrowthplatformsensure nevosirolimuselutingcoronarystent thesuccessfullaunchofthecompanysmanynewproductsand johnson johnson annual reportcontinuedgrowthofthecorebusinessesandprovideflexibilityto costsassociatedwiththerecallofcertainotcproductspartially adjusttothechangedandevolvingglobalenvironmentinthefiscal offsetbythegainonthedivestitureofmonistatin fourthquarterofthecompanyrecordedapretaxchargeof consumersegmentoperatingprofitdecreasedfrom billionofwhichmillionwasincludedincostofproductssold theprimaryreasonsforthedecreaseintheoperatingprofitwere seenotetotheconsolidatedfinancialstatementsfor lowersalesandhighercostsassociatedwiththerecallofcertain additionaldetailsrelatedtotherestructuring otcproductsandthesuspensionofproductionatmcneil consumerhealthcaresfortwashingtonpennsylvaniafacility otherincomeexpensenetotherincomeexpensenet includesroyaltyincomegainsandlossesrelatedtothesaleand pharmaceuticalsegmentinpharmaceuticalsegment writedownofcertaininvestmentsinequitysecuritiesheldby operatingprofitdecreasedfromtheprimarydriversof johnsonjohnsondevelopmentcorporationgainsandlosseson thedecreaseintheoperatingprofitmarginwerehigherlitigation thedisposalofpropertyplantandequipmentcurrencygainsand expensesrecordedintheimpactoftheushealthcare lossesnoncontrollinginterestsandlitigationsettlementsin reformfeeandlowermarginsandintegrationcostsincludingan theunfavorablechangeofbillioninotherincomeexpense inventorystepupchargeassociatedwiththecrucellacquisition netwasprimarilyduetolitigationexpensesofbillioninas thiswaspartiallyoffsetbygainsonthedivestituresoftheanimal comparedtoabillionnetgainfromlitigationsettlementsin healthbusinessandorthodermatologicsthegainrelatedtothe additionallyascomparedtoincludedhigher companysearlierinvestmentincrucellandlowermanufacturing expensesofbillionrelatedtoproductliabilitybillionfor costsinpharmaceuticalsegmentoperatingprofitincreased costsrelatedtothedepuyasrhiprecallprogramandanadjust fromtheprimaryreasonsfortheincreaseinoperating mentofbilliontothevalueofthecurrencyoptionanddeal profitwerelowermanufacturingcoststhegainonadivestitureand costsrelatedtotheplannedacquisitionofsynthesincincluded benefitsfromcostimprovementinitiativesrelatedtotherestruc inwerehighergainsonthedivestituresofbusinessesof turingplanimplementedinpartiallyoffsetbymillion billionascomparedto ofexpenserelatedtolitigationmattersincreasedproductliability inthefavorablechangeofbillioninotherincome expenseandtheimpactofthenewlyenactedushealthcare expensenetascomparedtowasprimarilyduetoanetgain reformlegislation fromlitigationsettlementsandgainsonthedivestitureofbusinesses medicaldevicesanddiagnosticssegmentinmedical partiallyoffsetbyproductliabilityexpenseinotherincome devicesanddiagnosticssegmentoperatingprofitdecreased expensenetincludednetlitigationsettlementsofbillion fromtheprimarydriversofthedeclineintheoperatingprofit margininthemedicaldevicesanddiagnosticssegmentwereprod operatingprofitbysegment uctliabilityandlitigationexpensescostsassociatedwiththedepuy operatingprofitsbysegmentofbusinesswereasfollows asrhiprecallprogramrestructuringexpensecostsincurred percentof relatedtotheplannedacquisitionofsynthesincandincreased segmentsales investmentspendinginmedicaldevicesanddiagnostics dollarsinmillions segmentoperatingprofitincreasedfromtheimproved consumer operatingprofitwasduetoagainofbillionfromnetlitigation pharmaceutical mattersandthegainonthedivestitureofthebreastcarebusiness medicaldevicesand recordedinthiswaspartiallyoffsetbyincreasedproduct diagnostics liabilityexpensemillionofcostsassociatedwiththedepuy total asrhiprecallprogramandpricereductionsincertainmedical lessexpensesnotallocated devicesanddiagnosticsbusinesses tosegments interestincomeexpenseinterestincomeindecreasedby earningsbeforeprovision millionascomparedtotheprioryearduetolowerratesofinter fortaxesonincome estearneddespitehigheraveragecashbalancescashcashequiva seenotetotheconsolidatedfinancialstatementsformoredetails lentsandmarketablesecuritiestotaledbillionattheendof amountsnotallocatedtosegmentsincludeinterestincomeexpensenoncontrolling andaveragedbillionascomparedtothebillion interestsandgeneralcorporateincomeexpenseincludedinwasabillion averagecashbalanceintheincreaseintheaveragecashbal expensefortheadjustmenttothevalueofthecurrencyoptionrelatedtotheplanned acquisitionofsynthesinc ancewasprimarilyduetocashgeneratedfromoperatingactivities andnetcashproceedsfromdivestitures operatingprofit interestexpenseinincreasedbymillionascompared bysegment toduetoahigheraveragedebtbalancethetotaldebtbalance inbillionsofdollars attheendofwasbillionascomparedtobillionat theendofthehigheraveragedebtbalanceofbillionin consumer versusbillioninwasduetoincreasedborrowings pharmaceutical thecompanyincreasedborrowingscapitalizingonfavorableterms medicaldevices inthecapitalmarketstheproceedsoftheborrowingswereused anddiagnostics forgeneralcorporatepurposes interestincomeinincreasedbymillionovertheprior yearduetohigheraveragecashbalancescashcashequivalents andmarketablesecuritiestotaledbillionattheendof andaveragedbillionascomparedtothebillionaverage cashbalanceintheincreaseintheaveragecashbalancewas consumersegmentinconsumersegmentoperatingprofit primarilyduetocashgeneratedfromoperatingactivitiesandnet decreasedfromtheprimarydriversofthedeclinein cashproceedsfromlitigationmattersanddivestitures operatingprofitwereunfavorableproductmixandremediation managements discussion analysis results operations financial condition interestexpenseinwasrelativelyflatascomparedto operating duetoaloweraverageratedespiteahigherdebtbalancethe cashflowand totaldebtbalanceattheendofwasbillionascompared capitalexpenditures tobillionattheendofthehigheraveragedebtbalance inbillionsofdollars ofbillioninversusbillioninwasdueto capitalexpenditures increasedborrowingsthecompanyincreasedborrowingscapital operatingcashflow izingonfavorabletermsinthecapitalmarketstheproceedsofthe borrowingswereusedforgeneralcorporatepurposes interestincomeindecreasedbymillionascom paredtoduetolowerratesofinterestearneddespitehigher averagecashbalancesthecashbalanceincludingmarketable securitieswasbillionattheendofandaveraged billionascomparedtothebillionaveragecashbalance intheincreaseintheaveragecashbalancewasprimarily concentrationofcreditrisk duetocashgeneratedfromoperatingactivities globalconcentrationofcreditriskwithrespecttotradeaccounts interestexpenseinincreasedbymillionascompared receivablescontinuestobelimitedduetothelargenumberofcus toduetoahigherdebtbalancethenetdebtbalanceatthe tomersgloballyandadherencetointernalcreditpoliciesandcredit endofwasbillionascomparedtobillionattheend limitsrecenteconomicchallengesinitalyspaingreeceandportu ofthehigheraveragedebtbalanceofbillionin galthesoutherneuropeanregionhaveimpactedcertainpayment versusbillioninwasprimarilyrelatedtofundingacquisi patternswhichhavehistoricallybeenlongerthanthoseexperi tionsandinvestmentsandthepurchaseofthecompanyscommon encedintheusandotherinternationalmarketsthetotalnet stockunderthecommonstockrepurchaseprogramannounced tradeaccountsreceivablebalanceinthesoutherneuropeanregion onjuly wasapproximatelybillionasofjanuaryandapproxi matelybillionasofjanuaryapproximatelybillion provisionfortaxesonincometheworldwideeffectiveincometax asofjanuaryandapproximatelybillionasofjanuary ratewasininandinthe ofthesoutherneuropeanregionnettradeaccountsreceivable taxrateincreasedascomparedtoduetocertainusexpenses balancerelatedtothecompanysconsumervisioncareand whicharenotfullytaxdeductibleandhigherusstatetaxespar diabetescarebusinessesaswellascertainpharmaceuticaland tiallyoffsetbyincreasesintaxableincomeinlowertaxjurisdictions medicaldevicesanddiagnosticscustomerswhichareinlinewith relativetohighertaxjurisdictionsthetaxratedecreasedas historicalcollectionpatterns comparedtoduetodecreasesintaxableincomeinhighertax theremainingbalanceofnettradeaccountsreceivableinthe jurisdictionsrelativetotaxableincomeinlowertaxjurisdictionsand southerneuropeanregionhasbeennegativelyimpactedbythe certainustaxadjustments timingofpaymentsfromcertaingovernmentownedorsupported healthcarecustomersaswellascertaindistributorsofthepharma liquidityandcapitalresources ceuticalandmedicaldevicesanddiagnosticslocalaffiliatesthe totalnettradeaccountsreceivablebalanceforthesecustomers liquiditycashflows cashandcashequivalentswerebillionattheendofas wereapproximatelybillionatjanuaryandjanuary comparedwithbillionattheendoftheprimarysources thecompanycontinuestoreceivepaymentsfromthesecus ofcashthatcontributedtothebillionincreaseversustheprior tomersandinsomecaseslatepaymentpremiumsforcustomers yearwerebillionofcashgeneratedfromoperatingactivities wherepaymentisexpectedoverperiodsoftimelongerthanone billionnetproceedsfromlongandshorttermdebtbillion yearrevenueandtradereceivableshavebeendiscountedoverthe proceedsfromthedisposalofassetsandproceedsfromnetinvest estimatedperiodoftimeforcollectionallowancesfordoubtful mentsalesofbillionthemajorusesofcashweredividends accountshavebeenincreasedforthesecustomersbuthavebeen toshareholdersofbillioncapitalspendingofbillion immaterialtodatethecompanywillcontinuetoworkclosely acquisitionsofbilliontherepurchaseofcommonstocknet withthesecustomersmonitortheeconomicsituationandtake ofproceedsfromtheexerciseofoptionsofbillionandotherof appropriateactionsasnecessary billionprimarilyrelatedtointangibleassets cashflowsfromoperationswerebillioninthemajor financingandmarketrisk sourcesofcashflowwerenetincomeofbillionadjustedfor thecompanyusesfinancialinstrumentstomanagetheimpactof noncashchargesfordepreciationandamortizationstockbased foreignexchangeratechangesoncashflowsaccordinglythe compensationanddeferredtaxprovisionofbilliontheremain companyentersintoforwardforeignexchangecontractstoprotect ingchangetooperatingcashflowofbillionwasprimarilydueto thevalueofcertainforeigncurrencyassetsandliabilitiesandto anincreaseinothercurrentandnoncurrentliabilitiesrelatedto hedgefutureforeigncurrencytransactionsprimarilyrelatedtoprod accrualsrecordedforlitigationmattersproductliabilityand uctcostsgainsorlossesonthesecontractsareoffsetbythegains employeebenefitplans orlossesontheunderlyingtransactionsaappreciationofthe inthecompanycontinuedtohaveaccesstoliquidity usdollarfromthejanuarymarketrateswouldincreasethe throughthecommercialpapermarketforadditionaldetailson unrealizedvalueofthecompanysforwardcontractsbymil borrowingsseenotetotheconsolidatedfinancialstatements lionconverselyadepreciationoftheusdollarfromthe thecompanyanticipatesthatoperatingcashflowsexisting januarymarketrateswoulddecreasetheunrealizedvalueof creditfacilitiesandaccesstothecommercialpapermarketswill thecompanysforwardcontractsbymillionineitherscenario providesufficientresourcestofundoperatingneedsin thegainorlossontheforwardcontractwouldbeoffsetbythegain orlossontheunderlyingtransactionandthereforewouldhaveno impactonfutureanticipatedearningsandcashflows thecompanyhedgestheexposuretofluctuationsincurrency exchangeratesandtheeffectoncertainassetsandliabilitiesin johnson johnson annual reportforeigncurrencybyenteringintocurrencyswapcontractsa combinationofavailablecashanddebtinadditionthecompany changeinthespreadbetweenusandforeigninterestratesonthe hasanannualprogramtorepurchasesharesforuseinemployee companysinterestratesensitivefinancialinstrumentswouldeither stockandincentiveplans increaseordecreasetheunrealizedvalueofthecompanysswap thecompanyincreaseditsdividendinforthethcon contractsbyapproximatelymillionineitherscenarioat secutiveyearcashdividendspaidwerepersharein maturitythegainorlossontheswapcontractwouldbeoffsetby comparedwithdividendsofpershareinandper thegainorlossontheunderlyingtransactionandthereforewould shareinthedividendsweredistributedasfollows havenoimpactonfutureanticipatedcashflows thecompanydoesnotenterintofinancialinstrumentsfor firstquarter tradingorspeculativepurposesfurtherthecompanyhasapolicy secondquarter ofonlyenteringintocontractswithpartiesthathaveatleastana orequivalentcreditratingthecounterpartiestothesecontracts thirdquarter aremajorfinancialinstitutionsandthereisnosignificantconcentra fourthquarter tionofexposurewithanyonecounterpartymanagementbelieves total theriskoflossisremote thecompanyhasaccesstosubstantialsourcesoffundsat onjanuarytheboardofdirectorsdeclaredaregularquar numerousbanksworldwideinseptemberthecompany terlycashdividendofpersharepayableonmarch securedanewdaycreditfacilitytotalcreditavailabletothe toshareholdersofrecordasoffebruarythecompany companyapproximatesbillionwhichexpiresseptember expectstocontinuethepracticeofpayingregularcashdividends interestchargedonborrowingsunderthecreditlineagree mentisbasedoneitherbidsprovidedbybankstheprimerateor otherinformation londoninterbankofferedratesliborplusapplicablemargins commitmentfeesundertheagreementarenotmaterial criticalaccountingpoliciesandestimates totalborrowingsattheendofandwerebillion managementsdiscussionandanalysisofresultsofoperations andbillionrespectivelytheincreaseinborrowingsbetween andfinancialconditionarebasedonthecompanysconsolidated andwasaresultoffinancingforgeneralcorporatepur financialstatementsthathavebeenpreparedinaccordancewith posesinnetcashcashandcurrentmarketablesecuritiesnet accountingprinciplesgenerallyacceptedintheusgaapthe ofdebtwasbillioncomparedtonetcashofbillionin preparationofthesefinancialstatementsrequiresthatmanagement totaldebtrepresentedoftotalcapitalshareholders makeestimatesandassumptionsthataffecttheamountsreported equityandtotaldebtinandoftotalcapitalin forrevenuesexpensesassetsliabilitiesandotherrelateddisclo shareholdersequitypershareattheendofwas suresactualresultsmayormaynotdifferfromtheseestimatesthe comparedwithatyearendanincreaseof companybelievesthattheunderstandingofcertainkeyaccounting asummaryofborrowingscanbefoundinnotetothe policiesandestimatesareessentialinachievingmoreinsightinto consolidatedfinancialstatements thecompanysoperatingresultsandfinancialconditionthesekey accountingpoliciesincluderevenuerecognitionincometaxeslegal andselfinsurancecontingenciesvaluationoflonglivedassets contractualobligationsandcommitments thecompanyscontractualobligationsareprimarilyforleasesdebt assumptionsusedtodeterminetheamountsrecordedforpensions andunfundedretirementplanswithnoothersignificantobliga andotheremployeebenefitplansandaccountingforstockoptions tionstosatisfytheseobligationsthecompanywillusecashfrom revenuerecognitionthecompanyrecognizesrevenuefrom operationsthefollowingtablesummarizesthecompanyscontrac productsaleswhengoodsareshippedordeliveredandtitleand tualobligationsandtheiraggregatematuritiesasofjanuary riskoflosspasstothecustomerprovisionsforcertainrebatessales seenotesandtotheconsolidatedfinancialstatementsfor incentivestradepromotionscouponsproductreturnsanddis furtherdetails countstocustomersareaccountedforasreductionsinsalesinthe sameperiodtherelatedsalesarerecorded longterm intereston unfunded debt debt retirement operating productdiscountsgrantedarebasedonthetermsofarrange dollarsinmillions obligations obligations plans leases total mentswithdirectindirectandothermarketparticipantsaswell asmarketconditionsincludingpriceschargedbycompetitors rebatesthelargestbeingthemedicaidrebateprovisionareesti matedbasedoncontractualtermshistoricalexperiencetrend analysisandprojectedmarketconditionsinthevariousmarkets servedthecompanyevaluatesmarketconditionsforproductsor groupsofproductsprimarilythroughtheanalysisofwholesalerand otherthirdpartysellthroughandmarketresearchdataaswellas total internallygeneratedinformation salesreturnsaregenerallyestimatedandrecordedbasedon fortaxmattersseenotetotheconsolidatedfinancialstatements historicalsalesandreturnsinformationproductsthatexhibit unusualsalesorreturnpatternsduetodatingcompetitionorother sharerepurchaseanddividends marketingmattersarespecificallyinvestigatedandanalyzedaspart onjulythecompanyannouncedthatitsboardofdirectors oftheaccountingforsalesreturnaccruals approvedastockrepurchaseprogramauthorizingthecompanyto salesreturnsallowancesrepresentareserveforproductsthat buybackuptobillionofthecompanyscommonstockas maybereturnedduetoexpirationdestructioninthefieldorin ofjanuarythecompanyrepurchasedanaggregateof specificareasproductrecallthereturnsreserveisbasedonhis millionsharesofjohnsonjohnsoncommonstockatacost toricalreturntrendsbyproductandbymarketasapercenttogross ofbillionandthestockrepurchaseprogramwascompleted salesinaccordancewiththecompanysaccountingpoliciesthe thecompanyfundedthesharerepurchaseprogramthrougha managements discussion analysis results operations financial condition companygenerallyissuescredittocustomersforreturnedgoods consumersegment thecompanyssalesreturnsreservesareaccountedforinaccor balanceat balanceat dancewiththeusgaapguidanceforrevenuerecognitionwhen beginning payments end rightofreturnexistssalesreturnsreservesarerecordedatfullsales dollarsinmillions ofperiod accruals credits ofperiod valuesalesreturnsintheconsumerandpharmaceuticalsegments arealmostexclusivelynotresalablesalesreturnsforcertainfran accruedrebates chisesinthemedicaldevicesanddiagnosticssegmentaretypically accruedreturns resalablebutarenotmaterialthecompanyrarelyexchangesprod accruedpromotions uctsfrominventoryforreturnedproductsthesalesreturnsreserve subtotal forthetotalcompanyhasrangedbetweenandofannual reservefordoubtfulaccounts nettradesalesduringthepriorthreefiscalreportingyears reserveforcashdiscounts promotionalprogramssuchasproductlistingallowancesand total cooperativeadvertisingarrangementsarerecordedintheyear incurredcontinuingpromotionalprogramsincludecouponsand accruedrebates volumebasedsalesincentiveprogramstheredemptioncostof accruedreturns consumercouponsisbasedonhistoricalredemptionexperienceby accruedpromotions productandvaluevolumebasedincentiveprogramsarebasedon estimatedsalesvolumesfortheincentiveperiodandarerecorded subtotal asproductsaresoldthecompanyalsoearnsservicerevenuefor reservefordoubtfulaccounts copromotionofcertainproductsforallyearspresentedservice reserveforcashdiscounts revenueswerelessthanoftotalrevenuesandareincludedin total salestocustomersthesearrangementsareevaluatedtodetermine includesreserveforcustomerrebatesofmillionatjanuaryandmillionat theappropriateamountstobedeferred januaryrecordedasacontraasset inadditionthecompanyentersintocollaborationarrange mentsthatcontainmultiplerevenuegeneratingactivitiesthe pharmaceuticalsegment revenueforthesearrangementsisrecognizedaseachactivityis performedordeliveredbasedontherelativefairvalueupfront balanceat balanceat beginning payments end feesreceivedaspartofthesearrangementsaredeferredandrecog dollarsinmillions ofperiod accruals credits ofperiod nizedasrevenueearnedovertheobligationperiodseenoteto theconsolidatedfinancialstatementsforadditionaldisclosures accruedrebates oncollaborations accruedreturns reasonablylikelychangestoassumptionsusedtocalculatethe accruedpromotions accrualsforrebatesreturnsandpromotionsarenotanticipatedto subtotal haveamaterialeffectonthefinancialstatementsthecompany currentlydisclosestheimpactofchangestoassumptionsinthe reservefordoubtfulaccounts quarterlyorannualfilinginwhichthereisamaterialfinancial reserveforcashdiscounts statementimpact total belowaretablesthatshowtheprogressionofaccruedrebates returnspromotionsreservefordoubtfulaccountsandreservefor accruedrebates cashdiscountsbysegmentofbusinessforthefiscalyearsended accruedreturns januaryandjanuary accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total includesreserveforcustomerrebatesofmillionatjanuaryandmillion atjanuaryrecordedasacontraasset includesadditionalsalesrebatestomedicaidmanagedcareorganizationsasaresultof theushealthcarereformlegislation johnson johnson annual reportmedicaldevicesanddiagnosticssegment futurecashflowsinevaluatingthevalueofthecompanysproperty plantandequipmentgoodwillandintangibleassetsasthese balanceat balanceat assumptionsandestimatesmaychangeovertimeitmayormaynot beginning payments end dollarsinmillions ofperiod accruals credits ofperiod benecessaryforthecompanytorecordimpairmentcharges employeebenefitplansthecompanysponsorsvariousretirement accruedrebates andpensionplansincludingdefinedbenefitdefinedcontribution accruedreturns andterminationindemnityplanswhichcovermostemployees accruedpromotions worldwidetheseplansarebasedonassumptionsforthediscount subtotal rateexpectedreturnonplanassetsexpectedsalaryincreasesand reservefordoubtfulaccounts healthcarecosttrendratesseenotetotheconsolidatedfinan reserveforcashdiscounts cialstatementsforfurtherdetailsontheseratesandtheeffecta ratechangewouldhaveonthecompanysresultsofoperations total stockbasedcompensationthecompanyrecognizescompensa tionexpenseassociatedwiththeissuanceofequityinstrumentsto accruedrebates employeesfortheirservicesthefairvalueofeachawardisesti accruedreturns matedonthedateofgrantusingtheblackscholesoptionvaluation accruedpromotions modelandisexpensedinthefinancialstatementsoverthevesting subtotal periodtheinputassumptionsusedindeterminingfairvalueare reservefordoubtfulaccounts theexpectedlifeexpectedvolatilityriskfreerateandthedividend reserveforcashdiscounts yieldseenotetotheconsolidatedfinancialstatementsfor total additionalinformation includesreserveforcustomerrebatesofmillionatjanuaryandmillion atjanuaryrecordedasacontraasset newaccountingpronouncements accrualsandpaymentscreditsforhavebeenrevisedbymilliontoappropriately refertonotetotheconsolidatedfinancialstatementsforrecently reflectnoncashcreditsadjustmentsconsistentwithcurrentyearpresentationrelatedto adoptedaccountingpronouncementsandrecentlyissuedaccount theethiconfranchisepreviouslyreportednetintheaccrualscolumn ingpronouncementsnotyetadoptedasofjanuary incometaxesincometaxesarerecordedbasedonamounts refundableorpayableforthecurrentyearandincludetheresultsof economicandmarketfactors anydifferencebetweenusgaapaccountingandtaxreporting thecompanyisawarethatitsproductsareusedinanenvironment recordedasdeferredtaxassetsorliabilitiesthecompanyestimates whereformorethanadecadepolicymakersconsumersandbusi deferredtaxassetsandliabilitiesbasedoncurrenttaxregulations nesseshaveexpressedconcernsabouttherisingcostofhealthcare andrateschangesintaxlawsandratesmayaffectrecorded inresponsetotheseconcernsthecompanyhasalongstanding deferredtaxassetsandliabilitiesinthefuturemanagementbelieves policyofpricingproductsresponsiblyfortheperiodin thatchangesintheseestimateswouldnothaveamaterialeffecton theunitedstatestheweightedaveragecompoundannualgrowth thecompanysresultsofoperationscashflowsorfinancialposition rateofthecompanysnetpriceincreasesforhealthcareproducts atjanuaryandjanuarythecumulative prescriptionandoverthecounterdrugshospitalandprofessional amountsofundistributedinternationalearningswereapproximately productswasbelowtheusconsumerpriceindexcpi billionandbillionrespectivelyatjanuaryand inflationratescontinuetohaveaneffectonworldwide januarythecompanysforeignsubsidiariesheldbalances economiesandconsequentlyonthewaycompaniesoperatethe ofcashandcashequivalentsintheamountsofbillionand companyaccountedforoperationsinvenezuelaashighlyinflation billionrespectivelythecompanyintendstocontinueto aryinandasthepriorthreeyearcumulativeinflation reinvestitsundistributedinternationalearningstoexpandits ratesurpassedinthefaceofincreasingcoststhecompany internationaloperationsthereforenoustaxexpensehasbeen strivestomaintainitsprofitmarginsthroughcostreductionpro recordedwithrespecttotheundistributedportionnotintended gramsproductivityimprovementsandperiodicpriceincreases forrepatriation thecompanyisexposedtofluctuationsincurrencyexchange seenotetotheconsolidatedfinancialstatementsfor ratesachangeinthevalueoftheusdollarascomparedto furtherinformationregardingincometaxes allforeigncurrenciesinwhichthecompanyhadsalesincomeor expenseinwouldhaveincreasedordecreasedthetranslation legalandselfinsurancecontingenciesthecompanyrecords offoreignsalesbyapproximatelymillionandincomeby accrualsforvariouscontingenciesincludinglegalproceedingsand million productliabilityclaimsastheseariseinthenormalcourseofbusi thecompanyfacesvariousworldwidehealthcarechanges nesstheaccrualsarebasedonmanagementsjudgmentastothe thatmaycontinuetoresultinpricingpressuresthatincludehealth probabilityoflossesandwhereapplicableactuariallydetermined carecostcontainmentandgovernmentlegislationrelatingtosales estimatesadditionallythecompanyrecordsinsurancereceivable promotionsandreimbursementofhealthcareproducts amountsfromthirdpartyinsurerswhenrecoveryisprobableas changesinthebehaviorandspendingpatternsofpurchasers appropriatereservesagainstthesereceivablesarerecordedforesti ofhealthcareproductsandservicesincludingdelayingmedical matedamountsthatmaynotbecollectedfromthirdpartyinsurers proceduresrationingprescriptionmedicationsreducingthe thecompanyfollowstheprovisionsofusgaapwhenrecord frequencyofphysicianvisitsandforegoinghealthcareinsurance inglitigationrelatedcontingenciesaliabilityisrecordedwhenaloss coverageasaresultofthecurrentglobaleconomicdownturn isprobableandcanbereasonablyestimatedthebestestimateofa maycontinuetoimpactthecompanysbusinesses losswithinarangeisaccruedhoweverifnoestimateintherangeis thecompanyalsooperatesinanenvironmentwhichhas betterthananyothertheminimumamountisaccrued becomeincreasinglyhostiletointellectualpropertyrightsgeneric longlivedandintangibleassetsthecompanyassesseschanges drugfirmshavefiledabbreviatednewdrugapplicationsandas ineconomicconditionsandmakesassumptionsregardingestimated managements discussion analysis results operations financial condition seekingtomarketgenericformsofmostofthecompanyskeyphar cautionaryfactorsthatmayaffect maceuticalproductspriortoexpirationoftheapplicablepatents futureresults coveringthoseproductsintheeventthecompanyisnotsuccessful indefendingthepatentclaimschallengedinandafilingsthe thisannualreportcontainsforwardlookingstatementsforward genericfirmswillthenintroducegenericversionsoftheproductat lookingstatementsdonotrelatestrictlytohistoricalorcurrentfacts issueresultinginthepotentialforsubstantialmarketshareand andanticipateresultsbasedonmanagementsplansthataresubject revenuelossesforthatproductforfurtherinformationseethe touncertaintyforwardlookingstatementsmaybeidentifiedby discussiononlitigationagainstfilersofabbreviatednewdrug theuseofwordssuchasplansexpectswillanticipates applicationsinnotetotheconsolidatedfinancialstatements estimatesandotherwordsofsimilarmeaninginconjunctionwith amongotherthingsdiscussionsoffutureoperationsfinancialper formancethecompanysstrategyforgrowthproductdevelopment legalproceedings johnsonjohnsonandcertainofitssubsidiariesareinvolvedin regulatoryapprovalmarketpositionandexpenditures variouslawsuitsandclaimsregardingproductliabilityintellectual forwardlookingstatementsarebasedoncurrentexpectations propertycommercialandothermattersgovernmentalinvestiga offutureeventsthecompanycannotguaranteethatanyforward tionsandotherlegalproceedingsthatarisefromtimetotimein lookingstatementwillbeaccuratealthoughthecompanybelieves theordinarycourseofbusiness thatithasbeenreasonableinitsexpectationsandassumptions thecompanyrecordsaccrualsforsuchcontingencieswhenit investorsshouldrealizethatifunderlyingassumptionsproveinac isprobablethataliabilitywillbeincurredandtheamountoftheloss curateorthatunknownrisksoruncertaintiesmaterializeactual canbereasonablyestimatedthecompanyhasaccruedforcertain resultscouldvarymateriallyfromthecompanysexpectationsand litigationmattersandcontinuestomonitoreachrelatedlegalissue projectionsinvestorsarethereforecautionednottoplaceundue andadjustaccrualsfornewinformationandfurtherdevelopments relianceonanyforwardlookingstatementsthecompanydoesnot inaccordancewithascfortheseandotherlitigation undertaketoupdateanyforwardlookingstatementsasaresultof andregulatorymatterscurrentlydisclosedforwhichalossisproba newinformationorfutureeventsordevelopments bleorreasonablypossiblethecompanyisunabletodeterminean risksanduncertaintiesincludebutarenotlimitedtogeneral estimateofthepossiblelossorrangeoflossbeyondtheamounts industryconditionsandcompetitioneconomicfactorssuchas alreadyaccruedthesematterscanbeaffectedbyvariousfactors interestrateandcurrencyexchangeratefluctuationstechnological includingwhetherdamagessoughtintheproceedingsareunsub advancesnewproductsandpatentsattainedbycompetitorschal stantiatedorindeterminatescientificandlegaldiscoveryhasnot lengesinherentinnewproductdevelopmentincludingobtaining commencedorisnotcompleteproceedingsareinearlystages regulatoryapprovalschallengestopatentssignificantlitigation matterspresentlegaluncertaintiestherearesignificantfactsin adversetothecompanyimpactofbusinesscombinationsfinancial disputeortherearenumerouspartiesinvolved distressandbankruptciesexperiencedbysignificantcustomers inthecompanysopinionbasedonitsexaminationofthese andsupplierschangestogovernmentallawsandregulationsand mattersitsexperiencetodateanddiscussionswithcounselthe usandforeignhealthcarereformstrendstowardhealthcarecost ultimateoutcomeoflegalproceedingsnetofliabilitiesaccruedin containmentincreasedscrutinyofthehealthcareindustrybygov thecompanysbalancesheetisnotexpectedtohaveamaterial ernmentagencieschangesinbehaviorandspendingpatternsof adverseeffectonthecompanysfinancialpositionhoweverthe purchasersofhealthcareproductsandservicesfinancialinstability resolutioninanyreportingperiodofoneormoreofthesematters ofinternationaleconomiesandsovereignriskdisruptionsdue eitheraloneorintheaggregatemayhaveamaterialadverse tonaturaldisastersmanufacturingdifficultiesordelaysproduct effectonthecompanysresultsofoperationsandcashflowsfor efficacyorsafetyconcernsresultinginproductrecallsor thatperiod regulatoryaction seenotetotheconsolidatedfinancialstatementsfor thecompanysreportonformkfortheyearendedjanuary furtherinformationregardinglegalproceedings includesinexhibitadiscussionofadditionalfactorsthat couldcauseactualresultstodifferfromexpectationsthecompany notesthesefactorsaspermittedbytheprivatesecuritieslitigation commonstockmarketprices thecompanyscommonstockislistedonthenewyorkstock reformactof exchangeunderthesymboljnjthecompositemarketpriceranges forjohnsonjohnsoncommonstockduringandwere high low high low firstquarter secondquarter thirdquarter fourthquarter yearendclose johnson johnson annual reportconsolidatedbalancesheets johnsonjohnsonandsubsidiaries atjanuaryandjanuarydollarsinmillionsexceptshareandpersharedatanote assets currentassets cashandcashequivalentsnotesand marketablesecuritiesnotesand accountsreceivabletradelessallowancesfordoubtfulaccounts inventoriesnotesand deferredtaxesonincomenote prepaidexpensesandotherreceivables totalcurrentassets propertyplantandequipmentnetnotesand intangibleassetsnetnotesand goodwillnotesand deferredtaxesonincomenote otherassets totalassets liabilitiesandshareholdersequity currentliabilities loansandnotespayablenote accountspayable accruedliabilities accruedrebatesreturnsandpromotions accruedcompensationandemployeerelatedobligations accruedtaxesonincome totalcurrentliabilities longtermdebtnote deferredtaxesonincomenote employeerelatedobligationsnotesand otherliabilities totalliabilities shareholdersequity preferredstockwithoutparvalue authorizedandunissuedshares commonstockparvaluepersharenote authorizedsharesissuedshares accumulatedothercomprehensiveincomenote retainedearnings lesscommonstockheldintreasuryatcostnote sharesandshares totalshareholdersequity totalliabilitiesandshareholdersequity seenotestoconsolidatedfinancialstatements consolidated financial statements consolidatedstatementsofearnings johnsonjohnsonandsubsidiaries dollarsinmillionsexceptpersharefiguresnote salestocustomers costofproductssold grossprofit sellingmarketingandadministrativeexpenses researchanddevelopmentexpense interestincome interestexpensenetofportioncapitalizednote otherincomeexpensenet restructuringnote earningsbeforeprovisionfortaxesonincome provisionfortaxesonincomenote netearnings basicnetearningspersharenotesand dilutednetearningspersharenotesand cashdividendspershare basicaveragesharesoutstandingnotesand dilutedaveragesharesoutstandingnotesand seenotestoconsolidatedfinancialstatements johnson johnson annual reportconsolidatedstatementsofequity johnsonjohnsonandsubsidiaries accumulated treasury comprehensive retained comprehensive commonstock stock dollarsinmillionsnote total income earnings income issuedamount amount balancedecember netearnings cashdividendspaid employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomenetoftax currencytranslationadjustment unrealizedlossesonsecurities employeebenefitplans gainsonderivativeshedges totalcomprehensiveincome balancejanuary netearnings cashdividendspaid employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomenetoftax currencytranslationadjustment unrealizedgainsonsecurities employeebenefitplans lossesonderivativeshedges totalcomprehensiveincome balancejanuary netearnings cashdividendspaid employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomenetoftax currencytranslationadjustment unrealizedgainsonsecurities employeebenefitplans lossesonderivativeshedges totalcomprehensiveincome balancejanuary seenotestoconsolidatedfinancialstatements consolidated financial statements consolidatedstatementsofcashflows johnsonjohnsonandsubsidiaries dollarsinmillionsnote cashflowsfromoperatingactivities netearnings adjustmentstoreconcilenetearningstocashflowsfrom operatingactivities depreciationandamortizationofpropertyandintangibles stockbasedcompensation deferredtaxprovision accountsreceivableallowances changesinassetsandliabilitiesnetofeffectsfromacquisitions increasedecreaseinaccountsreceivable increasedecreaseininventories increasedecreaseinaccountspayableandaccruedliabilities increasedecreaseinothercurrentandnoncurrentassets increaseinothercurrentandnoncurrentliabilities netcashflowsfromoperatingactivities cashflowsfrominvestingactivities additionstopropertyplantandequipment proceedsfromthedisposalofassets acquisitionsnetofcashacquirednote purchasesofinvestments salesofinvestments otherprimarilyintangibles netcashusedbyinvestingactivities cashflowsfromfinancingactivities dividendstoshareholders repurchaseofcommonstock proceedsfromshorttermdebt retirementofshorttermdebt proceedsfromlongtermdebt retirementoflongtermdebt proceedsfromtheexerciseofstockoptionsexcesstaxbenefits netcashusedbyfinancingactivities effectofexchangeratechangesoncashandcashequivalents increaseincashandcashequivalents cashandcashequivalentsbeginningofyearnote cashandcashequivalentsendofyearnote supplementalcashflowdata cashpaidduringtheyearfor interest incometaxes supplementalscheduleofnoncashinvestingandfinancingactivities treasurystockissuedforemployeecompensationand stockoptionplansnetofcashproceeds conversionofdebt acquisitions fairvalueofassetsacquired fairvalueofliabilitiesassumedandnoncontrollinginterests netcashpaidforacquisitions seenotestoconsolidatedfinancialstatements johnson johnson annual reportnotestoconsolidatedfinancialstatements summaryofsignificantaccountingpolicies expenseinthecompanysfinancialstatementandwillbeamortized principlesofconsolidation onastraightlinebasisfortheyearasperthefasbguidancethe theconsolidatedfinancialstatementsincludetheaccountsof adoptionofthisstandarddidnothaveamaterialimpactonthe johnsonjohnsonanditssubsidiariesthecompany companysresultsofoperationscashflowsorfinancialposition intercompanyaccountsandtransactionsareeliminated recentlyissuedaccountingstandards descriptionofthecompanyandbusinesssegments notadoptedasofjanuary thecompanyhasapproximatelyemployeesworldwide duringthefiscalthirdquarterofthefasbissuedamendments engagedintheresearchanddevelopmentmanufactureandsaleof togoodwillimpairmenttestingundertheamendmentsinthisupdate abroadrangeofproductsinthehealthcarefieldthecompany anentityhastheoptiontofirstassessqualitativefactorstodetermine conductsbusinessinvirtuallyallcountriesoftheworldanditspri whethertheexistenceofeventsorcircumstancesleadstoadetermi maryfocusisonproductsrelatedtohumanhealthandwellbeing nationthatitismorelikelythannotthatthefairvalueofareporting thecompanyisorganizedintothreebusinesssegments unitislessthanitscarryingamountifafterassessingthetotalityof consumerpharmaceuticalandmedicaldevicesanddiagnostics eventsorcircumstancesanentitydeterminesitisnotmorelikelythan theconsumersegmentincludesabroadrangeofproductsusedin notthatthefairvalueofareportingunitislessthanitscarrying thebabycareskincareoralcarewoundcareandwomenshealth amountthenperformingthetwostepimpairmenttestisunneces fieldsaswellasnutritionalandoverthecounterpharmaceutical saryhoweverifanentityconcludesotherwisethenitisrequiredto productsandwellnessandpreventionplatformstheseproducts performthefirststepofthetwostepimpairmenttestthisguidance aremarketedtothegeneralpublicandsoldbothtoretailoutlets iseffectiveforannualandinterimgoodwillimpairmenttestsper anddistributorsthroughouttheworldthepharmaceuticalsegment formedforfiscalyearsbeginningafterdecembertheadop includesproductsinthefollowingareasantiinfectiveantipsychotic tionofthisstandardisnotexpectedtohaveamaterialimpactonthe contraceptivedermatologygastrointestinalhematologyimmunol companysresultsofoperationscashflowsorfinancialposition ogyneurologyoncologypainmanagementthrombosisvaccines duringthefiscalsecondquarterofthefasbissuedan andinfectiousdiseasestheseproductsaredistributeddirectlyto amendmenttothedisclosurerequirementsforpresentationofcom retailerswholesalersandhealthcareprofessionalsforprescription prehensiveincometheamendmentrequiresthatallnonowner usethemedicaldevicesanddiagnosticssegmentincludesabroad changesinstockholdersequitybepresentedeitherinasinglecon rangeofproductsdistributedtowholesalershospitalsandretailers tinuousstatementofcomprehensiveincomeorintwoseparatebut usedprincipallyintheprofessionalfieldsbyphysiciansnursesthera consecutivestatementsthisguidanceiseffectiveretrospectively pistshospitalsdiagnosticlaboratoriesandclinicstheseproducts fortheinterimperiodsandannualperiodsbeginningafterdecem includecardiovascularcareselectrophysiologyandcirculatory berhoweverthefasbagreedtoanindefinitedeferralof diseasemanagementproductsdepuysorthopaedicjointrecon thereclassificationrequirementtheadoptionofthisstandardisnot structionspinalcareneurologicalandsportsmedicineproducts expectedtohaveamaterialimpactonthecompanysresultsof ethiconssurgicalcareaestheticsandwomenshealthproducts operationscashflowsorfinancialposition ethiconendosurgerysminimallyinvasivesurgicalproductsand duringthefiscalsecondquarterofthefasbissued advancedsterilizationproductsdiabetescaresbloodglucosemoni amendmentstodisclosurerequirementsforcommonfairvalue toringandinsulindeliveryproductsorthoclinicaldiagnostics measurementtheseamendmentsresultinconvergenceoffair professionaldiagnosticproductsandvisioncaresdisposable valuemeasurementanddisclosurerequirementsbetweenusgen contactlenses erallyacceptedaccountingprinciplesgaapandinternational financialreportingstandardsifrsthisguidanceiseffective newaccountingpronouncements prospectivelyfortheinterimperiodsandannualperiodsbeginning recentlyadoptedaccountingpronouncements afterdecemberearlyadoptionisprohibitedtheadoption duringthefiscalfirstquarterofthecompanyadoptedthe ofthisstandardisnotexpectedtohaveamaterialimpactonthe financialaccountingstandardsboardfasbguidanceandamend companysresultsofoperationscashflowsorfinancialposition mentsissuedrelatedtorevenuerecognitionunderthemilestone methodtheobjectiveoftheaccountingstandardupdateistopro cashequivalents videguidanceondefiningamilestoneanddeterminingwhenitmay thecompanyconsiderssecuritieswithmaturitiesofthreemonths beappropriatetoapplythemilestonemethodofrevenuerecognition orlesswhenpurchasedtobecashequivalents forresearchordevelopmenttransactionsthisupdatebecameeffec tiveonaprospectivebasisformilestonesachievedinfiscalyearsand investments interimperiodswithinthoseyearsbeginningonorafterjune shorttermmarketablesecuritiesarecarriedatcostwhichapproxi theadoptionofthisstandarddidnothaveamaterialimpacton matesfairvalueinvestmentsclassifiedasavailableforsaleare thecompanysresultsofoperationscashflowsorfinancialposition carriedatestimatedfairvaluewithunrealizedgainsandlosses duringthefiscalfirstquarterofthecompanyadopted recordedasacomponentofaccumulatedothercomprehensive thefasbguidanceonhowpharmaceuticalcompaniesshouldrecog incomelongtermdebtsecuritiesthatthecompanyhastheability nizeandclassifyinthecompanysfinancialstatementsthenon andintenttoholduntilmaturityarecarriedatamortizedcost deductibleannualfeepaidtothegovernmentinaccordancewiththe managementdeterminestheappropriateclassificationofitsinvest patientprotectionandaffordablecareactasamendedbythe mentindebtandequitysecuritiesatthetimeofpurchaseand healthcareandeducationreconciliationactthisfeeisbasedonan reevaluatessuchdeterminationateachbalancesheetdatethe allocationofacompanysmarketshareoftotalbrandedprescription companyperiodicallyreviewsitsinvestmentsinequitysecurities drugsalestousgovernmentprogramsfromtheprioryeartheesti forimpairmentandadjuststheseinvestmentstotheirfairvalue matedfeewasrecordedasasellingmarketingandadministrative whenadeclineinmarketvalueisdeemedtobeotherthan notes consolidated financial statements temporaryiflossesonthesesecuritiesareconsideredtobeother promotionalprogramssuchasproductlistingallowancesand thantemporarythelossisrecognizedinearnings cooperativeadvertisingarrangementsarerecordedintheyear incurredcontinuingpromotionalprogramsincludecouponsand propertyplantandequipmentanddepreciation volumebasedsalesincentiveprogramstheredemptioncostof propertyplantandequipmentarestatedatcostthecompany consumercouponsisbasedonhistoricalredemptionexperience utilizesthestraightlinemethodofdepreciationovertheestimated byproductandvaluevolumebasedincentiveprogramsarebased usefullivesoftheassets ontheestimatedsalesvolumesfortheincentiveperiodandare recordedasproductsaresoldthecompanyalsoearnsservicerev buildingandbuildingequipment years enueforcopromotionofcertainproductsandincludesitinsalesto landandleaseholdimprovements years customersthesearrangementsareevaluatedtodeterminethe machineryandequipment years appropriateamountstobedeferred thecompanycapitalizescertaincomputersoftwareanddevelopment costsincludedinmachineryandequipmentwhenincurredinconnec shippingandhandling tionwithdevelopingorobtainingcomputersoftwareforinternaluse shippingandhandlingcostsincurredweremillionmil capitalizedsoftwarecostsareamortizedovertheestimateduseful lionandmillioninandrespectivelyandare livesofthesoftwarewhichgenerallyrangefromtoyears includedinsellingmarketingandadministrativeexpensethe thecompanyreviewslonglivedassetstoassessrecoverability amountofrevenuereceivedforshippingandhandlingislessthan usingundiscountedcashflowswhencertaineventsorchangesin ofsalestocustomersforallperiodspresented operatingoreconomicconditionsoccuranimpairmentassessment maybeperformedontherecoverabilityofthecarryingvalueof inventories theseassetsiftheassetisdeterminedtobeimpairedthelossis inventoriesarestatedatthelowerofcostormarketdeterminedby measuredbasedonthedifferencebetweentheassetsfairvalueand thefirstinfirstoutmethod itscarryingvalueifquotedmarketpricesarenotavailablethe companywillestimatefairvalueusingadiscountedvalueof intangibleassetsandgoodwill estimatedfuturecashflows theauthoritativeliteratureonusgaaprequiresthatgoodwilland intangibleassetswithindefinitelivesbeassessedannuallyfor revenuerecognition impairmentthecompanycompletedtheannualimpairmenttest thecompanyrecognizesrevenuefromproductsaleswhenthe forinthefiscalfourthquarterandnoimpairmentwasdeter goodsareshippedordeliveredandtitleandriskoflosspasstothe minedfutureimpairmenttestswillbeperformedannuallyin customerprovisionsforcertainrebatessalesincentivestradepro thefiscalfourthquarterorsoonerifatriggeringeventoccurs motionscouponsproductreturnsanddiscountstocustomersare purchasedinprocessresearchanddevelopmentisaccountedforas accountedforasreductionsinsalesinthesameperiodtherelated anindefinitelivedintangibleassetuntiltheunderlyingprojectis salesarerecorded completedatwhichpointtheintangibleassetwillbeaccountedfor productdiscountsgrantedarebasedonthetermsofarrange asadefinitelivedintangibleassetorabandonedatwhichpointthe mentswithdirectindirectandothermarketparticipantsaswell intangibleassetwillbewrittenoff asmarketconditionsincludingpriceschargedbycompetitors intangibleassetsthathavefiniteusefullivescontinuetobe rebatesthelargestbeingthemedicaidrebateprovisionareesti amortizedovertheirusefullivesandarereviewedforimpairment matedbasedoncontractualtermshistoricalexperiencetrend whenwarrantedbyeconomicconditionsseenoteforfurther analysisandprojectedmarketconditionsinthevariousmarkets detailsonintangibleassetsandgoodwill servedthecompanyevaluatesmarketconditionsforproductsor groupsofproductsprimarilythroughtheanalysisofwholesalerand financialinstruments otherthirdpartysellthroughandmarketresearchdataaswellas asrequiredbyusgaapallderivativeinstrumentsarerecordedon internallygeneratedinformation thebalancesheetatfairvaluechangesinthefairvalueofderivatives salesreturnsaregenerallyestimatedandrecordedbasedon arerecordedeachperiodincurrentearningsorothercomprehensive historicalsalesandreturnsinformationproductsthatexhibit incomedependingonwhetherthederivativeisdesignatedaspartof unusualsalesorreturnpatternsduetodatingcompetitionor ahedgetransactionandifsothetypeofhedgetransaction othermarketingmattersarespecificallyinvestigatedandanalyzed thecompanydocumentsallrelationshipsbetweenhedged aspartoftheaccountingforsalesreturnsaccruals itemsandderivativestheoverallriskmanagementstrategy salesreturnsallowancesrepresentareserveforproductsthat includesreasonsforundertakinghedgetransactionsandentering maybereturnedduetoexpirationdestructioninthefieldorinspe intoderivativestheobjectivesofthisstrategyareminimize cificareasproductrecallthereturnsreserveisbasedonhistorical foreigncurrencyexposuresimpactonthecompanysfinancial returntrendsbyproductandbymarketasapercenttogrosssales performanceprotectthecompanyscashflowfromadverse inaccordancewiththecompanysaccountingpoliciesthe movementsinforeignexchangeratesensuretheappropriate companygenerallyissuescredittocustomersforreturnedgoods nessoffinancialinstrumentsandmanagetheenterpriserisk thecompanyssalesreturnsreservesareaccountedforinaccor associatedwithfinancialinstitutionsseenoteforadditional dancewithusgaapguidanceforrevenuerecognitionwhenright informationonfinancialinstruments ofreturnexistssalesreturnsreservesarerecordedatfullsales valuesalesreturnsintheconsumerandpharmaceuticalsegments productliability arealmostexclusivelynotresalablesalesreturnsforcertainfran accrualsforproductliabilityclaimsarerecordedonanundis chisesinthemedicaldevicesanddiagnosticssegmentaretypically countedbasiswhenitisprobablethataliabilityhasbeenincurred resalablebutarenotmaterialthecompanyrarelyexchangesprod andtheamountoftheliabilitycanbereasonablyestimatedbased uctsfrominventoryforreturnedproductsthesalesreturnsreserve onexistinginformationtheaccrualsareadjustedperiodicallyas forthetotalcompanyhasrangedbetweenandofannual additionalinformationbecomesavailableasaresultofcostand salestocustomersduringthepriorthreefiscalreportingyears availabilityfactorseffectivenovemberthecompany johnson johnson annual reportceasedpurchasingthirdpartyproductliabilityinsurancebasedon operationsingeneraltheincomestatementpresentationforthese theavailabilityofpriorcoveragereceivablesforinsurancerecover collaborationsisasfollows iesrelatedtoproductliabilityclaimsarerecordedonanundis naturetypeofcollaboration statementofearningspresentation countedbasiswhenitisprobablethatarecoverywillberealized thirdpartysaleofproduct salestocustomers royaltiesmilestonespaidto concentrationofcreditrisk collaborativepartner globalconcentrationofcreditriskwithrespecttotradeaccounts postregulatoryapproval costofgoodssold receivablescontinuestobelimitedduetothelargenumberof royaltiesreceivedfromcollaborativepartner otherincomeexpensenet customersgloballyandadherencetointernalcreditpoliciesand upfrontpaymentsmilestones creditlimitsrecenteconomicchallengesinitalyspaingreeceand paidtocollaborativepartner portugalthesoutherneuropeanregionhaveimpactedcertain preregulatoryapproval researchanddevelopmentexpense paymentpatternswhichhavehistoricallybeenlongerthanthose researchanddevelopmentpayments experiencedintheusandotherinternationalmarketsthetotal tocollaborativepartner researchanddevelopmentexpense nettradeaccountsreceivablebalanceinthesoutherneuropean researchanddevelopment regionwasapproximatelybillionasofjanuaryand paymentsreceivedfrom approximatelybillionasofjanuaryapproximately collaborativepartner reductionofresearchanddevelopmentexpense billionasofjanuaryandapproximatelybillionasof milestonesarecapitalizedasintangibleassetsandamortizedtocostofgoodssoldover januaryofthesoutherneuropeanregionnettradeaccounts theusefullife receivablebalancerelatedtothecompanysconsumervisioncare anddiabetescarebusinessesaswellascertainpharmaceutical advertising andmedicaldevicesanddiagnosticscustomerswhichareinline costsassociatedwithadvertisingareexpensedintheyearincurred withhistoricalcollectionpatterns andareincludedinsellingmarketingandadministrativeexpenses theremainingbalanceofnettradeaccountsreceivableinthe advertisingexpensesworldwidewhichcomprisedtelevisionradio southerneuropeanregionhasbeennegativelyimpactedbythe printmediaandinternetadvertisingwerebillionbillion timingofpaymentsfromcertaingovernmentownedorsupported andbillioninandrespectively healthcarecustomersaswellascertaindistributorsofthepharma ceuticalandmedicaldevicesanddiagnosticslocalaffiliatesthe incometaxes totalnettradeaccountsreceivablebalanceforthesecustomers incometaxesarerecordedbasedonamountsrefundableorpayable wereapproximatelybillionatjanuaryandjanuary forthecurrentyearandincludetheresultsofanydifference thecompanycontinuestoreceivepaymentsfromthesecus betweenusgaapaccountingandtaxreportingrecordedas tomersandinsomecaseslatepaymentpremiumsforcustomers deferredtaxassetsorliabilitiesthecompanyestimatesdeferred wherepaymentisexpectedoverperiodsoftimelongerthanone taxassetsandliabilitiesbasedoncurrenttaxregulationsandrates yearrevenueandtradereceivableshavebeendiscountedoverthe changesintaxlawsandratesmayaffectrecordeddeferredtax estimatedperiodoftimeforcollectionallowancesfordoubtful assetsandliabilitiesinthefuturemanagementbelievesthat accountshavebeenincreasedforthesecustomersbuthavebeen changesintheseestimateswouldnothaveamaterialeffectonthe immaterialtodatethecompanywillcontinuetoworkclosely companysresultsofoperationscashflowsorfinancialposition withthesecustomersmonitortheeconomicsituationandtake atjanuaryandjanuarythecumulative appropriateactionsasnecessary amountsofundistributedinternationalearningswereapproximately billionandbillionrespectivelyatjanuaryand researchanddevelopment januarythecompanysforeignsubsidiariesheldbalances researchanddevelopmentexpensesareexpensedasincurred ofcashandcashequivalentsintheamountsofbillionand upfrontandmilestonepaymentsmadetothirdpartiesinconnec billionrespectivelythecompanyintendstocontinueto tionwithresearchanddevelopmentcollaborationsareexpensedas reinvestitsundistributedinternationalearningstoexpandits incurreduptothepointofregulatoryapprovalpaymentsmadeto internationaloperationsthereforenoustaxexpensehasbeen thirdpartiessubsequenttoregulatoryapprovalarecapitalizedand recordedwithrespecttotheundistributedportionnotintended amortizedovertheremainingusefullifeoftherelatedproduct forrepatriation amountscapitalizedforsuchpaymentsareincludedinother seenotetotheconsolidatedfinancialstatementsfor intangiblesnetofaccumulatedamortization furtherinformationregardingincometaxes thecompanyentersintocollaborativearrangementstypically withotherpharmaceuticalorbiotechnologycompaniestodevelop netearningspershare andcommercializedrugcandidatesorintellectualpropertythese basicearningspershareiscomputedbydividingnetearningsavail arrangementstypicallyinvolvetwoormorepartieswhoareactive abletocommonshareholdersbytheweightedaveragenumberof participantsinthecollaborationandareexposedtosignificantrisks commonsharesoutstandingfortheperioddilutedearningsper andrewardsdependentonthecommercialsuccessoftheactivities sharereflectsthepotentialdilutionthatcouldoccurifsecurities thesecollaborationsusuallyinvolvevariousactivitiesbyoneor wereexercisedorconvertedintocommonstockusingthetreasury morepartiesincludingresearchanddevelopmentmarketingand stockmethod sellinganddistributionoftenthesecollaborationsrequireupfront milestoneandroyaltyorprofitsharepaymentscontingentuponthe useofestimates occurrenceofcertainfutureeventslinkedtothesuccessoftheasset thepreparationofconsolidatedfinancialstatementsinconformity indevelopmentamountsduefromcollaborativepartnersrelated withaccountingprinciplesgenerallyacceptedintheusrequires todevelopmentactivitiesaregenerallyreflectedasareductionof managementtomakeestimatesandassumptionsthataffectthe researchanddevelopmentexpensebecausetheperformanceof amountsreportedestimatesareusedwhenaccountingforsales contractdevelopmentservicesisnotcentraltothecompanys discountsrebatesallowancesandincentivesproductliabilities incometaxesdepreciationamortizationemployeebenefits notes consolidated financial statements contingenciesandintangibleassetandliabilityvaluationsfor inventories instanceindeterminingannualpensionandpostemploymentben attheendofandinventorieswerecomprisedof efitcoststhecompanyestimatestherateofreturnonplanassets dollarsinmillions andthecostoffuturehealthcarebenefitsactualresultsmayor rawmaterialsandsupplies maynotdifferfromthoseestimates thecompanyfollowstheprovisionsofusgaapwhenrecord goodsinprocess inglitigationrelatedcontingenciesaliabilityisrecordedwhenaloss finishedgoods isprobableandcanbereasonablyestimatedthebestestimateofa totalinventories losswithinarangeisaccruedhoweverifnoestimateintherangeis betterthananyothertheminimumamountisaccrued propertyplantandequipment annualclosingdate attheendofandpropertyplantandequipmentatcost thecompanyfollowstheconceptofafiscalyearwhichendsonthe andaccumulateddepreciationwere sundaynearesttotheendofthemonthofdecembernormally dollarsinmillions eachfiscalyearconsistsofweeksbuteveryfiveorsixyearsthe landandlandimprovements fiscalyearconsistsofweeksaswasthecaseinandwillbe buildingsandbuildingequipment thecaseagainin machineryandequipment reclassification constructioninprogress certainpriorperiodamountshavebeenreclassifiedtoconformto totalpropertyplantandequipmentgross currentyearpresentation lessaccumulateddepreciation totalpropertyplantandequipmentnet cashcashequivalentsandcurrent thecompanycapitalizesinterestexpenseaspartofthecostofcon marketablesecurities structionoffacilitiesandequipmentinterestexpensecapitalizedin attheendofandcashcashequivalentsandcurrent andwasmillionmillionandmillion marketablesecuritieswerecomprisedof respectively dollarsinmillions depreciationexpenseincludingtheamortizationofcapitalized cash interestinandwasbillionbillionand governmentsecuritiesandobligations billionrespectively corporatedebtsecurities uponretirementorotherdisposalofpropertyplantandequip mentthecostsandrelatedamountsofaccumulateddepreciation moneymarketfunds oramortizationareeliminatedfromtheassetandaccumulated timedeposits depreciationaccountsrespectivelythedifferenceifanybetween totalcashcashequivalentsand thenetassetvalueandtheproceedsarerecordedinearnings currentmarketablesecurities theestimatedfairvaluewasmillionasofjanuary intangibleassetsandgoodwill reflectingamillionunrealizedgainingovernmentsecuritiesand attheendofandthegrossandnetamountsof obligationstheestimatedfairvaluewasthesameasthecarrying intangibleassetswere valueasofjanuary asofjanuarycurrentmarketablesecuritiesconsisted dollarsinmillions ofmillionandmillionofgovernmentsecuritiesand intangibleassetswithdefinitelives obligationsandcorporatedebtsecuritiesrespectively patentsandtrademarksgross asofjanuarycurrentmarketablesecuritiesconsisted lessaccumulatedamortization ofmillionandmillionofgovernmentsecuritiesand patentsandtrademarksnet obligationsandcorporatedebtsecuritiesrespectively otherintangiblesgross fairvalueofgovernmentsecuritiesandobligationsandcorpo lessaccumulatedamortization ratedebtsecuritieswereestimatedusingquotedbrokerpricesin otherintangiblesnet activemarkets thecompanyinvestsitsexcesscashinbothdepositswith intangibleassetswithindefinitelives majorbanksthroughouttheworldandotherhighqualitymoney trademarks marketinstrumentsthecompanyhasapolicyofmakinginvest purchasedinprocessresearchanddevelopment mentsonlywithcommercialinstitutionsthathaveatleastana totalintangibleassetswithindefinitelives orequivalentcreditrating totalintangibleassetsnet theacquisitionofcrucellnvduringthefiscalfirstquarterof increasedpurchasedinprocessresearchanddevelopmentby approximatelybillionandpatentsandtrademarksbyapproxi matelybillionduringthefiscalsecondquarterofthe companyreclassifiedapproximatelybillionfrompurchased inprocessresearchanddevelopmenttoamortizableother intangiblestoreflectthecommercializationofzytiga johnson johnson annual reportgoodwillasofjanuaryandjanuaryasallocated currentearningseffectoftherelatedforeigncurrencyassetsand bysegmentofbusinesswasasfollows liabilitiesthecompanydoesnotenterintoderivativefinancial instrumentsfortradingorspeculativepurposesorcontaincreditrisk meddevices relatedcontingentfeaturesorrequirementstopostcollateralonan dollarsinmillions consumer pharmaceuticals anddiagnostics total ongoingbasisthecompanymonitorscounterpartycreditratings goodwillatjanuary thecompanyconsiderscreditnonperformancerisktobelow acquisitions becausethecompanyentersintoagreementswithcommercialinsti currencytranslationother tutionsthathaveatleastanaorequivalentcreditratingasof goodwillatjanuary januarythecompanyhadnotionalamountsoutstandingfor acquisitions forwardforeignexchangecontractsandcrosscurrencyinterestrate currencytranslationother swapsofbillionandbillionrespectively goodwillatjanuary allderivativeinstrumentsarerecordedonthebalancesheetat fairvaluechangesinthefairvalueofderivativesarerecordedeach includesreclassificationbetweensegments periodincurrentearningsorothercomprehensiveincomedepending theweightedaverageamortizationperiodsforpatentsandtrade onwhetherthederivativeisdesignatedaspartofahedgetransaction marksandotherintangibleassetsareyearsandyears andifsothetypeofhedgetransaction respectivelytheamortizationexpenseofamortizableassetswas thedesignationasacashflowhedgeismadeattheentrancedate millionmillionandmillionbeforetaxforthefiscal intothederivativecontractatinceptionallderivativesareexpected yearsendedjanuaryjanuaryandjanuary tobehighlyeffectivechangesinthefairvalueofaderivativethatis respectivelywhichincludesthewritedownsofcertainpatents designatedasacashflowhedgeandishighlyeffectivearerecorded andintangibleassetsthesewritedownsdidnothaveamaterial inaccumulatedothercomprehensiveincomeuntiltheunderlying impactonthecompanysresultsofoperationscashflowsor transactionaffectsearningsandarethenreclassifiedtoearningsin financialposition thesameaccountasthehedgedtransactiongainslossesonnet theestimatedamortizationexpenseforthefivesucceeding investmenthedgesareaccountedforthroughthecurrencytranslation yearsapproximatesmillionbeforetaxperyearsubstantially accountandareinsignificantonanongoingbasisthecompany alloftheamortizationexpenseisincludedincostofproductssold assesseswhethereachderivativecontinuestobehighlyeffectiveinoff settingchangesinthecashflowsofhedgeditemsifandwhenaderiva tiveisnolongerexpectedtobehighlyeffectivehedgeaccountingis fairvaluemeasurements discontinuedhedgeineffectivenessifanyisincludedincurrentperiod thecompanyusesforwardexchangecontractstomanageitsexpo earningsinotherincomeexpensenetrefertonotefordisclo suretothevariabilityofcashflowsprimarilyrelatedtotheforeign suresofmovementsinaccumulatedothercomprehensiveincome exchangeratechangesoffutureintercompanyproductandthird asofjanuarythebalanceofdeferrednetlosseson partypurchasesofrawmaterialsdenominatedinforeigncurrency derivativesincludedinaccumulatedothercomprehensiveincome thecompanyalsousescrosscurrencyinterestrateswapstomanage wasmillionaftertaxforadditionalinformationseenote currencyriskprimarilyrelatedtoborrowingsbothtypesofderivatives thecompanyexpectsthatsubstantiallyalloftheamountrelatedto aredesignatedascashflowhedgesthecompanyalsousesforward foreignexchangecontractswillbereclassifiedintoearningsoverthe exchangecontractstomanageitsexposuretothevariabilityofcash nextmonthsasaresultoftransactionsthatareexpectedtooccur flowsforrepatriationofforeigndividendsthesecontractsaredesig overthatperiodthemaximumlengthoftimeoverwhichthe natedasnetinvestmenthedgesadditionallythecompanyuses companyishedgingtransactionexposureismonthsexcluding forwardexchangecontractstooffsetitsexposuretocertainforeign interestrateswapstheamountultimatelyrealizedinearningswill currencyassetsandliabilitiestheseforwardexchangecontractsare differasforeignexchangerateschangerealizedgainsandlosses notdesignatedashedgesandthereforechangesinthefairvaluesof areultimatelydeterminedbyactualexchangeratesatmaturityof thesederivativesarerecognizedinearningstherebyoffsettingthe thederivative thefollowingtableisasummaryoftheactivityrelatedtodesignatedderivativesforthefiscalyearsendedjanuaryand january gainloss gainloss reclassifiedfrom gainloss recognizedin accumulatedoci recognizedin cashflowhedges accumulatedoci intoincome otherincomeexpense dollarsinmillions foreignexchangecontracts foreignexchangecontracts b b foreignexchangecontracts c c crosscurrencyinterestrateswaps foreignexchangecontracts e e total allamountsshowninthetableabovearenetoftax effectiveportion ineffectiveportion aincludedinsalestocustomers bincludedincostofproductssold cincludedinresearchanddevelopmentexpense dincludedininterestincomeinterestexpensenet eincludedinotherincomeexpensenet notes consolidated financial statements forthefiscalyearsendedjanuaryandjanuaryaloss thehierarchyaredescribedbelowwithlevelhavingthehighest ofmillionandmillionrespectivelywasrecognizedinother priorityandlevelhavingthelowest incomeexpensenetrelatingtoforeignexchangecontractsnot thefairvalueofaderivativefinancialinstrumentieforward designatedashedginginstruments exchangecontractcurrencyswapistheaggregationbycurrencyof inadditionduringthefiscalsecondquarterofthe allfuturecashflowsdiscountedtoitspresentvalueattheprevailing companyenteredintoanoptiontohedgethecurrencyriskassoci marketinterestratesandsubsequentlyconvertedtotheusdollar atedwiththecashportionofthepaymentfortheplannedacquisi atthecurrentspotforeignexchangeratethecompanydoesnot tionofsynthesinctheoptionwasnotdesignatedasahedgeand believethatfairvaluesofthesederivativeinstrumentsmaterially thereforechangesinthefairvalueoftheoptionarerecognizedin differfromtheamountsthatcouldberealizeduponsettlementor otherincomeexpensenetduringthefiscalyearendedjanuary maturityorthatthechangesinfairvaluewillhaveamaterialeffect themarktomarketadjustmenttoreducethevalueofthecur onthecompanysresultsofoperationscashflowsorfinancialposi rencyoptionwasmillionwhichexpiredinjanuarythe tionthecompanyalsoholdsequityinvestmentsthatareclassified costbasisoftheoptionwasmillion aslevelastheyaretradedinanactiveexchangemarket duringthefiscalfourthquarterofthecompanyreclassi thefollowingthreelevelsofinputsareusedtomeasure fiedforeigncurrencybondmarktomarketadjustmentsfromforeign fairvalue currencytranslationtogainlossonderivativesandhedgesthere levelquotedpricesinactivemarketsforidenticalassets wasnonetimpactwithinothercomprehensiveincomeasaresult andliabilities ofthisreclassification fairvalueistheexitpricethatwouldbereceivedtosellan levelsignificantotherobservableinputs assetorpaidtotransferaliabilityfairvalueisamarketbased levelsignificantunobservableinputs measurementthatshouldbedeterminedusingassumptionsthat marketparticipantswoulduseinpricinganassetorliability theauthoritativeliteratureestablishesathreelevelhierarchyto prioritizetheinputsusedinmeasuringfairvaluethelevelswithin thecompanyssignificantfinancialassetsandliabilitiesmeasuredatfairvalueasofjanuaryandjanuarywereasfollows dollarsinmillions level level level total total derivativesdesignatedashedginginstruments assets foreignexchangecontracts crosscurrencyinterestrateswaps total liabilities foreignexchangecontracts crosscurrencyinterestrateswaps total derivativesnotdesignatedashedginginstruments assets foreignexchangecontracts swissfrancoption total liabilities foreignexchangecontracts otherinvestments currencyoptionrelatedtotheplannedacquisitionofsynthesinc assetsandliabilitiesareallclassifiedaslevelwiththeexceptionofotherinvestmentsofmillionwhichareclassifiedaslevel includesmillionandmillionofnoncurrentassetsforthefiscalyearsendingjanuaryandjanuaryrespectively includesmillionandmillionofnoncurrentliabilitiesforthefiscalyearsendingjanuaryandjanuaryrespectively classifiedasnoncurrentotherassets seenotesandforfinancialassetsandliabilitiesheldatcarryingamountontheconsolidatedbalancesheet johnson johnson annual reportborrowings thecompanyhasashelfregistrationwiththeussecurities thecomponentsoflongtermdebtareasfollows andexchangecommissionthatenablesthecompanytoissuedebt securitiesandwarrantstopurchasedebtsecuritiesonatimely effective effective basisthecompanyissuedbondsinmayforatotalofbil dollarsinmillions rate rate lionforgeneralcorporatepurposes debenturesdue aggregatematuritiesoflongtermobligationscommencingin notesdue debenturesdue monthliborfrndue dollarsinmillions monthliborfrndue notesdue notesdue debenturesdue incometaxes debenturesdue theprovisionfortaxesonincomeconsistsof notesdue dollarsinmillions beuro currentlypayable beuro ustaxes zerocouponconvertible subordinateddebenturesdue internationaltaxes debenturesdue totalcurrentlypayable notesdue deferred debenturesdue ustaxes notesdue internationaltaxes mmgbp totaldeferred mmgbp provisionfortaxesonincome notesdue debenturesdue acomparisonofincometaxexpenseattheusstatutoryrateof notesdue inandtothecompanyseffectivetaxrateis debenturesdue asfollows debenturesdue dollarsinmillions notesdue us international earningsbeforetaxesonincome lesscurrentportion taxrates usstatutoryrate weightedaverageeffectiverate internationaloperationsexcludingireland translationrateatjanuary irelandandpuertoricooperations translationrateatjanuary researchandorphandrugtaxcredits theexcessofthefairvalueoverthecarryingvalueofdebtwasbillioninand billionin usstateandlocal usmanufacturingdeduction fairvalueofthenoncurrentdebtwasestimatedusingmarket ustaxoninternationalincome priceswhichwerecorroboratedbyquotedbrokerpricesin allother activemarkets thecompanyhasaccesstosubstantialsourcesoffundsat effectivetaxrate numerousbanksworldwideinseptemberthecompany includesusexpensesnotfullytaxdeductibleprimarilyrelatedtolitigationexpense securedanewdaycreditfacilitytotalcreditavailabletothe companyapproximatesbillionwhichexpiresseptember thecompanyhassubsidiariesoperatinginpuertoricoundervarious interestchargedonborrowingsunderthecreditlineagree taxincentivegrantstheincreaseinthetaxratewasprimarily mentsisbasedoneitherbidsprovidedbybankstheprimerateor duetocertainusexpenseswhicharenotfullytaxdeductible londoninterbankofferedratesliborplusapplicablemargins andhigherusstatetaxespartiallyoffsetbyincreasesintaxable commitmentfeesundertheagreementsarenotmaterial incomeinlowertaxjurisdictionsrelativetohighertaxjurisdictions throughoutthecompanycontinuedtohaveaccessto thedecreaseinthetaxrateascomparedtowasprima liquiditythroughthecommercialpapermarketshorttermborrow rilyduetodecreasesintaxableincomeinhighertaxjurisdictions ingsandthecurrentportionoflongtermdebtamountedtoapproxi relativetotaxableincomeinlowertaxjurisdictionsandcertain matelybillionattheendofofwhichbillionwas ustaxadjustments borrowedunderthecommercialpaperprogramtheremainder representsprincipallylocalborrowingbyinternationalsubsidiaries notes consolidated financial statements temporarydifferencesandcarryforwardsforand unrecognizedtaxbenefitswillsignificantlychangeoverthenext wereasfollows twelvemonthsthecompanyisnotabletoprovideareasonably reliableestimateofthetimingofanyotherfuturetaxpayments relatingtouncertaintaxpositions deferredtax deferredtax thecompanyclassifiesliabilitiesforunrecognizedtaxbenefits dollarsinmillions asset liability asset liability andrelatedinterestandpenaltiesaslongtermliabilitiesinterest employeerelatedobligations expenseandpenaltiesrelatedtounrecognizedtaxbenefitsareclas stockbasedcompensation sifiedasincometaxexpensethecompanyrecognizedaftertax depreciation interestofmillionexpensemillionincomeandmillion nondeductibleintangibles expenseinandrespectivelythetotalamountof internationalrdcapitalized accruedinterestwasmillionandmillioninand fortax respectively reservesliabilities incomereportedfortaxpurposes employeerelatedobligations netoperatingloss attheendofandemployeerelatedobligationsrecorded carryforwardinternational ontheconsolidatedbalancesheetwere miscellaneousinternational miscellaneousus dollarsinmillions pensionbenefits totaldeferredincometaxes postretirementbenefits thedifferencebetweenthenetdeferredtaxonincomeperthe postemploymentbenefits balancesheetandthenetdeferredtaxaboveisincludedintaxes deferredcompensation onincomeonthebalancesheetthecompanyhaswhollyowned totalemployeeobligations internationalsubsidiariesthathavecumulativenetlossesthe lesscurrentbenefitspayable companybelievesthatitismorelikelythannotthatthesesub employeerelatedobligationsnoncurrent sidiarieswillrealizefuturetaxableincomesufficienttoutilizethese deferredtaxassets prepaidemployeerelatedobligationsofmillionandmil thefollowingtablesummarizestheactivityrelatedto lionforandrespectivelyareincludedinotherassetson unrecognizedtaxbenefits theconsolidatedbalancesheet dollarsinmillions beginningofyear pensionsandotherbenefitplans increasesrelatedtocurrentyeartaxpositions thecompanysponsorsvariousretirementandpensionplans increasesrelatedtopriorperiodtaxpositions includingdefinedbenefitdefinedcontributionandtermination decreasesrelatedtopriorperiodtaxpositions indemnityplanswhichcovermostemployeesworldwidethe settlements companyalsoprovidespostretirementbenefitsprimarilyhealth caretoallusretiredemployeesandtheirdependents lapseofstatuteoflimitations manyinternationalemployeesarecoveredbygovernment endofyear sponsoredprogramsandthecosttothecompanyisnotsignificant retirementplanbenefitsareprimarilybasedontheemployees theunrecognizedtaxbenefitsofbillionatjanuaryif compensationduringthelastthreetofiveyearsbeforeretirement recognizedwouldaffectthecompanysannualeffectivetaxrate andthenumberofyearsofserviceinternationalsubsidiarieshave thecompanyconductsbusinessandfilestaxreturnsinnumerous plansunderwhichfundsaredepositedwithtrusteesannuitiesare countriesandcurrentlyhastaxauditsinprogresswithanumberof purchasedundergroupcontractsorreservesareprovided taxauthoritiestheusinternalrevenueserviceirshascom thecompanydoesnotfundretireehealthcarebenefitsin pleteditsauditforthetaxyearsthroughhowevertherearea advanceandhastherighttomodifytheseplansinthefuture limitednumberofissuesremainingopenforpriortaxyearsgoing thecompanyusesthedateofitsconsolidatedfinancial backtoinothermajorjurisdictionswherethecompanycon statementsjanuaryandjanuaryrespectivelyas ductsbusinesstheyearsremainopengenerallybacktotheyear themeasurementdateforallusandinternationalretirementand thecompanydoesnotexpectthatthetotalamountof otherbenefitplans johnson johnson annual reportnetperiodicbenefitcostsforthecompanysdefinedbenefitretirementplansandotherbenefitplansforandinclude thefollowingcomponents retirementplans otherbenefitplans dollarsinmillions servicecost interestcost expectedreturnonplanassets amortizationofpriorservicecost amortizationofnettransitionasset recognizedactuariallosses curtailmentsandsettlements netperiodicbenefitcost thenetperiodicbenefitcostattributabletousretirementplans unrecognizedgainsandlossesfortheuspensionplansareamor wasmillionmillionandmillioninand tizedovertheaverageremainingfutureserviceforeachplanfor respectively planswithnoactiveemployeestheyareamortizedovertheaverage amountsexpectedtoberecognizedinnetperiodicbenefitcost lifeexpectancytheamortizationofgainsandlossesfortheother inthecomingyearforthecompanysdefinedbenefitretirement usbenefitplansisdeterminedbyusingacorridorofthe plansandotherpostretirementplans greaterofthemarketvalueofassetsortheprojectedbenefitobliga tiontotalunamortizedgainsandlossesinexcessofthecorridorare dollarsinmillions amortizedovertheaverageremainingfutureservice amortizationofnettransitionobligation priorservicecostsbenefitsfortheuspensionplansare amortizationofnetactuariallosses amortizedovertheremainingfutureserviceofplanparticipantsat amortizationofpriorservicecost thetimeoftheplanamendmentpriorservicecostbenefitforthe otherusbenefitplansisamortizedovertheaverageremaining servicetofulleligibilityageofplanparticipantsatthetimeofthe planamendment theweightedaverageassumptionsinthefollowingtablerepresenttheratesusedtodeveloptheactuarialpresentvalueofprojected benefitobligationfortheyearlistedandalsothenetperiodicbenefitcostforthefollowingyear retirementplans otherbenefitplans dollarsinmillions usbenefitplans discountrate expectedlongtermrateofreturnonplanassets rateofincreaseincompensationlevels internationalbenefitplans discountrate expectedlongtermrateofreturnonplanassets rateofincreaseincompensationlevels thecompanysdiscountratesaredeterminedbyconsideringcur thefollowingtabledisplaystheassumedhealthcarecosttrend rentyieldcurvesrepresentinghighqualitylongtermfixedincome ratesforallindividuals instrumentstheresultingdiscountratesareconsistentwiththe healthcareplans durationofplanliabilities healthcarecosttrendrateassumedfornextyear theexpectedlongtermrateofreturnonplanassetsassump ratetowhichthecosttrendrateisassumed tionisdeterminedusingabuildingblockapproachconsidering todeclineultimatetrend historicalaveragesandrealreturnsofeachassetclassincertain yeartheratereachestheultimatetrendrate countrieswherehistoricalreturnsarenotmeaningfulconsidera tionisgiventolocalmarketexpectationsoflongtermreturns aonepercentagepointchangeinassumedhealthcarecosttrend rateswouldhavethefollowingeffect onepercentage onepercentage dollarsinmillions pointincrease pointdecrease healthcareplans totalinterestandservicecost postretirementbenefitobligation notes consolidated financial statements thefollowingtablesetsforthinformationrelatedtothebenefitobligationandthefairvalueofplanassetsatyearendandforthe companysdefinedbenefitretirementplansandotherpostretirementplans retirementplans otherbenefitplans dollarsinmillions changeinbenefitobligation projectedbenefitobligationbeginningofyear servicecost interestcost planparticipantcontributions amendments actuariallosses divestituresacquisitions curtailmentssettlementsrestructuring benefitspaidfromplan effectofexchangerates projectedbenefitobligationendofyear changeinplanassets planassetsatfairvaluebeginningofyear actualreturnonplanassets companycontributions planparticipantcontributions settlements divestituresacquisitions benefitspaidfromplanassets effectofexchangerates planassetsatfairvalueendofyear fundedstatusendofyear amountsrecognizedinthecompanysbalancesheetconsistofthefollowing noncurrentassets currentliabilities noncurrentliabilities totalrecognizedintheconsolidatedbalancesheetendofyear amountsrecognizedinaccumulatedothercomprehensiveincomeconsistofthefollowing netactuarialloss priorservicecostcredit unrecognizednettransitionobligation totalbeforetaxeffects accumulatedbenefitobligationsendofyear changesinplanassetsandbenefitobligationsrecognizedinothercomprehensiveincome netperiodicbenefitcost netactuarialloss amortizationofnetactuariallossgain priorservicecost amortizationofpriorservicecostcredit effectofexchangerates totalrecognizedinothercomprehensiveincomebeforetax totalrecognizedinnetperiodicbenefitcostandothercomprehensiveincome thecompanyplanstocontinuetofunditsusqualifiedplanstocomplywiththepensionprotectionactofinternationalplansare fundedinaccordancewithlocalregulationsadditionaldiscretionarycontributionsaremadewhendeemedappropriatetomeetthelong termobligationsoftheplansforcertainplansfundingisnotacommonpracticeasfundingprovidesnoeconomicbenefitconsequently thecompanyhasseveralpensionplansthatarenotfunded inthecompanycontributedmillionandmilliontoitsusandinternationalpensionplansrespectively johnson johnson annual reportthefollowingtabledisplaysthefundedstatusofthecompanysusqualifiednonqualifiedpensionplansandinternationalfunded andunfundedpensionplansatjanuaryandjanuaryrespectively usplans internationalplans qualifiedplans nonqualifiedplans fundedplans unfundedplans dollarsinmillions planassets projectedbenefitobligation accumulatedbenefitobligation overunderfundedstatus projectedbenefitobligation accumulatedbenefitobligation planswithaccumulatedbenefitobligationsinexcessofplanassetshaveanaccumulatedbenefitobligationprojectedbenefitobligation andplanassetsofbillionbillionandbillionrespectivelyattheendofandbillionbillionandbillion respectivelyattheendof thefollowingtabledisplaystheprojectedfuturebenefitpaymentsfromthecompanysretirementandotherbenefitplans dollarsinmillions projectedfuturebenefitpayments retirementplans otherbenefitplansgross medicarerebates otherbenefitplansnet thefollowingtabledisplaystheprojectedfutureminimumcontributionstothecompanysusandinternationalunfundedretirement planstheseamountsdonotincludeanydiscretionarycontributionsthatthecompanymayelecttomakeinthefuture dollarsinmillions projectedfuturecontributions unfundedusretirementplans unfundedinternationalretirementplans eachpensionplanisoverseenbyalocalcommitteeorboardthatisresponsiblefortheoveralladministrationandinvestmentofthepension plansindetermininginvestmentpoliciesstrategiesandgoalseachcommitteeorboardconsidersfactorsincludinglocalpensionrules andregulationslocaltaxregulationsavailabilityofinvestmentvehiclesseparateaccountscommingledaccountsinsurancefundsetc fundedstatusoftheplansratioofactivestoretireesdurationofliabilitiesandotherrelevantfactorsincludingdiversificationliquidityof localmarketsandliquidityofbasecurrencyamajorityofthecompanyspensionfundsareopentonewentrantsandareexpectedtobe ongoingplanspermittedinvestmentsareprimarilyliquidandorlistedwithlittlerelianceonilliquidandnontraditionalinvestmentssuch ashedgefundsanassetallocationofequitiesandfixedincomeisgenerallypursuedunlesslocalregulationsandilliquidity requireotherwise thecompanysretirementplanassetallocationattheendofandandtargetallocationsforareasfollows percentof target planassets allocation usretirementplans equitysecurities debtsecurities totalplanassets internationalretirementplans equitysecurities debtsecurities totalplanassets thecompanysotherbenefitplansareunfundedexceptforuslife thefairvalueofjohnsonjohnsoncommonstockdirectly insurancecontractassetsofmillionandmillionatjanuary heldinplanassetswasmillionoftotalplanassetsat andjanuaryrespectively januaryandmillionoftotalplanassetsat january notes consolidated financial statements determinationoffairvalueofplanassets similarcharacteristicsordiscountedcashflowswhenquoted theplanhasanestablishedandwelldocumentedprocessfor marketpricesforasecurityarenotavailableinanactivemarket determiningfairvaluesfairvalueisbaseduponquotedmarket theyareclassifiedaslevel priceswhereavailableiflistedpricesorquotesarenotavailable debtinstrumentsalimitednumberoftheseinvestmentsare fairvalueisbaseduponmodelsthatprimarilyuseasinputs valuedattheclosingpricereportedonthemajormarketonwhich marketbasedorindependentlysourcedmarketparametersinclud theindividualsecuritiesaretradedwherequotedpricesareavail ingyieldcurvesinterestratesvolatilitiesequityordebtprices ableinanactivemarkettheinvestmentsareclassifiedaslevelif foreignexchangeratesandcreditcurves quotedmarketpricesarenotavailableforthespecificsecuritythen whiletheplanbelievesitsvaluationmethodsareappropriate fairvaluesareestimatedbyusingpricingmodelsquotedpricesof andconsistentwithothermarketparticipantstheuseofdifferent securitieswithsimilarcharacteristicsordiscountedcashflowsand methodologiesorassumptionstodeterminethefairvalueofcertain areclassifiedaslevelleveldebtinstrumentsarepricedbased financialinstrumentscouldresultinadifferentestimateoffairvalue onunobservableinputs atthereportingdate equitysecuritiescommonstocksarevaluedattheclosing pricereportedonthemajormarketonwhichtheindividualsecuri valuationhierarchy tiesaretradedsubstantiallyallcommonstockisclassifiedwithin theauthoritativeliteratureestablishesathreelevelhierarchyto levelofthevaluationhierarchy prioritizetheinputsusedinmeasuringfairvaluethelevelswithin thehierarchyaredescribedinthetablebelowwithlevelhaving commingledfundstheinvestmentsarepublicinvestment thehighestpriorityandlevelhavingthelowest vehiclesvaluedusingthenavprovidedbythefundadministrator afinancialinstrumentscategorizationwithinthevaluation thenavisbasedonthevalueoftheunderlyingassetsownedby hierarchyisbaseduponthelowestlevelofinputthatissignificant thefundminusitsliabilitiesandthendividedbythenumberof tothefairvaluemeasurement sharesoutstandingassetsinthelevelcategoryhaveaquoted followingisadescriptionofthevaluationmethodologiesused marketpriceinamarketthatisnotactive fortheinvestmentsmeasuredatfairvalue insurancecontractstheinstrumentsareissuedbyinsurance shortterminvestmentscashandquotedshortterminstru companiesthefairvalueisbasedonnegotiatedvalueandthe mentsarevaluedattheclosingpriceortheamountheldondeposit underlyinginvestmentsheldinseparateaccountportfoliosaswell bythecustodianbankotherinvestmentsarethroughinvestment asconsideringthecreditworthinessoftheissuertheunderlying vehiclesvaluedusingthenetassetvaluenavprovidedbythe investmentsaregovernmentassetbackedandfixedincomesecuri administratorofthefundthenavisbasedonthevalueofthe tiesingeneralinsurancecontractsareclassifiedaslevelasthere underlyingassetsownedbythefundminusitsliabilitiesandthen arenoquotedpricesnorotherobservableinputsforpricing dividedbythenumberofsharesoutstandingthenavisaquoted otherassetsotherassetsarerepresentedprimarilybylimited priceinamarketthatisnotactiveandclassifiedaslevel partnershipsandrealestateinvestmentsaswellascommercial governmentandagencysecuritiesalimitednumberofthese loansandcommercialmortgagesthatarenotclassifiedascorporate investmentsarevaluedattheclosingpricereportedonthemajor debtotherassetsthatareexchangelistedandactivelytradedare marketonwhichtheindividualsecuritiesaretradedwherequoted classifiedaslevelwhileinactivelytradedassetsareclassifiedas pricesareavailableinanactivemarkettheinvestmentsareclassi levelmostlimitedpartnershipsrepresentinvestmentsinprivate fiedwithinlevelofthevaluationhierarchyifquotedmarketprices equityandsimilarfundsthatarevaluedbythegeneralpartners arenotavailableforthespecificsecuritythenfairvaluesareesti theseaswellasanyotherassetsvaluedusingunobservableinputs matedbyusingpricingmodelsquotedpricesofsecuritieswith areclassifiedaslevel thefollowingtablesetsforththetrustinvestmentsmeasuredatfairvalueasofjanuaryandjanuary quotedprices significant inactive significant marketsfor observable unobservable identicalassets inputs inputs level level level totalassets dollarsinmillions shortterminvestmentfunds governmentandagencysecurities debtinstruments equitysecurities commingledfunds insurancecontracts otherassets trustinvestmentsatfairvalue johnson johnson annual reportlevelgainsandlosses thetablebelowsetsforthasummaryofchangesinthefairvalueoftheplanslevelassetsfortheyearsendedjanuaryand january debt equity commingled insurance total dollarsinmillions instruments securities funds contracts assets level balancejanuary realizedgainslosses unrealizedgainslosses purchasessalesissuancesandsettlementsnet balancejanuary realizedgainslosses unrealizedgainslosses purchasessalesissuancesandsettlementsnet balancejanuary savingsplan accumulatedothercomprehensiveincome thecompanyhasvoluntaryksavingsplansdesignedto componentsofothercomprehensiveincomelossconsistof enhancetheexistingretirementprogramscoveringeligibleemploy thefollowing eesthecompanymatchesapercentageofeachemployees total contributionsconsistentwiththeprovisionsoftheplanforwhich gains accumulated hesheiseligibletotalcompanymatchingcontributionstothe foreign gains losseson plansweremillionmillionandmillionin currency losseson employee derivatives comprehensive dollarsinmillions translation securities benefitplans hedges incomeloss andrespectively december changes capitalandtreasurystock unrealizedgainloss changesintreasurystockwere netamountreclassed tonetearnings amountsinmillionsexcepttreasury treasurystock netchanges stocksharesinthousands shares amount balanceatdecember january employeecompensationandstockoptionplans changes repurchaseofcommonstock unrealizedgainloss netamountreclassed balanceatjanuary tonetearnings employeecompensationandstockoptionplans netchanges repurchaseofcommonstock january balanceatjanuary changes employeecompensationandstockoptionplans unrealizedgainloss repurchaseofcommonstock netamountreclassed balanceatjanuary tonetearnings netchanges aggregatesharesofcommonstockissuedwereapproximately sharesattheendofand january cashdividendspaidwerepershareincompared withdividendsofpershareinandpershare thetaxeffectontheunrealizedgainslossesonequitysecurities wasexpenseofmillioninexpenseofmillionin andincomeofmillioninthetaxeffectrelatedto employeebenefitplanswasmillionmillionandmil lioninandrespectivelythetaxeffectonthe gainslossesonderivativesandhedgeswasincomeofmillion inandexpenseofmillionandmillioninand respectivelyseenoteforadditionalinformationrelating toderivativesandhedging thecurrencytranslationadjustmentsarenotadjustedfor incometaxesastheyrelatetopermanentinvestmentsin internationalsubsidiaries notes consolidated financial statements internationalcurrencytranslation commonstockstockoptionplansandstock fortranslationofitssubsidiariesoperatinginnonusdollarcur compensationagreements renciesthecompanyhasdeterminedthatthelocalcurrenciesofits atjanuarythecompanyhadstockbasedcompensa internationalsubsidiariesarethefunctionalcurrenciesexceptthose tionplansthesharesoutstandingareforcontractsunderthe inhighlyinflationaryeconomieswhicharedefinedasthosewhich companysstockoptionplanthelongtermincentive havehadcompoundcumulativeratesofinflationoformore planthenonemployeedirectorsplanandsciosincstock duringthepastthreeyearsorwhereasubstantialportionofits optionplansduringnooptionsorrestrictedshareswere cashflowsarenotinthelocalcurrency grantedunderanyoftheseplansexceptunderthelongterm inconsolidatinginternationalsubsidiariesbalancesheetcur incentiveplan rencyeffectsarerecordedasacomponentofaccumulatedother thecompensationcostthathasbeenchargedagainstincome comprehensiveincomethisequityaccountincludestheresults fortheseplanswasmillionmillionandmillionfor oftranslatingallbalancesheetassetsandliabilitiesatcurrent andrespectivelythetotalincometaxbenefit exchangeratesexceptforthoselocatedinhighlyinflationary recognizedintheincomestatementforsharebasedcompensation economiesthetranslationofbalancesheetaccountsforhighly costswasmillionmillionandmillionfor inflationaryeconomiesarereflectedintheoperatingresults andrespectivelythetotalunrecognizedcompensation ananalysisofthechangesduringandfor costwasmillionmillionandmillionfor foreigncurrencytranslationadjustmentsisincludedinnote andrespectivelytheweightedaverageperiodforthiscost netcurrencytransactiongainsandlossesincludedinother toberecognizedwasyearsyearsandyearsfor incomeexpensewerelossesofmillionmillionand andrespectivelysharebasedcompensationcosts millioninandrespectively capitalizedaspartofinventorywereinsignificantinallperiods stockoptions earningspershare stockoptionsexpireyearsfromthedateofgrantandvest thefollowingisareconciliationofbasicnetearningspershareto overserviceperiodsthatrangefromsixmonthstofouryears dilutednetearningspershareforthefiscalyearsendedjanuary alloptionsaregrantedattheaverageofthehighandlowpricesof januaryandjanuary thecompanyscommonstockonthenewyorkstockexchange onthedateofgrantunderthelongtermincentiveplan inmillionsexceptpersharedata thecompanymayissueuptomillionsharesofcommonstock basicnetearningspershare sharesavailableforfuturegrantsunderthelongterm averageshares incentiveplanweremillionattheendof outstandingbasic thecompanysettlesemployeestockoptionexerciseswith potentialsharesexercisable treasurysharestreasurysharesarereplenishedthroughoutthe understockoptionplans yearforthenumberofsharesusedtosettleemployeestock lesssharesrepurchased optionexercises undertreasurystockmethod thefairvalueofeachoptionawardwasestimatedonthedate convertibledebtshares ofgrantusingtheblackscholesoptionvaluationmodelthatuses adjustedaverageshares theassumptionsnotedinthefollowingtableexpectedvolatility outstandingdiluted representsablendedrateofyeardailyhistoricalaveragevolatility dilutednetearningspershare rateandaweekaverageimpliedvolatilityratebasedonatthe moneytradedjohnsonjohnsonoptionswithalifeofyears thedilutednetearningspersharecalculationincludesthedilutive historicaldataisusedtodeterminetheexpectedlifeoftheoption effectofconvertibledebtthatisoffsetbytherelatedreduction theriskfreeratewasbasedontheustreasuryyieldcurvein ininterestexpenseofmillionaftertaxforyears effectatthetimeofgrant theaveragefairvalueofoptionsgrantedwasand dilutednetearningspershareexcludesmillionmillion inandrespectivelythefairvaluewas andmillionsharesunderlyingstockoptionsforand estimatedbasedontheweightedaverageassumptionsof respectivelyastheexercisepriceoftheseoptionswas greaterthantheiraveragemarketvaluewhichwouldresultinan antidilutiveeffectondilutedearningspershare riskfreerate expectedvolatility expectedlife yrs yrs yrs rentalexpenseandleasecommitments dividendyield rentalsofspacevehiclesmanufacturingequipmentandofficeand dataprocessingequipmentunderoperatingleaseswereapproxi matelymillionmillionandmillioninand respectively theapproximateminimumrentalpaymentsrequiredunder operatingleasesthathaveinitialorremainingnoncancelablelease termsinexcessofoneyearatjanuaryare dollarsinmillions total commitmentsundercapitalleasesarenotsignificant johnson johnson annual reportasummaryofoptionactivityundertheplanasofjanuary stockoptionsexercisableatjanuaryandjanuary januaryandjanuaryandchangesduringtheyears wereatanaveragepriceofandanaveragelifeof endingonthosedatesispresentedbelow yearsandatanaveragepriceofandanaverage lifeofyearsrespectively weighted aggregate outstanding average intrinsicvalue sharesinthousands shares exerciseprice dollarsinmillions restrictedshareunits sharesatdecember thecompanygrantsrestrictedshareunitswithavestingperiodof threeyearsthecompanysettlesemployeestockissuanceswith optionsgranted treasurysharestreasurysharesarereplenishedthroughoutthe optionsexercised yearforthenumberofsharesusedforemployeestockissuances optionscanceledforfeited asummaryofshareactivityundertheplanasofjanuary sharesatjanuary outstanding optionsgranted sharesinthousands shares optionsexercised sharesatdecember optionscanceledforfeited granted sharesatjanuary issued optionsgranted canceledforfeited optionsexercised sharesatjanuary optionscanceledforfeited granted sharesatjanuary issued canceledforfeited thetotalintrinsicvalueofoptionsexercisedwasmillion sharesatjanuary millionandmillioninandrespectively granted thefollowingtablesummarizesstockoptionsoutstandingand issued exercisableatjanuary canceledforfeited sharesinthousands outstanding exercisable sharesatjanuary average average exercise average exercise exercise theaveragefairvalueoftherestrictedshareunitsgrantedwas pricerange options life price options price andinandrespectively usingthefairmarketvalueatthedateofgrantthefairvalueof restrictedshareunitswasdiscountedfordividendswhichare notpaidontherestrictedshareunitsduringthevestingperiod thefairvalueofrestrictedshareunitssettledwasmillion millionandmillioninand respectively averagecontractualliferemaininginyears notes consolidated financial statements segmentsofbusinessandgeographicareas salestocustomers dollarsinmillions consumer unitedstates international total pharmaceutical unitedstates international total medicaldevicesanddiagnostics unitedstates international total worldwidetotal operatingprofit identifiableassets dollarsinmillions consumer pharmaceutical medicaldevicesanddiagnostics total lessexpensenotallocatedtosegments generalcorporate worldwidetotal additionstoproperty depreciationand plantequipment amortization dollarsinmillions consumer pharmaceutical medicaldevicesanddiagnostics segmentstotal generalcorporate worldwidetotal salestocustomers longlivedassets dollarsinmillions unitedstates europe westernhemisphereexcludingus asiapacificafrica segmentstotal generalcorporate othernonlonglivedassets worldwidetotal seenoteforadescriptionofthesegmentsinwhichthecompanyoperates exportsalesarenotsignificantinandthecompanydidnothaveacustomerthatrepresentedoftotalrevenues amountsnotallocatedtosegmentsincludeinterestincomeexpensenoncontrollinginterestsandgeneralcorporateincomeexpenseincludedinwasabillionexpensefor theadjustmenttothevalueofthecurrencyoptionrelatedtotheplannedacquisitionofsynthesinc generalcorporateincludescashandmarketablesecurities includesmillionofnetlitigationexpensecomprisedofmillionandmillioninthepharmaceuticalandmedicaldevicesanddiagnosticssegmentsrespectivelyincludes millionofproductliabilityexpensecomprisedofmillioninthepharmaceuticalsegmentandmillioninthemedicaldevicesanddiagnosticssegmentincludes millionofnetrestructuringexpensecomprisedofmillionexpenseinthemedicaldevicesanddiagnosticssegmentandagainofmillioninthepharmaceuticalsegment themedicaldevicesanddiagnosticssegmentalsoincludesmillionexpenseforthecostassociatedwiththedepuyasrhiprecallprogram includesmillionofnetlitigationgaincomprisedofmillionexpenseinthepharmaceuticalsegmentandagainofmillioninthemedicaldevicesanddiagnosticssegment includesmillionofproductliabilityexpensecomprisedofmillioninthepharmaceuticalsegmentandmillioninthemedicaldevicesanddiagnosticssegmentthemedical devicesanddiagnosticssegmentalsoincludesmillionexpenseforthecostassociatedwiththedepuyasrhiprecallprogram includesmillionofrestructuringexpensecomprisedofmillionmillionandmillionfortheconsumerpharmaceuticalandmedicaldevicesanddiagnostics segmentsrespectivelyincludesmillionoffourthquarternetlitigationgaincomprisedofamillionexpenseinthepharmaceuticalsegmentandagainofmillioninthe medicaldevicesanddiagnosticssegment longlivedassetsincludepropertyplantandequipmentnetforandofandrespectivelyandintangibleassetsandgoodwillnetfor andofandrespectively johnson johnson annual reportselectedquarterlyfinancialdataunaudited selectedunauditedquarterlyfinancialdatafortheyearsandaresummarizedbelow first second third fourth first second third fourth dollarsinmillionsexceptpersharedata quarter quarter quarter quarter quarter quarter quarter quarter segmentsalestocustomers consumer pharmaceutical medicaldevicesanddiagnostics totalsales grossprofit earningsbeforeprovisionfortaxesonincome netearnings basicnetearningspershare dilutednetearningspershare thefirstquarterofincludesanaftertaxchargeofmillionfromlitigationandproductliabilityexpensesanddepuyasrhiprecallcosts thesecondquarterofincludesaftertaxchargesofmillionforrestructuringmillionfromlitigationproductliabilityexpensesanddepuyasrhiprecallcostspartially offsetbyamillionaftertaxgainassociatedwithanadjustmenttothevalueofthecurrencyoptionrelatedtotheplannedacquisitionofsynthesinc thethirdquarterofincludesamillionaftertaxchargeassociatedwithanadjustmenttothevalueofthecurrencyoptionanddealcostsrelatedtotheplannedacquisitionof synthesinc thefourthquarterofincludesaftertaxchargesofmillionfromnetlitigationsettlementsmillionforproductliabilityexpensesmillionforthecostassociatedwith thedepuyasrhiprecallprogramandmillionassociatedwithanadjustmenttothevalueofthecurrencyoptionanddealcostsrelatedtotheplannedacquisitionofsynthesinc thefirstquarterofincludesmillionaftertaxofincomefromnetlitigation thesecondquarterofincludesmillionaftertaxofincomefromnetlitigation thefourthquarterofincludesanaftertaxchargeofmillionfromnetlitigationsettlementsanaftertaxchargeofmillionforproductliabilityexpenseandanaftertax chargeofmillionforthecostassociatedwiththedepuyasrhiprecallprogram businesscombinationsanddivestitures commonstocksubjecttocertainconditionswouldbeexchanged certainbusinesseswereacquiredformillionincashand forapproximatelyincashandinjohnsonjohnson millionofliabilitiesassumedduringtheseacquisitions commonstocksynthesincisapremierglobaldeveloperand wereaccountedforbythepurchasemethodandaccordingly manufactureroforthopaedicsdevicesondecembera resultsofoperationshavebeenincludedinthefinancialstatements specialmeetingofstockholderswasheldatthesynthesofficesand fromtheirrespectivedatesofacquisition thesynthesshareholdersapprovedtheproposaltoadopttheagree theacquisitionsincludedcrucellnvaglobalbiophar mentandplanofmergertheacquisitionisexpectedtocloseinthe maceuticalcompanyfocusedontheresearchanddevelopment firsthalfof productionandmarketingofvaccinesandantibodiesagainstinfec certainbusinesseswereacquiredformillionincashand tiousdiseaseworldwidetheoverthecounterotcbrandsof millionofliabilitiesassumedduringtheseacquisitions jbchemicalspharmaceuticalslimitedincludingrinzarussias wereaccountedforbythepurchasemethodandaccordingly leadingmultisymptomcoughandcoldbrandanddoktormom resultsofoperationshavebeenincludedinthefinancialstatements russiasnumbertwosellingcoughbrandaswellasseveralother fromtheirrespectivedatesofacquisition brandsfullownershipofthejohnsonjohnsonmerckconsumer theacquisitionsincludedacclarentincaprivatelyheld pharmaceuticalscojointventureintheusfrommercksharp medicaltechnologycompanydedicatedtodesigningdeveloping dohmecorpandsterilmedincaleaderinthereprocessingand andcommercializingdevicesthataddressconditionsaffectingthe remanufacturingofmedicaldevicesintheus earnoseandthroatentrespivertltdaprivatelyhelddrug theexcessofpurchasepriceovertheestimatedfairvalueof discoverycompanyfocusedondevelopingsmallmoleculeinhaled tangibleassetsacquiredamountedtomillionandhasbeen therapiesforthetreatmentofpulmonarydiseasesandmicrus assignedtoidentifiableintangibleassetswithanyresidualrecorded endovascularcorporationaglobaldeveloperandmanufacturerof togoodwillofthisamountapproximatelymillionhasbeen minimallyinvasivedevicesforhemorrhagicandischemicstroke identifiedasthevalueofiprdassociatedwiththeacquisitionof theexcessofpurchasepriceovertheestimatedfairvalueof crucellnv tangibleassetsacquiredamountedtomillionandhasbeen theiprdrelatedtotheacquisitionofcrucellnvofmil assignedtoidentifiableintangibleassetswithanyresidualrecorded lionisassociatedwithvaccinesandantibodiesthatpreventandor togoodwillofthisamountapproximatelymillionhasbeen treatinfectiousdiseasesthevalueoftheiprdwascalculated identifiedasthevalueofiprdassociatedwiththeacquisitionsof usingcashflowprojectionsdiscountedfortheriskinherentinsuch acclarentincrespivertltdandmicrusendovascularcorporation projectsprobabilityofsuccessfactorsrangingfromwere theiprdrelatedtotheacquisitionofacclarentincwas usedtoreflectinherentclinicalandregulatoryriskthediscountrate millionandisassociatedwithnovelendoscopiccatheter appliedwas baseddevicestomeettheneedsofentpatientsthevalueofthe duringthefiscalsecondquarterofthecompanyentered iprdwascalculatedusingcashflowprojectionsdiscountedfor intoadefinitiveagreementtoacquiresynthesincforapproximately theriskinherentinsuchprojectsprobabilityofsuccessfactors billionapproximatelybillionnetofcashacquiredsubject rangingfromwereusedtoreflectinherentclinicaland tothetermsofthemergeragreementandcurrencyvaluesatthetime regulatoryriskthediscountrateappliedwas ofclosingunderthetermsoftheagreementeachshareofsynthes notes consolidated financial statements theiprdrelatedtotheacquisitionofrespivertltdwas millionrepresentsthefairvalueoftheinvestmentin millionandisassociatedwithnarrowspectrumkinase elanbasedonelanssharepriceinanactivelytradedmarketasof inhibitorswithauniqueprofileofantiinflammatoryactivitiesas thedateofthistransactiontheiprdrelatedtothistransaction treatmentsformoderatetosevereasthmachronicobstructive wasmillionandisassociatedwithbapineuzumabapotential pulmonarydiseasecopdandcysticfibrosiscfthevalueof firstinclasstreatmentthatisbeingevaluatedforslowingthepro theiprdwascalculatedusingcashflowprojectionsdiscounted gressionofalzheimersdiseasethevalueoftheiprdwascalcu fortheriskinherentinsuchprojectsprobabilityofsuccessfactors latedusingcashflowprojectionsdiscountedfortheriskinherentin rangingfromwereusedtoreflectinherentclinicaland suchprojectsprobabilityofsuccessfactorsrangingfrom regulatoryriskthediscountrateappliedwas wereusedtoreflectinherentclinicalandregulatoryriskthedis theiprdrelatedtotheacquisitionofmicrusendovascular countrateappliedwasthenoncontrollinginterestrelatedto corporationwasmillionandisassociatedwithischemicand thistransactionwasmillionwhichthecompanyhasrecorded flowdivertertechnologiesthevalueoftheiprdwascalculated inothernoncurrentliabilities usingcashflowprojectionsdiscountedfortheriskinherentinsuch supplementalproformainformationforandin projectsprobabilityofsuccessfactorsrangingfromwere accordancewithusgaapstandardsrelatedtobusinesscombina usedtoreflectinherentclinicalandregulatoryriskthediscount tionsandgoodwillandotherintangibleassetsisnotprovidedas rateappliedwas theimpactoftheaforementionedacquisitionsdidnothaveamate certainbusinesseswereacquiredformillionincash rialeffectonthecompanysresultsofoperationscashflowsor andmillionofliabilitiesassumedandnoncontrollinginterests financialposition duringtheseacquisitionswereaccountedforbythepur duringthecompanydivestituresincludedtheanimal chasemethodandaccordinglyresultsofoperationshavebeen healthbusinesstoelancoadivisionofelilillymonistatin includedinthefinancialstatementsfromtheirrespectivedates canadatheusanditsterritoriesincludingpuertoricoassets ofacquisition oftheorthodermatologicsdivisionintheustosubsidiariesof theacquisitionsincludedmentorcorporationaleading valeantpharmaceuticalsinternationalincandthesurgicalinstru supplierofmedicalproductsfortheglobalaestheticsmarket mentsbusinessofcodmanshurtleffincinthegainson cougarbiotechnologyincadevelopmentstagebiopharmaceutical thedivestituresofbusinesseswerebillionduringthe companywithaspecificfocusononcologyfinsburyorthopaedics companydivestituresincludedthebreastcarebusinessofethicon limitedaprivatelyheldukbasedmanufacturerandglobaldis endosurgeryincthegainsonthedivestitureswererecognizedin tributoroforthopaedicimplantsglostereuropeaprivatelyheld otherincomeexpensenet developerofinnovativedisinfectionprocessesandtechnologiesto preventhealthcareacquiredinfectionsandsubstantiallyallofthe legalproceedings assetsandrightsofelansalzheimersimmunotherapyprogram throughanewlyformedcompanyofwhichthecompanyowns johnsonjohnsonandcertainofitssubsidiariesareinvolvedin andelanowns variouslawsuitsandclaimsregardingproductliabilityintellectual theexcessofpurchasepriceovertheestimatedfairvalueof propertycommercialandothermattersgovernmentalinvestiga tangibleassetsacquiredamountedtomillionandhasbeen tionsandotherlegalproceedingsthatarisefromtimetotimein assignedtoidentifiableintangibleassetswithanyresidualrecorded theordinarycourseoftheirbusiness togoodwillofthisamountapproximatelymillionhasbeen thecompanyrecordsaccrualsforsuchcontingencieswhenit identifiedasthevalueofiprdprimarilyassociatedwiththeacqui isprobablethataliabilitywillbeincurredandtheamountoftheloss sitionsofcougarbiotechnologyincandsubstantiallyallofthe canbereasonablyestimatedasofjanuarythecompany assetsandrightsofelansalzheimersimmunotherapyprogram hasdeterminedthattheliabilitiesassociatedwithcertainlitigation additionallyapproximatelymillionhasbeenidentifiedas mattersareprobableandcanbereasonablyestimatedthe thevalueofotherintangibleassetsincludingpatentsandtechnol companyhasaccruedforthesemattersandwillcontinuetomoni ogyandcustomerrelationshipsprimarilyassociatedwiththe toreachrelatedlegalissueandadjustaccrualsfornewinformation acquisitionofmentorcorporation andfurtherdevelopmentsinaccordancewithascfor theiprdrelatedtotheacquisitionofcougarbiotechnology theseandotherlitigationandregulatorymatterscurrentlydisclosed incwasmillionandisassociatedwithabirateroneacetatea forwhichalossisprobableorreasonablypossiblethecompanyis latestagefirstinclasscompoundforthetreatmentofprostate unabletodetermineanestimateofthepossiblelossorrangeof cancerthevalueoftheiprdwascalculatedusingcashflowpro lossbeyondtheamountsalreadyaccruedthesematterscanbe jectionsdiscountedfortheriskinherentinsuchprojectsprobability affectedbyvariousfactorsincludingwhetherdamagessoughtin ofsuccessfactorsrangingfromwereusedtoreflect theproceedingsareunsubstantiatedorindeterminatescientificand inherentclinicalandregulatoryriskthediscountrateapplied legaldiscoveryhasnotcommencedorisnotcompleteproceedings areinearlystagesmatterspresentlegaluncertaintiesthereare duringthecompanyacquiredsubstantiallyallofthe significantfactsindisputeortherearenumerouspartiesinvolved assetsandrightsofelansalzheimersimmunotherapyprogram inthecompanysopinionbasedonitsexaminationofthese throughanewlyformedcompanyjanssenalzheimerimmunother mattersitsexperiencetodateanddiscussionswithcounselthe apyjaiofwhichthecompanyownsandelanowns ultimateoutcomeoflegalproceedingsnetofliabilitiesaccruedinthe inadditionthecompanypurchasedapproximatelymillion companysbalancesheetisnotexpectedtohaveamaterialadverse newlyissuedamericandepositaryreceiptsadrsofelanrepre effectonthecompanysfinancialpositionhowevertheresolution sentingofelansoutstandingordinarysharesaspartofthis inanyreportingperiodofoneormoreofthesematterseitheralone transactionthecompanypaidmilliontoelanandcommitted orintheaggregatemayhaveamaterialadverseeffectonthe tofunduptomillionofelansshareofresearchanddevelop companysresultsofoperationsandcashflowsforthatperiod mentspendingbyjaiofthistotalconsiderationofmillion johnson johnson annual reportproductliability eesintheunitedstatesdistrictcourtforthedistrictofconnecti certainofjohnsonjohnsonssubsidiariesareinvolvedinnumerous cutallegingthatseveralfeaturesofeessharmonicscalpel productliabilitycasesthedamagesclaimedaresubstantialand infringedfourtycopatentsinoctoberonmotionsforsum whilethesesubsidiariesareconfidentoftheadequacyofthewarn maryjudgmentpriortotheinitialtrialanumberofclaimswere ingsandinstructionsforusethataccompanytheproductsatissueit foundinvalidandanumberwerefoundinfringedhowevernoclaim isnotfeasibletopredicttheultimateoutcomeoflitigationthe wasfoundbothvalidandinfringedtrialcommencedindecember companyhasestablishedproductliabilityaccrualsincompliance andthecourtdismissedthecasewithoutprejudiceon withascbasedoncurrentlyavailableinformationwhichin groundsthattycodidnotownthepatentsinsuitthedismissal somecasesmaybelimitedchangestotheaccrualsmayberequired withoutprejudicewasaffirmedonappealinjanuarytyco inthefutureasadditionalinformationbecomesavailable filedanothercomplaintintheunitedstatesdistrictcourtforthe multipleproductsofjohnsonjohnsonssubsidiariesaresub districtofconnecticutassertinginfringementofthreeofthefour jecttoproductliabilityclaimsandlawsuitsinwhichclaimantsseek patentsfromthepreviouslawsuitandaddingnewproductstyco substantialcompensatoryandwhereavailablepunitivedamages isseekingmonetarydamagesandinjunctivereliefthiscaseis includinglevaquintheasrxlacetabularsystemanddepuy scheduledtobetriedinmay asrhipresurfacingsystemthepinnacleacetabularcup startinginmarchcordiscorporationcordisfiled systemrisperdalpelvicmeshesthecypherstentand patentinfringementlawsuitsintheunitedstatesdistrictcourts duragesicfentanylpatchesasofjanuarytherewere forthedistrictsofnewjerseyanddelawareagainstguidant approximatelyclaimantswithpendinglawsuitsregarding corporationguidantabbottlaboratoriesincabbottboston injuriesallegedlyduetolevaquinwithrespecttothe scientificcorporationbostonscientificandmedtronicaveinc asrxlacetabularsystemanddepuyasrhipresurfacing medtronicallegingthatthexiencevabbottpromus systemwithrespecttothepinnacleacetabularcup bostonscientificandendeavormedtronicdrugelutingstents systemwithrespecttorisperdalwithrespectto infringeseveralofcordisswrightfaloticopatentscordissought pelvicmesheswithrespecttothecypherstentandwith monetaryreliefinjanuaryinoneofthecasesagainstboston respecttoduragesicfentanylpatches scientifictheunitedstatesdistrictcourtforthedistrictof inaugustdepuyorthopaedicsincdepuyannounced delawarefoundthewrightfaloticopatentsinvalidforlackofwrit aworldwidevoluntaryrecallofitsasrxlacetabularsystemand tendescriptionandorlackofenablementinjunethecourtof depuyasrhipresurfacingsystemusedinhipreplacementsur appealsforthefederalcircuitaffirmedtherulingandinseptember geryclaimsforpersonalinjuryhavebeenmadeagainstdepuyand itdeniedcordissmotionforarehearing johnsonjohnsonandthenumberofpendinglawsuitscontinues inoctoberbrucesaffransaffranfiledapatentinfringe toincreasethecompanycontinuestoreceiveinformationwith mentlawsuitagainstjohnsonjohnsonandcordisintheunited respecttopotentialcostsassociatedwiththisrecallinthefourth statesdistrictcourtfortheeasterndistrictoftexasalleging quarterofthecompanyincreaseditsaccrualsforthedepuy infringementonuspatentnoinjanuaryajury asrhiprecallprogramandrelatedproductliabilityafterthe returnedaverdictfindingthatcordisssalesofitscypherstent companycompletedananalysisofnewinformationincludingthe willfullyinfringedapatentissuedtosaffranthejuryawarded numberofexpectedclaimsrecentlyupdatedrevisionratesofthe saffranmillioninmarchthecourtenteredjudgment recalledproductsandproductliabilityexpensepercasechanges againstcordisintheamountofmillionrepresentingthejury totheseaccrualsmayberequiredinthefutureasadditional verdictplusmillioninprejudgmentinterestthedistrict informationbecomesavailable courthasdeniedcordissmotiontooverturnthejuryverdictandto thecompanybelievesthattheultimateresolutionofthese vacatethejudgmentcordishasappealedthejudgmentbecause mattersbasedonhistoricalandreasonablylikelyfuturetrendsisnot thecompanybelievesthatthepotentialforanunfavorableoutcome expectedtohaveamaterialadverseeffectonthecompanysfinan isnotprobableithasnotestablishedanaccrualwithrespectto cialpositionannualresultsofoperationsandcashflowstheresolu thecase tioninanyinterimreportingperiodcouldhaveamaterialimpacton innovemberrochediagnosticsoperationsincetal thecompanysresultsofoperationsandcashflowsforthatperiod rochefiledapatentinfringementlawsuitagainstlifescaninc lifescanintheunitedstatesdistrictcourtforthedistrictof intellectualproperty delawareaccusinglifescansentireonetouchlineofblood certainofjohnsonjohnsonssubsidiariesaresubjectfromtime glucosemonitoringsystemsofinfringementoftwopatentsrelated totimetolegalproceedingsandclaimsrelatedtopatenttrademark totheuseofmicroelectrodesensorsinseptemberlifescan andotherintellectualpropertymattersarisingoutoftheirbusiness obtainedafavorablerulingonclaimconstructionthatprecludeda themostsignificantofthesemattersaredescribedbelow findingofinfringementthecourtenteredjudgmentagainstroche injulyandrocheappealedthecourtofappealsreversedthe patentinfringement districtcourtsrulingonclaimconstructionandremandedthecase certainofjohnsonjohnsonssubsidiariesareinvolvedinlawsuits tothedistrictcourtfornewfindingsontheissuerocheisseeking challengingthecoverageandorvalidityofthepatentsontheir monetarydamagesandinjunctiverelief productsalthoughthesesubsidiariesbelievethattheyhavesub startinginfebruarycordisfiledpatentinfringement stantialdefensestothesechallengeswithrespecttoallmaterial lawsuitsintheunitedstatesdistrictcourtforthedistrictofnew patentstherecanbenoassuranceastotheoutcomeofthese jerseyagainstguidantabbottbostonscientificandmedtronic mattersandalossinanyofthesecasescouldpotentiallyadversely allegingthatthexiencevabbottpromusbostonscientific affecttheabilityofthesesubsidiariestoselltheirproductsor andendeavormedtronicdrugelutingstentsinfringeseveralof requirethepaymentofpastdamagesandfutureroyalties wyethsnowpfizerincmorrispatentswhichhavebeenlicensed tocordiscordissoughtmonetaryreliefinjanuarythedis medicaldevicesanddiagnostics trictcourtgrantedthedefendantsmotiontoinvalidatethemorris inoctobertycohealthcaregrouplptycoandussurgi patentsforlackofenablementandfailuretoadequatelydescribe calcorporationfiledalawsuitagainstethiconendosurgeryinc notes consolidated financial statements thefullscopeoftheinventioncordiswillappealthisdecisiontothe ingermanyandthenetherlandsthecourtinthenetherlandsheld courtofappealsforthefederalcircuit thedutchpatentinvalidandenteredjudgmentinfavorofjbiseuro injunerembrandtvisiontechnologieslprembrandt peanaffiliatejanssenbiologicsbvbayerappealedthatjudgment filedapatentinfringementlawsuitagainstjohnsonjohnsonvision inthenetherlandsinadditioninmarchjanssencilagnv careincjjvcintheunitedstatesdistrictcourtfortheeastern filedarevocationactioninthehighcourtinlondonseekingto districtoftexasallegingthatjjvcsmanufactureandsaleofits invalidatebayersukpatentrelatingtohumanantitnfantibodies acuvueadvanceandacuvueoasyshydrogelcontact inmayjbisettledallofthesecasesandreceivedapaidup lensesinfringetheiruspatentnothechangpatent royaltyfreelicensetothefamilyofpatentsinsuit rembrandtisseekingmonetaryreliefthecaseisscheduledfortrial inapril litigationagainstfilersofabbreviatednewdrug innovemberhowmedicaosteonicscorphowmedica applicationsandas andstrykerirelandltdstrykerfiledapatentinfringementlawsuit thefollowingsummarizeslawsuitspendingagainstgenericcompa againstdepuyorthopaedicsincdepuyintheunitedstatesdistrict niesthatfiledabbreviatednewdrugapplicationsandasseek courtforthedistrictofnewjerseyalleginginfringementbydepuys ingtomarketgenericformsofproductssoldbyvarioussubsidiaries pinnacleacetabularcupsystemandduralocacetabularcup ofjohnsonjohnsonpriortoexpirationoftheapplicablepatents systemofapatentrelatingtoaduallockingmechanismfeatureinan coveringthoseproductstheseandastypicallyincludeallegations acetabularcupsystemhowmedicaandstrykerareseekingmonetary ofnoninfringementinvalidityandunenforceabilityofthese damagesandinjunctivereliefnotrialdatehasbeenset patentsintheeventthesesubsidiariesarenotsuccessfulinthese actionsorthestatutorymonthstaysexpirebeforetheunited pharmaceutical statesdistrictcourtrulingsareobtainedthethirdpartycompanies inaprilcentocorinccentocornowjanssenbiotechinc involvedwillhavetheabilityuponapprovaloftheunitedstates jbifiledapatentinfringementlawsuitagainstabbottlaborato foodanddrugadministrationfdatointroducegenericversions riesincabbottintheunitedstatesdistrictcourtfortheeastern oftheproductsatissueresultinginverysubstantialmarketshare districtoftexasallegingthatabbottshumiraantitnfalpha andrevenuelossesforthoseproducts productinfringescentocorsuspatentinjunea juryreturnedaverdictfindingthepatentvalidandinfringedand concerta awardedjbidamagesofapproximatelybillioninfebruary injanuaryalzacorporationalzaandorthomcneil thecourtofappealsreversedthejunedecisionandthe janssenpharmaceuticalsincomjpinowjanssenpharmaceuti judgmentofthedistrictcourtandinfebruarytheunited calsincjpifiledapatentinfringementlawsuitintheunited statessupremecourtdeclinedtoreviewthedecision statesdistrictcourtforthedistrictofdelawareagainstkremers inmayabbottbiotechnologyltdabbottfileda urbanllcandkudcoirelandltdcollectivelykudcoin patentinfringementlawsuitagainstcentocornowjbiinthe responsetokudcosandaseekingapprovaltomarketageneric unitedstatesdistrictcourtforthedistrictofmassachusetts versionofconcertabeforetheexpirationoftwoofalzaand allegingthatsimponiinfringesabbottsuspatentnos jpispatentsrelatingtoconcertakudcofiledcounterclaims andthesalfeldpatentsabbottisseeking allegingnoninfringementandinvalidityalzaandjpisubsequently monetarydamagesandinjunctivereliefnotrialdatehasbeenset removedoneofthepatentsfromthelawsuitinseptemberthe thepartieswillparticipateinanarbitrationinaprilonthe partiesenteredintoasettlementagreementpursuanttowhich issueofjbisdefensethatabbottisequitablystoppedfrom kudcowasgrantedalicensetomarketitsgenericversionof assertingthepatents concertastartingonjulyassumingkudcoobtains inaugustabbottgmbhcoabbottgmbhand fdaapproval abbottbioresearchcenterfiledapatentinfringementlawsuit innovemberalzaandomjpinowjpifiledapatent againstcentocornowjbiintheunitedstatesdistrictcourtfor infringementlawsuitintheunitedstatesdistrictcourtforthe thedistrictofmassachusettsallegingthatstelarainfringestwo districtofdelawareagainstimpaxlaboratoriesincimpaxteva unitedstatespatentsassignedtoabbottgmbhjbifiledacom pharmaceuticalsusaincandtevapharmaceuticalindustriesltd plaintintheunitedstatesdistrictcourtforthedistrictofcolumbia collectivelytevainresponsetoimpaxandtevasfilingofamajor foradeclaratoryjudgmentofnoninfringementandinvalidityof amendmenttoitsandaseekingapprovaltomarketageneric theabbottgmbhpatentsaswellasacomplaintforreviewofa versionofconcertabeforetheexpirationofalzaandjpis patentinterferencedecisionthatgrantedpriorityofinventionon patentrelatingtoconcertaimpaxandtevafiledcounterclaims oneofthetwoassertedpatentstoabbottgmbhthecaseshave allegingnoninfringementandinvalidityinmayalzaand beentransferredfromthedistrictofcolumbiatothedistrictof jpifiledasecondlawsuitagainsttevainresponsetotevasfiling massachusettsnotrialdatehasbeensetalsoinaugust ofasecondmajoramendmenttoitsandaseekingapprovalto abbottgmbhandabbottlaboratorieslimitedbroughtapatent marketadditionaldosagestrengthsofitsgenericconcerta infringementlawsuitinthefederalcourtofcanadaallegingthat productbeforetheexpirationofalzaandjpispatentrelatingto stelarainfringesabbottgmbhscanadianpatentnotrialdate concertaineachoftheabovecasesalzaandjpiareseeking hasbeensetinthecanadiancaseineachofthesecasesabbott anorderenjoiningthedefendantsfrommarketingitsgeneric isseekingmonetarydamagesandinjunctiverelief versionofconcertapriortotheexpirationofalzaandjpis inaugustbayerhealthcarellcbayerfiledapatent concertapatent infringementlawsuitagainstcentocororthobiotechincnowjbi inunitedstatesdistrictcourtforthedistrictofmassachusetts orthotricyclenlo allegingthatthemanufactureandsalebyjbiofsimponiinfringes inoctoberomjpinowjpiandjohnsonjohnsonpharma abayerpatentrelatingtohumanantitnfantibodiesinjanuary ceuticalresearchdevelopmentllcnowjanssenresearch thecourtissuedjudgmentdismissingbayersinfringement developmentllcjrdfiledapatentinfringementlawsuitagainst claimsbayerappealedthisrulinginadditioninnovember watsonlaboratoriesincandwatsonpharmaceuticalsinc bayerfiledalawsuitunderitseuropeancounterparttothesepatents collectivelywatsonintheunitedstatesdistrictcourtforthe johnson johnson annual reportdistrictofnewjerseyinresponsetowatsonsandaseeking inmarchtibotecandgdsearlefiledapatentinfringe approvaltomarketagenericversionofjpisproductpriortothe mentlawsuitagainsttevapharmaceuticalsusaincandteva expirationofjpispatentrelatingtoorthotricyclenlothe pharmaceuticalsltdcollectivelytevaintheunitedstates otclopatentwatsonfiledacounterclaimalleginginvalidityof districtcourtforthedistrictofnewjerseyinresponsetotevas thepatentinadditioninjanuaryjpifiledapatentinfringe andaseekingapprovaltomarketagenericversionofprezista mentlawsuitagainstlupinltdandlupinpharmaceuticalsinc beforetheexpirationofcertainpatentsrelatingtoprezistathat collectivelylupinintheunitedstatesdistrictcourtforthe tiboteceitherownsorexclusivelylicensesfromgdsearle districtofnewjerseyinresponsetolupinsandaseeking inmarchtibotecfiledapatentinfringementlawsuit approvaltomarketagenericversionoforthotricyclenlo againstheterodrugsltdunitiiiandheterousainccollectively priortotheexpirationoftheotclopatentlupinfiledacounter heterointheunitedstatesdistrictcourtforthedistrictofnew claimalleginginvalidityofthepatentthelupinandwatsoncases jerseyinresponsetoheterosandaseekingapprovaltomarketa havebeenconsolidatedinfebruaryjpiandwatsonentered genericversionofprezistabeforetheexpirationofcertain intoasettlementagreementpursuanttothesettlementagreement patentsrelatingtoprezistathattibotecexclusivelylicensesfrom thepartiesenteredintoasupplyagreementwherebyjpiwillsupply gdsearleinjulyuponagreementbythepartiesthecourt towatsonacombinationaloralcontraceptivecontainingcertain enteredastayofthelawsuitpendingafinaldecisioninthelawsuit specifiedcompoundsfromdecemberorearlierunder againsttevawithrespecttothevalidityandorenforceabilityofthe certaincircumstancesthroughtheexpirationofthepatenton patentsthattiboteclicensesfromgdsearlewithheteroagreeing decemberinadditionintheeventwatsondoesnotwishto tobeboundbysuchfinaldecision exerciseitsrightsunderthesupplyagreementjpihasgrantedwat inseptemberthecourtconsolidatedtheabovelawsuits sonalicensetomarketwatsonsandaproductfromdecember aswellaslawsuitsbroughtbytheunitedstatesgovernment orearlierundercertaincircumstancesthroughdecember againsteachofthedefendantsforinfringementofaunitedstates atrialdateforthelupincasehasbeensetformarch governmentownedpatentrelatingtoprezistaforpurposesof innovemberomjpinowjpifiledapatentinfringe pretrialdiscoveryandtrialwiththeprovisothatafterdiscoveryis mentlawsuitagainstmylanincandmylanpharmaceuticalsinc completedanypartycanmovetohavethecasesdeconsolidated collectivelymylanandfamycareltdfamycareintheunited fortrial statesdistrictcourtforthedistrictofnewjerseyinresponseto ineachoftheabovelawsuitstibotecisseekinganorder famycaresandaseekingapprovaltomarketagenericversionof enjoiningthedefendantsfrommarketingtheirgenericversionsof orthotricyclenlopriortotheexpirationoftheotclo prezistabeforetheexpirationoftherelevantpatents patentmylanandfamycarefiledcounterclaimsalleginginvalidity ofthepatent otherintellectualpropertymatters inoctoberjpifiledapatentinfringementlawsuitagainst inseptembercentocororthobiotechproductslpnow sunpharmaglobalfzeandsunpharmaceuticalindustriescollec janssenproductslpjplpintervenedinaninventorshiplawsuit tivelysunintheunitedstatesdistrictcourtforthedistrictof filedbytheuniversityofkansascenterforresearchinckucr newjerseyinresponsetosunsandaseekingapprovaltomarketa againsttheunitedstatesofamericausaintheunitedstates genericversionoforthotricyclenlopriortotheexpiration districtcourtforthedistrictofkansaskucrallegesthattwo oftheotclopatent kucrscientistsshouldbeaddedasinventorsontwousaowned ineachoftheabovecasesjrdandorjpiareseekingan patentsrelatingtovelcadetheusalicensedthepatentsand orderenjoiningthedefendantsfrommarketingtheirgeneric theirforeigncounterpartstomillenniumpharmaceuticalsinc versionsoforthotricyclenlobeforetheexpirationofthe mpiwhointurnsublicensedthepatentsandtheirforeign otclopatent counterpartstojplpforcommercialmarketingoutsidetheunited statesinjulythepartiesreachedasettlementagreementto prezista resolvethedisputesinthiscaseandwillsubmittheinventorship innovembertibotecincnowtibotecllcandtibotec issuetoarbitrationthecasehasbeenstayedpendingthearbitra pharmaceuticalsinccollectivelytibotecfiledapatentinfringe tionasaresultofthesettlementagreementtheoutcomeof mentlawsuitagainstlupinltdlupinpharmaceuticalsinc thearbitrationregardinginventorshipwilldeterminewhetherpre collectivelylupinmylanincandmylanpharmaceuticalsinc specifiedpaymentswillbemadetokucrbutwillnotaffectjplps collectivelymylanintheunitedstatesdistrictcourtforthedis righttomarketvelcadethearbitrationtookplaceindecember trictofnewjerseyinresponsetolupinsandmylansrespective andadecisionisexpectedinapril andasseekingapprovaltomarketgenericversionsoftibotecs indecemberthestateofisraelfiledalawsuitinthedis prezistaproductbeforetheexpirationoftibotecspatentrelat trictcourtintelavivjaffaagainstomrixbiopharmaceuticalsinc ingtoprezistalupinandmylaneachfiledcounterclaimsalleging andvariousaffiliatesomrixinthelawsuitthestateclaimsthat noninfringementandinvalidityinjulytibotecfiledanother anemployeeofagovernmentownedhospitalwastheinventoron patentinfringementlawsuitagainstlupinintheunitedstatesdis severalpatentsrelatedtofibringluetechnologythattheemployee trictcourtforthedistrictofnewjerseyinresponsetolupinssup developedwhilehewasagovernmentemployeethestateclaims plementtoitsandatoaddnewdosagestrengthsforitsproposed thathehadnorighttotransferanyintellectualpropertytoomrix productinaugusttibotecandgdsearlecompanygd becauseitbelongstothestatethestateisseekingdamagesplus searlefiledapatentinfringementlawsuitagainstlupinandmylan royaltiesonquixilandevicelproductsoralternatively inresponsetotheirnoticelettersadvisingthattheirandasare transferofthepatentstothestate seekingapprovaltomarketgenericversionsoftibotecsprezista productbeforetheexpirationoftwopatentsrelatingtoprezista thattibotecexclusivelylicensesfromgdsearle notes consolidated financial statements injanuarygenentechincgenentechinitiatedan risperdal arbitrationagainstucbcelltechcelltechseekingdamagesfor injanuaryjanssenpharmaceuticaincjanssennow allegedlycooperatingwithcentocornowjbitoimproperly janssenpharmaceuticalsincjpireceivedasubpoenafromthe terminateaprioragreementinwhichjbiwassublicensedunder officeoftheinspectorgeneraloftheunitedstatesofficeofper genentechscabillypatentsjbihasanindemnityagreementwith sonnelmanagementseekingdocumentsconcerningsalesandmar celltechandcelltechhasassertedthatjbiisliableforanydamages ketingofanyandallpaymentstophysiciansinconnectionwith celltechmayberequiredtopaygenentechinthatarbitrationtrial salesandmarketingofandclinicaltrialsforrisperdalfrom isscheduledforjune todocumentssubsequenttohavealsobeenrequested bythedepartmentofjusticeanadditionalsubpoenaseekinginfor governmentproceedings mationaboutmarketingofandadversereactionstorisperdal likeothercompaniesinthepharmaceuticalandmedicaldevices wasreceivedfromtheunitedstatesattorneysofficefortheeast anddiagnosticsindustriesjohnsonjohnsonandcertainofits erndistrictofpennsylvaniainnovembernumeroussubpoe subsidiariesaresubjecttoextensiveregulationbynationalstate nasseekingtestimonyfromvariouswitnessesbeforeagrandjury andlocalgovernmentagenciesintheunitedstatesandothercoun werealsoreceivedjpicooperatedinrespondingtotheserequests triesinwhichtheyoperateasaresultinteractionwithgovernment fordocumentsandwitnessestheunitedstatesdepartmentof agenciesisongoingthemostsignificantlitigationbroughtbyand justiceandtheunitedstatesattorneysofficefortheeasterndis investigationsconductedbygovernmentagenciesarelistedbelow trictofpennsylvaniathegovernmentarecontinuingtoactively itispossiblethatcriminalchargesandsubstantialfinesandorcivil pursuebothcriminalandcivilactionsinfebruarythegovern penaltiesordamagescouldresultfromgovernmentinvestigations mentservedcivilinvestigativedemandsseekingadditionalinfor orlitigation mationrelatingtosalesandmarketingofrisperdalandsales andmarketingofinvegathefocusofthesemattersisthe averagewholesalepriceawplitigation allegedpromotionofrisperdalandinvegaforofflabeluses johnsonjohnsonandseveralofitspharmaceuticalsubsidiaries thegovernmenthasnotifiedjpithattherearealsopendingquitam thejjawpdefendantsalongwithnumerousotherpharmaceu actionsallegingofflabelpromotionofrisperdalthegovern ticalcompaniesaredefendantsinaseriesoflawsuitsinstateand mentinformedjpithatitwillinterveneinthesequitamactionsand federalcourtsinvolvingallegationsthatthepricingandmarketing fileasupersedingcomplaint ofcertainpharmaceuticalproductsamountedtofraudulentand discussionshavebeenongoinginanefforttoresolvecriminal otherwiseactionableconductbecauseamongotherthingsthe penaltiesunderthefooddrugandcosmeticactrelatedtothe companiesallegedlyreportedaninflatedaveragewholesaleprice promotionofrisperdalanagreementinprincipleonkeyissues awpforthedrugsatissuepayorsallegedthattheyusedthose relevanttoadispositionofcriminalchargespursuanttoasingle awpsincalculatingproviderreimbursementlevelsmanyofthese misdemeanorviolationofthefooddrugandcosmeticacthasbeen casesbothfederalactionsandstateactionsremovedtofederal reachedbutcertainissuesremainopenbeforeasettlementcanbe courtwereconsolidatedforpretrialpurposesinamultidistrict finalizedduringthecompanyaccruedamountstocoverthe litigationmdlintheunitedstatesdistrictcourtforthedistrict financialcomponentoftheproposedcriminalsettlement ofmassachusetts inadditiondiscussionswithstateandfederalgovernment theplaintiffsinthesecasesincludedthreeclassesofprivate representativestoresolvetheseparatecivilclaimsrelatedtothe personsorentitiesthatpaidforanyportionofthepurchaseofthe marketingofrisperdalandinvegaincludingthoseunderthe drugsatissuebasedonawpandstategovernmententitiesthat falseclaimsactthequitamactionsarestillongoingalthough mademedicaidpaymentsforthedrugsatissuebasedonawpin itstillremainsunclearwhetherasettlementcanbereachedwith juneafteratrialonthemeritsthemdlcourtdismissedthe respecttothefederalandstatecivilclaimstherehasbeenasub claimsoftwooftheplaintiffclassesagainstthejjawpdefen stantialnarrowingoftheissuesandpotentialliabilityandinthe dantsinmarchthecourtdismissedtheclaimsofthethird companyestablishedanaccrualtocovertheestimatedfinancial classagainstthejjawpdefendantswithoutprejudice componentofthepotentialfederalcivilsettlementifanegotiated awpcasesbroughtbyvariousattorneysgeneralhavepro resolutioncannotbereachedcivillitigationrelatingtotheallegations ceededtotrialagainstothermanufacturersseveralstatecases ofofflabelpromotionofrisperdalandorinvegaislikely againstcertainofjohnsonjohnsonssubsidiarieshavebeenset theattorneysgeneralofmultiplestatesincludingalaska tledincludingkentuckywhichhadbeensetfortrialinjanuary arkansaslouisianamassachusettsmississippimontananew kansasissetfortrialinmarchandotherstatecasesare mexicopennsylvaniasouthcarolinatexasandutahhavepending likelytobesetfortrialinadditionanawpcaseagainstthejj actionsagainstjanssennowjpiseekingoneormoreofthefollow awpdefendantsbroughtbythecommonwealthofpennsylvania ingremediesreimbursementofmedicaidorotherpublicfundsfor wastriedincommonwealthcourtinoctoberandnovember risperdalprescriptionswrittenforofflabelusecompensation thecourtfoundinthecommonwealthsfavorwithregardtocertain fortreatingtheircitizensforallegedadversereactionsto ofitsclaimsunderthepennsylvaniaunfairtradepracticesandcon risperdalcivilfinesorpenaltiesdamagesforoverpayments sumerprotectionlawutplenteredaninjunctionandawarded bythestateandothersviolationsofstateconsumerfraudstatutes millioninrestitutionandmillionincivilpenaltiesthe punitivedamagesorotherreliefrelatingtoallegedunfairbusiness courtfoundinthejjawpdefendantsfavoronthecommon practicescertainoftheseactionsalsoseekinjunctivereliefrelating wealthsclaimsofunjustenrichmentmisrepresentationfraudcivil tothepromotionofrisperdalinjanuaryjpiagreedto conspiracyandoncertainofthecommonwealthsclaimsunderthe settlealawsuitfiledbytheattorneygeneraloftexastrialinthe utplthejjawpdefendantshaveappealedthecommonwealth lawsuitbroughtbytheattorneygeneralofarkansasisscheduled courtsutplrulingtothepennsylvaniasupremecourtthe tocommenceinmarchjpihasfiledmotionsforsummary companybelievesthatthejjawpdefendantshavestrongargu judgmentinthearkansasmatter mentssupportingtheirappealbecausethecompanybelievesthat theattorneygeneralofwestvirginiacommencedsuitin thepotentialforanunfavorableoutcomeisnotprobableithasnot againstjanssennowjpibasedonclaimsofallegedcon establishedanaccrualwithrespecttotheverdict sumerfraudastoduragesicaswellasrisperdaljpiwas johnson johnson annual reportfoundliableanddamageswereassessedatmillionjpifiledan mcneilconsumerhealthcare appealandinnovemberthewestvirginiasupremecourt startinginjunemcneilconsumerhealthcaredivisionof reversedthetrialcourtsdecisionindecembertheattorney mcneilppcincmcneilconsumerhealthcareandcertainaffili generalofwestvirginiadismissedthecaseasitrelatedto atesincludingjohnsonjohnsonthecompaniesreceivedgrand risperdalwithoutanypaymentthereafterjpisettledthecase jurysubpoenasfromtheunitedstatesattorneysofficefortheeast insofarasitrelatedtoduragesic erndistrictofpennsylvaniarequestingdocumentsbroadlyrelatingto intheattorneygeneraloflouisianafiledamulticount recentrecallsofvariousproductsofmcneilconsumerhealthcare complaintagainstjanssennowjpijohnsonjohnsonwaslater andthefdainspectionsofthefortwashingtonpennsylvaniaand addedasadefendantthecasewastriedinoctoberthe lancasterpennsylvaniamanufacturingfacilitiesaswellascertain issuetriedtothejurywaswhetherjohnsonjohnsonorjpihad documentsrelatingtorecentrecallsofasmallnumberofproducts violatedthestatesmedicaidfraudacttheactthroughmisrepre ofothersubsidiariesinadditioninfebruarythegovernment sentationsallegedlymadeinthemailingofanovemberdear servedmcneilppcincmcneilppcwithacivilinvestigative healthcareprofessionalletterregardingrisperdalthejury demandseekingrecordsrelevanttoitsinvestigationtodetermineif returnedaverdictthatjpiandjohnsonjohnsonhadviolatedthe therewasaviolationofthefederalfalseclaimsactthecompanies actandawardedmillionindamagesthetrialjudgesubse arecooperatingwiththeunitedstatesattorneysofficeinrespond quentlyawardedtheattorneygeneralcounselfeesandexpensesin ingtothesesubpoenas theamountofmillionjohnsonjohnsonsandjpismotionfor thecompanieshavealsoreceivedcivilinvestigativedemands anewtrialwasdeniedjohnsonjohnsonandjpihavefiledan frommultiplestateattorneysgeneralofficesbroadlyrelatingto appealandbelievethattheyhavestrongargumentssupportingthe themcneilrecallissuesthecompaniescontinuetocooperatewith appealthecompanybelievesthatthepotentialforanunfavorable theseinquiriesinjanuarytheoregonattorneygeneralfileda outcomeisnotprobableandthereforethecompanyhasnot civilcomplaintagainstjohnsonjohnsonmcneilppcand establishedanaccrualwithrespecttotheverdict mcneilhealthcarellcinstatecourtallegingcivilviolationsofthe intheofficeofgeneralcounselofthecommonwealth oregonunlawfultradepracticesactrelatingtoanearlierrecallofa ofpennsylvaniafiledalawsuitagainstjanssennowjpionamulti mcneilotcproductafteraremovaltofederalcourtthecasewas countcomplaintrelatedtojanssenssaleofrisperdaltothe remandedbacktostatecourtinoregonthecompaniesfileda commonwealthsmedicaidprogramthetrialoccurredinjune motiontodismissinfebruary thetrialjudgedismissedthecaseafterthecloseofthe inmarchtheunitedstatesfiledacomplaintforinjunctive plaintiffsevidencethecommonwealthsposttrialmotionswere reliefintheunitedstatesdistrictcourtfortheeasterndistrictof deniedthecommonwealthfiledanappealinapriltheoral pennsylvaniaagainstmcneilppcandtwoofitsemployeesalleg argumentisscheduledtotakeplaceinmay ingthatmcneilppcisinviolationoffdaregulationsregardingthe intheattorneygeneralofsouthcarolinafiledalawsuit manufactureofdrugsatthefacilitiesitoperatesinlancasterpenn againstjohnsonjohnsonandjanssennowjpionseveralcounts sylvaniafortwashingtonpennsylvaniaandlaspiedraspuerto inmarchthematterwastriedonliabilityonlyatwhichtime ricoonthesamedaythepartiesfiledaconsentdecreeofperma thelawsuitwaslimitedtoclaimsofviolationofthesouthcarolina nentinjunctionresolvingtheclaimssetforthinthecomplaintthe unfairtradepracticeactincludingamongothersquestionsof courtapprovedandenteredtheconsentdecreeonmarch whetherjohnsonjohnsonorjpiengagedinunfairordeceptive theconsentdecreewhichissubjecttoongoingenforcement actsorpracticesintheconductofanytradeorcommerceby bythecourtrequiresmcneilppctotakeenhancedmeasuresto distributingthenovemberdearhealthcareprofessional remediatethethreefacilitiesthefortwashingtonfacilitywhich letterregardingrisperdalorintheiruseoftheproducts wasvoluntarilyshutdowninaprilwillremainshutdownuntil fdaapprovedlabelthejuryfoundinfavorofjohnsonjohnson athirdpartyconsultantcertifiesthatitsoperationswillbeincom andagainstjpiinjunethecourtawardedcivilpenaltiesof pliancewithapplicablelawandthefdaconcurswiththethird approximatelymillionjpihasappealedthisjudgmentthe partycertificationthelancasterandlaspiedrasfacilitiesmay companybelievesthatjpihasstrongargumentssupportingan continuetomanufactureanddistributedrugsprovidedthatathird appealandthatthepotentialforanunfavorableoutcomeisnot partyreviewsmanufacturingrecordsforselectedbatchesofdrugs probablethereforethecompanyhasnotestablishedanaccrual releasedfromthefacilitiesandcertifiesthatanydeviations withrespecttotheverdict revieweddonotadverselyaffectthequalityoftheselectedbatches theattorneysgeneralofapproximatelyotherstateshave mcneilppchassubmittedaworkplantothefdaforremediation indicatedapotentialinterestinpursuingsimilarlitigationagainst ofthelancasterandlaspiedrasfacilitiesthatplanissubjectto jpiandhaveobtainedatollingagreementstayingtherunningofthe fdaapprovalthirdpartybatchrecordreviewmayceaseifthefda statuteoflimitationswhiletheypursueacoordinatedcivilinvesti hasstatedthatthefacilitiesappeartobeincompliancewithappli gationofjpiregardingpotentialconsumerfraudactionsinconnec cablelaweachfacilityissubjecttoafiveyearauditperiodbya tionwiththemarketingofrisperdal thirdpartyafterthefacilityhasbeendeemedbythefdatobein inthecompanyestablishedanaccrualwithrespectto apparentcompliancewithapplicablelaw theabovestatematters inthecompanysopiniontheultimateresolutionofanyof theaboverisperdalmattersisnotexpectedtohaveamaterial adverseeffectonthecompanysfinancialpositionalthoughthe resolutioninanyreportingperiodcouldhaveamaterialimpacton thecompanysresultsofoperationsandcashflowsforthatperiod notes consolidated financial statements omnicare inseptemberjohnsonjohnsonreceivedasubpoenafrom injulysciosincsciosreceivedasubpoenafromtheunited theunitedstatesattorneysofficeforthedistrictofmassachusetts statesattorneysofficeforthedistrictofmassachusettsseeking seekingdocumentsrelatedtothesalesandmarketingofeightdrugs documentsrelatedtothesalesandmarketingofnatrecor toomnicareincomnicareamanagerofpharmaceuticalbene inaugustscioswasadvisedthattheinvestigationwouldbe fitsforlongtermcarefacilitiesinapriljohnsonjohnson handledbytheunitedstatesattorneysofficeforthenorthern andcertainofitspharmaceuticalsubsidiarieswereservedintwo districtofcaliforniainsanfranciscoinfebruarytwoquitam civilquitamcasesassertingclaimsunderthefederalfalseclaims complaintswereunsealedintheunitedstatesdistrictcourtfor actandrelatedstatelawclaimsallegingthatthedefendantspro thenortherndistrictofcaliforniaallegingamongotherthings videdomnicarewithrebatesandotherallegedkickbackscausing improperactivitiesinthepromotionofnatrecorinjune omnicaretofilefalseclaimswithmedicaidandothergovernment theunitedstatesgovernmentintervenedinoneofthequitam programsinjanuarythegovernmentintervenedinbothof actionsandfiledacomplaintagainstsciosandjohnsonjohnson thesecasesnamingjohnsonjohnsonorthomcneiljanssen seekingreliefunderthefederalfalseclaimsactandassertinga pharmaceuticalsincnowjanssenpharmaceuticalsincjpi claimofunjustenrichmentthecivilcaseisproceedinganddiscovery andjohnsonjohnsonhealthcaresystemsincasdefendants isongoinginoctoberthecourtapprovedasettlementofthe subsequentlythecommonwealthofmassachusettsvirginiaand criminalcaseinwhichsciospledguiltytoasinglemisdemeanorvio kentuckyandthestatesofcaliforniaandindianaintervenedinthe lationofthefooddrugcosmeticactandpaidafineofmillion actionthedefendantsmovedtodismissthecomplaintsandin infebruaryjohnsonjohnsonvoluntarilydisclosedto februarytheunitedstatesdistrictcourtforthedistrictof theunitedstatesdepartmentofjusticedojandtheunited massachusettsdismissedonequitamcaseentirelyanddismissed statessecuritiesexchangecommissionsecthatsubsidiaries theothercaseinpartrejectingallegationsthatthedefendantshad outsidetheunitedstatesarebelievedtohavemadeimproperpay violatedtheirobligationtoreportitsbestpricetohealthcarepro mentsinconnectionwiththesaleofmedicaldevicesintwosmall gramofficialsthedefendantssubsequentlymovedthecourtto marketcountrieswhichpaymentsmayfallwithinthejurisdiction reconsideritsdecisionnottodismissthesecondcaseinitsentirety oftheforeigncorruptpracticesactfcpainthecourseof whichthecourtdeniedinmaytheclaimsoftheunitedstates continuingdialogueswiththeagenciesotherissuespotentially andindividualstatesremainpending risingtotheleveloffcpaviolationsinadditionalmarketswere innovemberalawsuitwasfiledundersealbyscott broughttotheattentionoftheagenciesbyjohnsonjohnsonin bartzaformeremployeeintheunitedstatesdistrictcourtforthe additioninfebruaryjohnsonjohnsonreceivedasubpoena easterndistrictofpennsylvaniaagainstjohnsonjohnsonandcer fromthesecrequestingdocumentsrelatingtotheparticipation tainofitspharmaceuticalsubsidiariesthejjdefendantsalong byseveralofitssubsidiariesintheunitednationsiraqoilforfood withcodefendantsmckessoncorporationmckessonandomni programinapriljohnsonjohnsonresolvedthefcpa careincthebartzcomplaintraisesmanyissuesincommonwith andoilforfoodmattersthroughsettlementswiththedojsec theomnicarerelatedlitigationdiscussedabovealreadypending andunitedkingdomseriousfraudofficethesesettlements beforetheunitedstatesdistrictcourtforthedistrictofmassachu requiredpaymentsofapproximatelymillioninfinancialpenal settssuchasbestpriceandanumberofkickbackallegationsafter tiesaspartofthesettlementwiththedojjohnsonjohnson investigationtheunitedstatesdeclinedtointervenethecasewas enteredintoadeferredprosecutionagreementthatrequires subsequentlyunsealedinjanuaryinfebruarytheplain johnsonjohnsontocompleteathreeyeartermofenhanced tifffiledanamendedcomplaintwhichwasplacedunderseal compliancepractices thereafteronthejjdefendantsmotionthecasewastransferred injunejohnsonjohnsonreceivedasubpoenafrom totheunitedstatesdistrictcourtforthedistrictofmassachusetts theunitedstatesattorneysofficeforthedistrictofmassachu whereitiscurrentlypendinginapriltheamendedcomplaint settsrelatingtothemarketingofbiliarystentsbycordiscorpora wasorderedunsealedandallegesavarietyofcausesofactionunder tioncordiscordisiscurrentlycooperatinginrespondingtothe thefederalfalseclaimsactandcorrespondingstateandlocal subpoenainadditioninjanuaryacomplaintwasunsealedin statutesincludingthatthejjdefendantsengagedinvarious theunitedstatesdistrictcourtforthenortherndistrictoftexas impropertransactionsthatwereallegedlydesignedtoreportfalse seekingdamagesagainstcordisforallegedviolationsofthefederal prescriptiondrugpricestothefederalgovernmentinorderto falseclaimsactandseveralsimilarstatelawsinconnectionwith reducethejjdefendantsmedicaidrebateobligationsthecom themarketingofbiliarystentstheunitedstatesdepartmentof plaintfurtherallegesthatthejjdefendantsimproperlyretaliated justiceandseveralstateshavedeclinedtointerveneatthistimein againsttheplaintiffforhavingraisedtheseallegationsinternally apriltheunitedstatesdistrictcourtforthenortherndistrict bartzseeksmultipleformsofreliefincludingdamagesandrein oftexasdismissedthecomplaintwithoutprejudice statementtoapositionwiththesamesenioritystatus inoctobertheeuropeancommissionannouncedthat thejjdefendantssubsequentlymovedtodismissthecom itopenedaninvestigationconcerninganagreementbetween plaintinmayandoralargumentwasheldinaugustin janssencilagbvandsandozbvrelatingtothesupplyoffentanyl junebartzfiledanoticeofintenttovoluntarilydismiss patchesinthenetherlandstheinvestigationseekstodetermine mckessonandomnicarefromthecaseandaddedmckesson whethertheagreementinfringeseuropeancompetitionlaw specialtypharmaceuticalsllcasacodefendantthepartiesare inrecentyearsjohnsonjohnsonhasreceivednumerous awaitingarulingonthemotiontodismiss requestsfromavarietyofunitedstatescongressionalcommittees toproduceinformationrelevanttoongoingcongressionalinquiries itisjohnsonjohnsonspolicytocooperatewiththeseinquiriesby producingtherequestedinformation johnson johnson annual reportgenerallitigation merckcoincmerckandscheringploughconstituteda inseptemberplaintiffsinanemploymentdiscriminationliti changeofcontrolunderthetermsofthedistributionagreements gationinitiatedagainstjohnsonjohnsoninintheunited thatpermittedjbitoterminatetheagreementsinapril statesdistrictcourtforthedistrictofnewjerseymovedtocertify johnsonjohnsonjbiandmerckannouncedanagreementto aclassofallafricanamericanandhispanicsalariedemployeesof amendthedistributionagreementsthisagreementconcluded johnsonjohnsonanditsaffiliatesintheunitedstateswhowere thearbitrationproceeding employedatanytimefromnovembertothepresentplaintiffs pursuanttothetermsoftheamendeddistributionagree soughtmonetarydamagesfortheperiodthroughthepresent mentsonjulymerckssubsidiaryscheringploughireland includingpunitivedamagesandequitablereliefthecourtdenied relinquishedexclusivemarketingrightsforremicadeand plaintiffsclasscertificationmotionindecemberandtheir simponitojohnsonjohnsonsjanssenpharmaceuticalcompa motionforreconsiderationinaprilplaintiffssoughttoappeal niesinterritoriesincludingcanadacentralandsouthamericathe thesedecisionsandinaprilthecourtofappealsruledthat middleeastafricaandasiapacificrelinquishedterritoriesmerck plaintiffsappealofthedenialofclasscertificationwasuntimelyin retainedexclusivemarketingrightsthroughouteuroperussiaand julyplaintiffsfiledamotionforcertificationofamodified turkeyretainedterritoriestheretainedterritoriesrepresent classwhichjohnsonjohnsonopposedthedistrictcourtdenied approximatelypercentofmercksrevenueofapproxi plaintiffsmotioninjulyandthecourtofappealsdenied matelybillionfromremicadeandsimponiwhilethe plaintiffsrequestforleavetoappealthedenialofcertificationofthe relinquishedterritoriesrepresentapproximatelypercentin modifiedclassinmaythecasewasdismissedwithprejudice additionasofjulyallprofitderivedfrommercksexclusive startinginjulyfivelawsuitswerefiledinunitedstates distributionofthetwoproductsintheretainedterritoriesisbeing districtcourtforthedistrictofnewjerseybyvariousemployers equallydividedbetweenmerckandjbiunderthepriortermsofthe andemployeebenefitplansandfundsseekingtorecoveramounts distributionagreementsthecontributionincomeprofitsplit theypaidforrisperdalforplanparticipantsingeneralplaintiffs whichwasatpercenttomerckandpercenttojbiwouldhave allegethatjohnsonjohnsonandcertainofitspharmaceutical declinedformerckandincreasedforjbieachyearuntilwhen subsidiariesengagedinofflabelmarketingofrisperdalin itwouldhavebeenequallydividedjbialsoreceivedaonetime violationofthefederalandnewjerseyricostatutesinaddition paymentofmillioninaprilwhichisbeingamortized plaintiffsassertedvariousstatelawclaimsallofthecaseswere overtheperiodoftheagreement consolidatedintoonecaseseekingclassactionstatusbutshortly inaprilaputativeclassactionlawsuitwasfiledinthe thereafteroneactionwasvoluntarilydismissedindecember unitedstatesdistrictcourtforthenortherndistrictofcalifornia thecourtdismissedtheactionsofthefourremainingplain byrepresentativesofnursinghomeresidentsortheirestates tiffsinaprilthoseplaintiffsfiledanewconsolidatedclass againstjohnsonjohnsonomnicareincomnicareandother actionagainstjohnsonjohnsonandjanssenlpnowjanssen unidentifiedcompaniesorindividualsinfebruaryplaintiffs pharmaceuticalsincjpiandinmarchthatactionwasdis filedasecondamendedcomplaintassertingthatcertainrebate missedinapriloneofthoseplaintiffsfiledanoticeofappeal agreementsbetweenjohnsonjohnsonandomnicareincreased withtheunitedstatescourtofappealsforthethirdcircuitthat theamountofmoneyspentonpharmaceuticalsbythenursing appealwasdismissedinjuly homeresidentsandviolatedtheshermanactandthecalifornia inaprilorthoclinicaldiagnosticsincocdreceived businessprofessionscodethesecondamendedcomplaintalso agrandjurysubpoenafromtheunitedstatesdepartmentof assertedaclaimofunjustenrichmentplaintiffssoughtmultiple justiceantitrustdivisionrequestingdocumentsandinformation formsofmonetaryandinjunctivereliefjohnsonjohnsonmoved fortheperiodbeginningseptemberthroughthepresent todismissthesecondamendedcomplaintinmarchthecourt pertainingtoaninvestigationofallegedviolationsoftheantitrust grantedthemotioninitsentiretyinaugustdismissingall lawsinthebloodreagentsindustryocdcompliedwiththesub claimsassertedbyplaintiffsinoctoberthecourtdismissed poenainfebruaryocdreceivedaletterfromtheantitrust theactionwithprejudicetheplaintiffsfiledanoticeofappealin divisionindicatingthatithadcloseditsinvestigationinnovember novembertheappealispendingbeforetheunitedstates injunefollowingthepublicannouncementthatocd courtofappealsfortheninthcircuit hadreceivedagrandjurysubpoenamultipleclassactioncom startinginaprilanumberofshareholderderivativelaw plaintsseekingdamagesforallegedpricefixingwerefiledagainst suitswerefiledintheunitedstatesdistrictcourtforthedistrictof ocdthevariouscaseswereconsolidatedforpretrialpurposes newjerseyagainstcertaincurrentandformerdirectorsandofficers intheunitedstatesdistrictcourtfortheeasterndistrictof ofjohnsonjohnsonjohnsonjohnsonisnamedasanominal pennsylvaniadiscoveryisongoing defendanttheseactionswereconsolidatedinaugustintoone inmaycentocororthobiotechincnowjanssen lawsuitinrejohnsonjohnsonderivativelitigationanamendedcon biotechincjbicommencedanarbitrationproceedingbefore solidatedcomplaintwasfiledindecemberadditionallyin theamericanarbitrationassociationagainstscheringploughcor septemberanothershareholderderivativelawsuitwasfiled porationanditssubsidiaryscheringploughirelandcompanycol innewjerseysuperiorcourtagainstcertaincurrentandformer lectivelyscheringploughjbiandscheringplougharepartiestoa directorsandofficersofjohnsonjohnsonjohnsonjohnsonis seriesofagreementsdistributionagreementsthatgrantschering namedasanominaldefendantinthisactionaswellthepartiesto ploughtheexclusiverighttodistributethedrugsremicadeand thisactionhavestipulatedthatitshallbestayeduntiltheinre simponiworldwideexceptwithintheunitedstatesjapan johnsonjohnsonderivativelitigationiscompletelyresolved taiwanindonesiaandthepeoplesrepublicofchinaincluding hongkongjbidistributesremicadeandsimponithenext generationtreatmentwithintheunitedstatesinthearbitration jbisoughtadeclarationthattheagreementandmergerbetween notes consolidated financial statements theseshareholderderivativeactionsaresimilarintheirclaims wasfiledindecemberinjanuaryjohnsonjohnson andcollectivelytheyassertavarietyofallegedbreachesoffiduciary movedtodismissorstaythestatelawsuitspendingresolutionof dutiesincludingamongotherthingsthatthedefendantsallegedly thefederallawsuitinadditionjohnsonjohnsonintendsto engagedinapprovedoforfailedtoremedyorpreventdefective movetodismissorstaythestatelawsuitsonthegroundsthatthe medicaldevicesimproperpharmaceuticalrebatesimproperoff plaintiffsfailedtomakeademandontheboardofdirectors labelmarketingofpharmaceuticalandmedicaldeviceproducts inseptembertwoadditionalshareholderderivativelaw violationsofcurrentgoodmanufacturingpracticeregulationsthat suitswerefiledintheunitedstatesdistrictcourtforthedistrictof resultedinproductrecallsandthattheyfailedtodisclosetheafore newjerseynamingjohnsonjohnsonscurrentdirectorsandone mentionedallegedmisconductinthecompanysfilingsunderthe formerdirectorasdefendantsandjohnsonjohnsonasthenominal securitiesexchangeactofeachcomplaintseeksavarietyof defendanttheselawsuitsallegethatthedefendantsbreachedtheir reliefincludingmonetarydamagesandcorporategovernance fiduciarydutiesintheirdecisionswithrespecttothecompensation reformsjohnsonjohnsonmovedtodismisstheseactionsonthe ofthechiefexecutiveofficerduringtheperiodfromthrough groundsinteraliathattheplaintiffsfailedtomakeademandupon thepresentandthatthedefendantsmademisleadingstatementsin theboardofdirectorsinseptemberinrejohnsonjohnson johnsonjohnsonsannualproxystatementsoneoftheselawsuits derivativelitigationwasdismissedwithoutprejudiceandwithleave hasbeenvoluntarilydismissedanamendedcomplainthasbeen tofileanamendedcomplaint filedintheotherindecemberjohnsonjohnsonmovedto johnsonjohnsonfiledareportintheinrejohnsonjohnson dismisstheremaininglawsuitonthegroundsthattheplaintifffailed derivativelitigationmatterinjulypreparedbyaspecialcom tomakeademandupontheboardofdirectors mitteeoftheboardofdirectorswhichinvestigatedtheallegations startinginmaymultiplecomplaintsseekingclassaction containedinthederivativeactionsandinanumberofshareholder certificationrelatedtothemcneilrecallshavebeenfiledagainst demandlettersthattheboardreceivedinraisingsimilar mcneilconsumerhealthcareandcertainaffiliatesincluding issuesthespecialcommitteewasassistedinitsinvestigationby johnsonjohnsonintheunitedstatesdistrictcourtfortheeast independentcounselthespecialcommitteesreportrecom erndistrictofpennsylvaniathenortherndistrictofillinoisthe mendedithatjohnsonjohnsonrejecttheshareholderdemands centraldistrictofcaliforniathesoutherndistrictofohioandthe andtakewhateverstepsarenecessaryorappropriatetosecuredis easterndistrictofmissouritheseconsumercomplaintsallegegen missalofthederivativelitigationandiithattheboardofdirectors erallythatpurchasersofvariousmcneilmedicinesareowedmone createanewregulatoryandcompliancecommitteechargedwith tarydamagesandpenaltiesbecausetheypaidpremiumpricesfor responsibilityformonitoringandoversightofthecompanyshealth defectivemedicationsratherthanlessexpensivealternativemedica carecomplianceandqualitycompliancesystemsandissues tionsallbutonecomplaintseekscertificationofanationwideclass johnsonjohnsonsboardofdirectorsunanimouslyadoptedthe ofpurchasersofthesemedicineswhereasonecomplaintthehar specialcommitteesrecommendationsinaugusttwoshare veycaseseekscertificationofaclassofmotrinibpurchasers holderswhohadsubmittedshareholderdemandlettersin inmissouriinoctoberthejudicialpanelonmultidistrict filedshareholderderivativelawsuitsintheunitedstatesdistrict litigationjpmlconsolidatedalloftheconsumercomplaints courtforthedistrictofnewjerseynamingvariouscurrentand exceptfortheharveycasewhichwasconsolidatedinmarch formerofficersanddirectorsasdefendantsandchallengingthe forpretrialproceedingsintheunitedstatesdistrictcourtforthe boardsrejectionoftheirdemandsinnovemberthecourt easterndistrictofpennsylvaniainjanuarytheplaintiffsin consolidatedthesetwocasesjohnsonjohnsonhassecuredan allofthecasesexcepttheharveycasefiledaconsolidated extensionoftimetorespondtothecomplaintandwillifnecessary amendedcivilconsumerclassactioncomplaintcacnaming movetoterminatetheselawsuitsonthebasisoftheboards additionalpartiesandclaimsinjulythecourtgranted decisiontoadoptthespecialcommitteesrecommendations johnsonjohnsonsmotiontodismissthecacwithoutprejudice twoadditionalshareholderderivativelawsuitswerefiledin butpermittedtheplaintiffstofileanamendedcomplaintwithinthirty mayintheunitedstatesdistrictcourtforthedistrictofnew daysofthedismissalorderinaugusttheplaintiffsfileda jerseyandtwoothershareholderderivativelawsuitswerefiledin secondamendedcivilconsumerclassactioncomplaintsac newjerseysuperiorcourtinmayandaugustall johnsonjohnsonmovedtodismissthesacinseptember namingjohnsonjohnsonscurrentdirectorsasdefendantsand thissecondmotiontodismissispending johnsonjohnsonasthenominaldefendantthecomplaintsallege separatelyinseptemberjohnsonjohnson breachesoffiduciarydutiesrelatedtothecompanyscompliance johnsonjohnsonincandmcneilconsumerhealthcaredivision withtheforeigncorruptpracticesactandparticipationinthe ofjohnsonjohnsonincreceivedanoticeofcivilclaimfiledin unitednationsiraqoilforfoodprogramthatthecompanyhas thesupremecourtofbritishcolumbiacanadathecanadiancivil suffereddamagesasaresultofthoseallegedbreachesandthatthe claimthecanadiancivilclaimisaputativeclassactionbrought defendantsfailedtodisclosetheallegedmisconductinthe onbehalfofpersonswhoresideinbritishcolumbiaandwhopur companysfilingsunderthesecuritiesexchangeactofplain chasedvariousmcneilchildrensoverthecountermedicines tiffsseekmonetarydamagesandoneplaintiffalsoseekscorporate duringtheperiodbetweenseptemberandthepresent governancereformsthefederallawsuitswereconsolidatedinjuly thecanadiancivilclaimallegesthatthedefendantsviolatedthe andanamendedconsolidatedcomplaintwasfiledinaugust canadianbusinesspracticesandconsumerprotectionactand inoctoberjohnsonjohnsonmovedtodismissthe othercanadianstatutesandcommonlawsbysellingmedicines consolidatedfederallawsuitonthegroundsthattheplaintiffsfailed thatdidnotcomplywithcanadiangoodmanufacturingpractices tomakeademandupontheboardofdirectorsthestatelawsuits wereconsolidatedinnovemberandaconsolidatedcomplaint johnson johnson annual reportinseptemberashareholderronaldmonkfiledalawsuit restructuring intheunitedstatesdistrictcourtforthedistrictofnewjersey inthefiscalsecondquarterofcordiscorporationasubsidiary seekingclasscertificationandallegingthatjohnsonjohnsonand ofjohnsonjohnsonannouncedthediscontinuationofitsclinical certainindividualsincludingexecutiveofficersandemployeesof developmentprogramforthenevosirolimuselutingcoronary johnsonjohnsonfailedtodisclosethatanumberofmanufactur stentandcessationofthemanufactureandmarketingofcypher ingfacilitieswerefailingtomaintaincurrentgoodmanufacturing andcypherselectplussirolimuselutingcoronarystentsby practicesandthatasaresultthepriceofjohnsonjohnsons theendofthecompanywillfocusonothercardiovascular stockhasdeclinedsignificantlyplaintiffseekstopursueremedies therapieswheresignificantpatientneedsexist underthesecuritiesexchangeactoftorecoverhisalleged asaresultoftheabovementionedrestructuringplan economiclossesindecemberjohnsonjohnsonsmotionto announcedbycordiscorporationthecompanyrecorded dismisswasgrantedinpartanddeniedinpartplaintiffhasmoved millioninrelatedpretaxchargesofwhichapproximately thecourttoreconsiderpartofthedecemberrulingdefen millionofthepretaxrestructuringchargesrequirecashpay dantsfiledanswerstotheremainingclaimsoftheamended mentsthemillionofrestructuringchargesconsistsofasset complaintinfebruary writeoffsofmillionandmillionrelatedtoleaseholdand inaprilomjpharmaceuticalsincomjprfileda contractobligationsandotherexpensesthemillionofasset lawsuitagainsttheunitedstatesinunitedstatesdistrictcourtfor writeoffsrelatetopropertyplantandequipmentofmillion thedistrictofpuertoricoallegingoverpaymentoffederalincome intangibleassetsofmillionandinventoryofmillion taxesforthetaxyearsendednovemberandnovember recordedincostofproductssoldthecordisrestructuring omjprallegesthattheinternalrevenueserviceerro programhasbeensubstantiallycompleted neouslycalculatedomjprstaxcreditsundersectionofthe thecompanyrecordedanaccrualforrestructuringinthe taxcodediscoveryisongoing fourthquarterofwhichwassubstantiallycompletedin inaugustanarbitrationpanelruledthatmitsubishi foradditionalinformationontherestructuringasitrelatesto tanabepharmacorporationtanabejanssenbiotechincsjbis thesegmentsseenote distributorofremicadeinjapancouldseektomodifythepropor tionofnetsalesrevenuethattanabemustremittojbiinexchange fordistributionrightsandcommercialsupplyofremicadethe supplypricetanabecommencedthearbitrationagainstcentocor orthobiotechincnowjbiinpursuanttotheparties distributionagreementwhichgrantstanabetherighttodistribute remicadeinjapanandcertainotherpartsofasiajbihascoun terclaimedforanincreaseinthesupplypriceahearingwasheldin novembertodeterminetheappropriatesplitofrevenueanda decisionisanticipatedinthesecondhalfof johnsonjohnsonoritssubsidiariesarealsopartiestoanum berofproceedingsbroughtunderthecomprehensiveenvironmen talresponsecompensationandliabilityactcommonlyknownas superfundandcomparablestatelocalorforeignlawsinwhichthe primaryreliefsoughtisthecostofpastandorfutureremediation notes consolidated financial statements reportofindependentregisteredpublicaccountingfirm totheshareholdersandboardofdirectorsofjohnsonjohnson andevaluatingthedesignandoperatingeffectivenessofinternal controlbasedontheassessedriskourauditsalsoincludedper inouropiniontheaccompanyingconsolidatedbalancesheetsand formingsuchotherproceduresasweconsiderednecessaryinthe therelatedconsolidatedstatementsofearningsstatementsof circumstanceswebelievethatourauditsprovideareasonable equityandstatementsofcashflowspresentfairlyinallmaterial basisforouropinions respectsthefinancialpositionofjohnsonjohnsonanditssub acompanysinternalcontroloverfinancialreportingisa sidiariesthecompanyatjanuaryandjanuary processdesignedtoprovidereasonableassuranceregardingthe andtheresultsoftheiroperationsandtheircashflowsforeachof reliabilityoffinancialreportingandthepreparationoffinancial thethreeyearsintheperiodendedjanuaryinconformity statementsforexternalpurposesinaccordancewithgenerally withaccountingprinciplesgenerallyacceptedintheunitedstates acceptedaccountingprinciplesacompanysinternalcontrolover ofamericaalsoinouropinionthecompanymaintainedinall financialreportingincludesthosepoliciesandproceduresthati materialrespectseffectiveinternalcontroloverfinancialreporting pertaintothemaintenanceofrecordsthatinreasonabledetail asofjanuarybasedoncriteriaestablishedininternal accuratelyandfairlyreflectthetransactionsanddispositionsofthe controlintegratedframeworkissuedbythecommitteeofspon assetsofthecompanyiiprovidereasonableassurancethattrans soringorganizationsofthetreadwaycommissioncosothe actionsarerecordedasnecessarytopermitpreparationoffinancial companysmanagementisresponsibleforthesefinancialstate statementsinaccordancewithgenerallyacceptedaccountingprin mentsformaintainingeffectiveinternalcontroloverfinancial ciplesandthatreceiptsandexpendituresofthecompanyarebeing reportingandforitsassessmentoftheeffectivenessofinternal madeonlyinaccordancewithauthorizationsofmanagementand controloverfinancialreportingincludedintheaccompanying directorsofthecompanyandiiiprovidereasonableassurance managementsreportoninternalcontroloverfinancialreport regardingpreventionortimelydetectionofunauthorizedacquisi ingourresponsibilityistoexpressopinionsonthesefinancial tionuseordispositionofthecompanysassetsthatcouldhavea statementsandonthecompanysinternalcontroloverfinancial materialeffectonthefinancialstatements reportingbasedonourintegratedauditsweconductedouraudits becauseofitsinherentlimitationsinternalcontroloverfinan inaccordancewiththestandardsofthepubliccompanyaccounting cialreportingmaynotpreventordetectmisstatementsalsopro oversightboardunitedstatesthosestandardsrequirethatwe jectionsofanyevaluationofeffectivenesstofutureperiodsare planandperformtheauditstoobtainreasonableassuranceabout subjecttotheriskthatcontrolsmaybecomeinadequatebecauseof whetherthefinancialstatementsarefreeofmaterialmisstatement changesinconditionsorthatthedegreeofcompliancewiththe andwhethereffectiveinternalcontroloverfinancialreportingwas policiesorproceduresmaydeteriorate maintainedinallmaterialrespectsourauditsofthefinancialstate mentsincludedexaminingonatestbasisevidencesupportingthe amountsanddisclosuresinthefinancialstatementsassessingthe accountingprinciplesusedandsignificantestimatesmadeby managementandevaluatingtheoverallfinancialstatementpresen tationourauditofinternalcontroloverfinancialreportingincluded obtaininganunderstandingofinternalcontroloverfinancialreport newyorknewyork ingassessingtheriskthatamaterialweaknessexistsandtesting february report independent registered public accounting firmmanagementsreportoninternalcontroloverfinancialreporting undersectionofthesarbanesoxleyactofmanage establishedbythecommitteeofsponsoringorganizationsofthe mentisrequiredtoassesstheeffectivenessofthecompanysinter treadwaycommissioncosoininternalcontrolintegrated nalcontroloverfinancialreportingasoftheendofeachfiscalyear frameworkthesecriteriaareintheareasofcontrolenvironment andreportbasedonthatassessmentwhetherthecompanys riskassessmentcontrolactivitiesinformationandcommunication internalcontroloverfinancialreportingiseffective andmonitoringthecompanysassessmentincludedextensive managementofthecompanyisresponsibleforestablishing documentingevaluatingandtestingthedesignandoperating andmaintainingadequateinternalcontroloverfinancialreporting effectivenessofitsinternalcontrolsoverfinancialreporting thecompanysinternalcontroloverfinancialreportingisdesigned basedonthecompanysprocessesandassessmentas toprovidereasonableassuranceastothereliabilityofthecompanys describedabovemanagementhasconcludedthatasofjanuary financialreportingandthepreparationofexternalfinancialstate thecompanysinternalcontroloverfinancialreporting mentsinaccordancewithgenerallyacceptedaccountingprinciples waseffective internalcontrolsoverfinancialreportingnomatterhowwell theeffectivenessofthecompanysinternalcontrolover designedhaveinherentlimitationsthereforeinternalcontrolover financialreportingasofjanuaryhasbeenauditedby financialreportingdeterminedtobeeffectivecanprovideonly pricewaterhousecoopersllpanindependentregisteredpublic reasonableassurancewithrespecttofinancialstatementprepara accountingfirmasstatedintheirreportwhichappearsherein tionandmaynotpreventordetectallmisstatementsmoreover projectionsofanyevaluationofeffectivenesstofutureperiodsare subjecttotheriskthatcontrolsmaybecomeinadequatebecauseof changesinconditionsorthatthedegreeofcompliancewiththe policiesorproceduresmaydeteriorate thecompanysmanagementhasassessedtheeffectivenessof williamcweldon dominicjcaruso thecompanysinternalcontroloverfinancialreportingasofjanuary chairmanboardofdirectors vicepresidentfinance inmakingthisassessmentthecompanyusedthecriteria andchiefexecutiveofficer andchieffinancialofficer managements report internal control financial reporting summaryofoperationsandstatisticaldata dollarsinmillionsexceptpersharefigures salestocustomersus salestocustomersinternational totalsales costofproductssold sellingmarketingandadministrativeexpenses researchanddevelopmentexpense purchasedinprocessresearchanddevelopment interestincome interestexpensenetofportioncapitalized otherincomeexpensenet restructuring earningsbeforeprovisionfortaxesonincome provisionfortaxesonincome netearnings percentofsalestocustomers dilutednetearningspershareofcommonstock percentreturnonaverageshareholdersequity percentincreasedecreaseoverpreviousyear salestocustomers dilutednetearningspershare supplementaryexpensedata costofmaterialsandservices totalemploymentcosts depreciationandamortization maintenanceandrepairs totaltaxexpense supplementarybalancesheetdata propertyplantandequipmentnet additionstopropertyplantandequipment totalassets longtermdebt operatingcashflow commonstockinformation dividendspaidpershare shareholdersequitypershare marketpricepershareyearendclose averagesharesoutstandingmillionsbasic diluted employeesthousands alsoincludedincostofmaterialsandservicescategory includestaxesonincomepayrollpropertyandotherbusinesstaxes summary operations statistical datashareholderreturnperformancegraphs setforthbelowarelinegraphscomparingthecumulativetotalshareholderreturnonthecompany'scommonstockforperiodsoffiveyears andtenyearsendingdecemberagainstthecumulativetotalreturnofthestandardpoor'sstockindexthestandardpoor 's pharmaceuticalindexandthestandardpoor'shealthcareequipmentindexthegraphsandtablesassumethatwasinvested ondecemberanddecemberineachofthecompany'scommonstockthestandardpoor'sstockindexthe standardpoor'spharamaceuticalindexandthestandardpoor'shealthcareequipmentindexandthatalldividendswerereinvested yearcumulative totalshareholderreturn johnson johnson spindex sppharmaceutical index sphealthcare equipmentindex yearcagr jj sp sppharm sp hc equip johnsonjohnson spindex sp pharmaceutical index sphealthcareequipmentindex yearcumulative totalshareholderreturn johnson johnson spindex sppharmaceutical index sp health care equipment index yearcagr jj sp sppharm sp hc equip johnsonjohnson spindex sppharmaceuticalindex sp healthcare equipment index shareholder return performance graphs reconciliationofnongaapfinancialmeasures thetablesbelowareprovidedtoreconcilecertainfinancialdisclosuresinthelettertoshareholderspage vs vs dollarsinmillionsexceptpersharedata change change earningsbeforeprovisionfortaxesonincomeasreported netlitigationsettlementslossgain productliabilityexpenses restructuringexpense depuyasrhiprecallprogram adjustmenttothevalueofthecurrencyoptionandcostsrelatedtoplannedacquisitionofsynthesinc inprocessresearchanddevelopment earningsbeforeprovisionfortaxesonincomeasadjusted netearningsasreported netlitigationsettlementslossgain productliabilityexpenses restructuringexpense depuyasrhiprecallprogram adjustmenttothevalueofthecurrencyoptionandcostsrelatedtoplannedacquisitionofsynthesinc inprocessresearchanddevelopment netearningsasadjusted dilutednetearningspershareasreported netlitigationsettlementslossgain productliabilityexpenses restructuringexpense depuyasrhiprecallprogram adjustmenttothevalueofthecurrencyoptionandcostsrelatedtoplannedacquisitionofsynthesinc inprocessresearchanddevelopment dilutednetearningspershareasadjusted vs vs dollarsinmillions change change netcashflowsfromoperatingactivities additionstopropertyplantandequipment freecashflow thecompanyprovidesearningsbeforeprovisionfortaxesonincomenetearningsnetearningspersharedilutedandnetcashflows fromoperatingactivitiesonanadjustedbasisbecausemanagementbelievesthatthesemeasuresprovideusefulinformationtoinvestors amongotherthingsthesemeasuresmayassistinvestorsinevaluatingthecompanysresultsofoperationsperiodoverperiodinvarious periodsthesemeasuresmayexcludesuchitemsassignificantcostsassociatedwithacquisitionsrestructuringlitigationandchangesin applicablelawsandregulationsincludingsignificantaccountingortaxmattersthesespecialitemsmaybehighlyvariabledifficultto predictandofasizethatsometimeshassubstantialimpactonthecompanysreportedresultsofoperationsforaperiodmanagement usesthesemeasuresinternallyforplanningforecastingandevaluatingtheperformancesofthecompanysbusinessesincludingallocating resourcesandevaluatingresultsrelativetoemployeeperformancecompensationtargetsunlikeearningsbeforeprovisionfortaxeson incomenetearningsnetearningspersharedilutedandnetcashflowsfromoperatingactivitiespreparedinaccordancewithgaap adjustedearningsbeforeprovisionfortaxesonincomeadjustednetearningsadjustednetearningspersharedilutedandfreecashflow maynotbecomparablewiththecalculationofsimilarmeasuresforothercompaniesthesenongaapfinancialmeasuresarepresented solelytopermitinvestorstomorefullyunderstandhowmanagementassessestheperformanceofthecompanythelimitationsofusing thesenongaapfinancialmeasuresasperformancemeasuresarethattheyprovideaviewofthecompanysresultsofoperationswithout includingalleventsduringaperiodsuchastheeffectsofanacquisitionrestructuringlitigationandchangesinapplicablelawsand regulationsincludingsignificantaccountingortaxmattersanddonotprovideacomparableviewofthecompanysperformancetoother companiesinthehealthcareindustryinvestorsshouldconsidernongaapfinancialmeasuresinadditiontoandnotasreplacementsfor orsuperiortomeasuresoffinancialperformancepreparedinaccordancewithgaap reconciliation nongaap financial measuresprincipal office common stock johnson johnson web one johnson johnson plaza listed new york stock exchange company website wwwjnjcom new brunswick new jersey stock symbol jnj online annual report shareholder relations contact wwwinvestorjnjcomannualreport annual meeting douglas k chia annual meeting shareholders take corporate secretary blog wwwjnjbtwcom place april hyatt regency new brunswick albany street new brunswick history blog wwwkilmerhousecom investor relations contact new jersey meeting convene louise mehrotra shareholders cordially invited attend vice president investor relations wwwfacebookcomjnj formal notice meeting proxy statement proxy sent shareholders jnjcomm jnjstories jnjvideo jnjhistory corporate governance transfer agent registrar copies companys annual report questions regarding stock holdings wwwyoutubecomjnjhealth quarterly reports form certificate replacementtransfer dividends q current reports form k address changes directed securities exchange commission proxy computershare trust company na statement annual report available scan code royall street online wwwinvestorjnjcomsecfilingscfm smartphone view canton shareholders without charge upon written multimedia version request secretary companys report outside us principal address calling wwwcomputersharecom addition companys corporate dividend reinvestment plan governance website wwwinvestorjnjcom plan allows full partial governancematerialscfm shareholders dividend reinvestment additional monthly view companys principles corporate cash investments per year governance charters audit committee johnson johnson common stock without compensation benefits committee brokerage commissions service charges nominating corporate governance stock purchases interested committee policy business conduct participating plan need authoriza employees code business conduct tion form andor information please call ethics members board directors computershare trust company na executive officers copies documents available shareholders outside us without charge upon written request secretary companys principal address hearing impaired shareholders inquiries regarding company required file exhibit stockrelated matters communicate directly fiscal year certifications computershare trust company na section sarbanesoxley act via telecommunications device tdd signed chief executive officer telephone number service chief financial officer addition outside company required submit certification us paper used publication made signed chief executive officer postconsumer recycled fiber new york stock exchange within days electronic delivery notification forest stewardship council certified following annual meeting shareholders registered shareholders wish receive chain custody manufactured copies certifications filed previous electronic notice online access future green energy credits purchase electricity years posted companys corporate annual reports proxy materials instead generated renewableenergy sources governance website future certifications paper copies may register online wind lowimpact hydro resources posted promptly upon filing wwwcomputersharenacomgreen beneficial johnson johnson shareholders shares broker bank register online delivery materials going httpenrollicsdeliverycomjnj johnson johnson annual report contains many valuable trademarks trade names owned used johnson johnson family companies united states internationally distinguish products services outstanding quality johnson johnson corporate shareholder informationone johnson johnson plaza new brunswick new jersey